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ABSTRACT 
This study focused on the role of RANKL in prostate cancer EMT progression and metastasis. 
Activation of RANK, a receptor activator of NF-κB, by its ligand RANKL, in a paracrine 
manner is responsible for osteoclast differentiation and bone remodeling. RANK activation in 
cancer cells, however, is thought to be promoted by both autocrine and paracrine mechanisms 
because RANKL has been shown to be derived from either tumor or its microenvironment, such 
as osteoblasts, infiltrating inflammatory cells and stromal fibroblasts.  In the present study, we 
demonstrated that autocrine and paracrine RANKL-RANK signaling could be responsible for 
driving prostate cancer bone metastasis by promoting epithelial to mesenchymal transition 
(EMT). We further characterized a novel converging RANKL-c-Met signaling network in which 
the activation of RANKL was found to promote the expression of both RANKL and c-Met in an 
autocrine manner in prostate cancer cells. The induced RANKL and c-Met in prostate cancer 
cells is biologically functional and contributes to increased osteoclastogenesis, epithelial to 
mesenchymal transition (EMT), cell motility, migration and invasion and conferred bone and 
soft tissue metastases.  Remarkably, RANKL expression by 1,000 prostate cancer cells can 
provoke bone and soft tissue metastases of a “dormant” population of prostate cancer cells which 
by themselves failed to form tumors and colonize mouse skeleton, suggesting RANKL can serve 
as a factor in “reawakening” cancer dormancy to initiate the re-growth and metastasis of cancer 
cells. We also showed that RANKL-induced RANKL feed-forward autocrine regulation is 
mediated through cMyc transactivation, allowing the establishment of a “vicious cycle” further 
promoting prostate cancer growth and metastasis. The converging RANKL-c-Met signaling 
network is therefore a novel target that could be further manipulated for delaying the lethal 
progression of castration-resistant human prostate cancer bone metastasis.  
INDEX WORDS: Rankl, Rank, C-met, C-myc, Castration-resistant, Epithelial to mesenchymal 
transition, Osteoclast, Prostate cancer, Metastasis, Bone metastasis, Vicious cycle, Cancer 
dormancy 
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CHAPTER 1 INTRODUCTION 
Prostate Cancer and its Progression to Castration-Resistant Disease 
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of death 
among men in the United States and other Western countries. In 2004, approximately 230,000 
men were diagnosed with prostate cancer and an estimated 30,000 deaths were due to advanced 
prostate cancer (Jemal et al., 2004). Prostate epithelial cell growth is dependent on androgens, 
which promote proliferation and inhibit apoptotic death of the prostate epithelium (Isaacs, 1994). 
Primary prostate tumors derived from the prostate epithelial cells, produce prostate-specific 
antigen (PSA), which has been used as an initial screening test for prostate cancer detection. The 
growth of early prostate tumors is androgen dependent, and androgen ablation therapy is the 
current primary treatment of choice, leading to initial cancer regression with decreased tumor 
volume and lower PSA levels. However, androgen ablation therapies are not effective for 
metastatic prostate cancer and a sub-population of prostate cancer cells develops resistance and 
becomes androgen-independent/insensitive, resulting in metastatic castration-resistant prostate 
cancers (CRPCs). The underlying mechanism of androgen-independence is not fully understood 
but androgen receptor (AR) has been identified as the central molecule that mediates androgen 
independence. Androgen receptor is a ligand-activated transcription factor. Upon androgen 
stimulation, activated AR translocates to the nucleus and binds to androgen responsive elements 
(AREs) along with other co-regulators to modulate the genes involved in the differentiation, 
development, and proliferation of target cells (McEwan, 2000; Trapman & Cleutjens, 1997). In 
CRPC, AR levels are maintained and not affected by androgen ablation, thus leading to 
proliferation of prostate cancer cells. The autonomous AR activation in CRPC can arise from AR 
amplification, gain of function mutations, ligand-independent receptor activation, and increased 
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interaction and overexpression of AR coactivators (Heinlein & Chang, 2004). Studies have 
shown that 20% to 30% of CRPC patients are associated with AR gene amplification (Elo & 
Visakorpi, 2001), and AR protein levels are also increased in tumors without gene amplification 
(Koivisto & Helin, 1999; Linja et al., 2001). Elevated AR gene and protein expression levels 
may allow cancer cells to grow and survive in androgen-deprived conditions (Feldman & 
Feldman, 2001). Moreover, genetic mutations of AR have been detected in CRPC. 
Approximately 80 mutations have been identified (Gottlieb, Beitel, Wu, & Trifiro, 2004). Most 
of the AR mutations are gain of functions which have been found to be associated with primary 
as well as advanced and metastatic tumors (Marcelli et al., 2000). AR mutants have been 
predominantly characterized with loss of androgen specificity and increased agonistic 
stimulation through non-androgen hormones or anti-androgens, leading to increased AR 
sensitivity and/or constitutively active AR (Ceraline et al., 2004; Suzuki et al., 1993; Veldscholte 
et al., 1992). The most studied AR mutation is AR T877A, which was detected in the human 
prostatic LNCaP cell line as well as in human prostate tumors (Gaddipati et al., 1994).  T877A 
mutations resulted in increased AR sensitivity to low levels of androgens and allowed mutant AR 
to become responsive to anti-androgens, such as estrogen, progesterone, and glucorticoid, which 
act as androgen agonists (Gaddipati et al., 1994; Veldscholte et al., 1992; Veldscholte, Ris-
Stalpers et al., 1990; Veldscholte, Voorhorst-Ogink et al., 1990). Coactivators have also been 
shown to directly interact with AR and enhance AR-dependent gene transcriptional activity 
(Heinlein & Chang, 2004), and increased levels of a subset of AR coactivators may contribute to 
the sensitization of AR to low levels of androgen after androgen deprivation therapy (Gregory, 
Johnson, Mohler, French, & Wilson, 2001). Coactivators, such as SRC-1, TIF-2, and SRC-3 
have been found to be overexpressed in hormone refractory prostate cancer and high Gleason 
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scored prostate cancer (Gnanapragasam, Leung, Pulimood, Neal, & Robson, 2001; Gregory, He 
et al., 2001; Heinlein & Chang, 2002; McKenna, Lanz, & O'Malley, 1999). In addition, the AR 
coactivator ARA70 has also been found to be elevated in prostate cancer specimens (Yeh & 
Chang, 1996) as well as in CWR22 xenograft tumors, which have become hormone refractory 
after castration (Gregory et al., 1998). Moreover, several tumor suppressor genes have been 
shown to interact with AR to regulate AR transcriptional activity. Phosphorylated Rb (Yeh et al., 
1998) and BRCA1 and 2 can function as AR coactivators and increase AR transcriptional 
activation (Shin & Verma, 2003; Yeh et al., 2000). Whereas, the umor suppressor PTEN, a 
negative regulatory of PI3K/Akt survival pathway, inhibits AR transcriptional activity and 
degradation of AR; loss of PTEN promotes prostate cancer progression through activation of 
both AR and PI3K/Akt signaling (Heinlein & Chang, 2004).  
AR transcriptional activity can also be activated by many growth factors, such as IGF-1, KGF, 
and EGF, in the absence of androgen (Culig et al., 1994). Cytokines, such as IL-6, also 
stimulates AR transcriptional activity in LNCaP and DU145 cells (Drachenberg, Elgamal, 
Rowbotham, Peterson, & Murphy, 1999; Hobisch et al., 1998). Elevated expression of 
Her2/Neu/ErbB2 receptor tyrosine kinase has been shown to mediate androgen-independent 
activation of AR in CRPC (Signoretti et al., 2000) through MAPK and PI3K dependent pathways 
(Campbell, Khosravi-Far, Rossman, Clark, & Der, 1998; Yart et al., 2001). Moreover, 
overexpression of anti-apoptotic protein Bcl-2 allows survival and cell growth of LNCaP cells 
and xenograft prostate tumors during androgen ablation by preventing androgen depletion-
induced apoptosis of prostate cancer cells. However, Bcl-2 expression was reduced when 
androgen was re-supplemented, implicating that Bcl-2 might be regulated by AR signaling 
(Raffo et al., 1995). Therefore, multiple molecular mechanisms potentially promote the 
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development of CRPC all through modulations of AR function. Androgen ablation leads to 
amplification and mutation of the AR gene as well as the activation of AR co-activators and 
many growth factors, which all lead to abnormally up-regulated transcriptional activity of AR 
allowing the survival and proliferation of prostate cancer cells and progression of CRPC.  
Prostate Cancer Lethal Bone Metastasis 
Advanced prostate cancers, such as CRPC have a propensity to metastasize to bone, and 
approximately 90% of CRPC patients will develop bone metastases (Bubendorf et al., 2000; 
Horwich, 2004; Loberg, Logothetis, Keller, & Pienta, 2005). Prostate cancer-induced bone 
metastasis is considered incurable (Cheville et al., 2002), and the median survival time for 
patients with bone metastasis is approximately 20 months (Rajpar et al., 2010). Bone metastases 
result in significant complications for patients, such as bone pain, pathological fractures, 
impaired mobility, spinal cord compression, and symptomatic hypercalcemia (Coleman, 1997, 
2001; Ye, Kynaston, & Jiang, 2007). Bone metastases can be either osteoblastic (bone forming) 
or osteoclastic (bone resorbing). Even though prostate cancer bone metastases are predominantly 
osteoblastic, emerging histological evidence indicates considerable osteolysis is also involved, 
leading to a heterogeneous mixture of osteolytic and osteoblastic lesions of prostate cancer 
(Keller & Brown, 2004; Roudier et al., 2008; Zhang et al., 2001). In normal conditions, bone 
undergoes a balanced and coupled remodeling process initiated by osteoclast-mediated bone 
resorption and subsequently followed by osteoblast-mediated bone formation (Guise et al., 2010). 
In prostate cancer bone lesions, the increased bone production is via an overall increased bone 
remodeling with osteoblast-mediated bone formation outweighing the increased osteoclastic 
resorption (Keller & Brown, 2004; Vela et al., 2007).  Interestingly, the serum levels of the bone-
resorption markers, such as N-telepeptide of type-I collagen (NTx), seem to be better correlated 
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with prostate cancer progression and to be a stronger predictor of overall survival in CRPC 
patients with bone metastases than the bone-formation marker, bone alkaline phosphatase (BALP) 
(Sturge, Caley, & Waxman, 2011). 
Metastasis of prostate cancer to bone involves a complex and sequential cascade of events 
dependent on interactions between the cancer cells and their surrounding microenvironment. The 
metastatic process is generally initiated by detachment of cancer cells from the primary or local 
site through disruption of the intercellular adhesion and invasion to the surrounding tissues in 
close proximity by breaking the extracellular matrix. The invasive cancer cells then intravasate to 
the capillaries generated from tumor vasculature and then to the main circulation as well as the 
lymphatic system (Guise et al., 2010). Once they survive immune surveillance and mechanical 
stresses in the circulation, the cancer cells can extravasate from circulation and gain entry to 
distant hospitable sites to establish and expand through proliferation and induction of 
angiogenesis. The precise mechanism by which prostate cancer preferentially homes to bone is 
still unclear, but several hypotheses have been proposed. The essential roles of bone 
microenvironment and prostate cancer osteomimicry have also been increasing acknowledged 
and implicated in the process of prostate cancer metastasis to bone. 
Batson first proposed the concept of the vertebral vein system, known as the Batson’s venous 
plexus in 1940, which is a network of valveless veins richly surrounding the prostate and 
connected to the venous plexuses of the internal spine allowing the dissemination of cancer cells 
to the skeletal system (Batson, 1940). However, such a theory based on anatomical structure 
could not explain the preferential homing to bone and other common metastatic sites. The “seed 
and soil” hypothesis proposed by Stephen Paget in 1989 first suggested that the interplay 
between the metastatic properties of the cancer cells (seed) and the particular organ 
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microenvironment (soil) determines the favorable and selective homing and growth of the cancer 
cells (Paget, 1989). Therefore, tumor metastasis involves bi-directional interactions between 
cancer cells and the bone microenvironment. The “soil”, such as the bone microenvironment 
must provide favorable conditions for the prostate cancer cells to colonize, survive, expand, and 
establish. Bone is enriched with abundant sources of immobilized growth factors, such as TGF-β, 
IGF, FGF, PDGF, and BMPs, cytokines, chemokines, and cell adhesion molecules, which can be 
released and activated during bone resorption, thus serving as a fertile environment for the 
cancer cells to grow and proliferate (Roodman, 2004). On the other hand, the prostate cancer 
cells can also alter bone homeostasis by secreting pro-osteoclastic and pro-osteoblastic factors 
that directly or indirectly impact bone resorption and formation in the bone microenvironment 
(Vela et al., 2007). Osteolysis is required before osteoblast bone mineralization in metastatic 
deposits, and prostate cancer cells can secret a number of pro-osteoclastic factors, such as PTHrP, 
RANKL, and IL-6, which can activate osteoclast precursors and lead to osteoclastic bone 
resorption (Fili, Karalaki, & Schaller, 2009). Osteolysis then releases all the growth factors 
stored in the bone matrix, which allows prostate tumor cells to survive and proliferate, leading to 
more production of the osteolytic factors by the cancer cells. Moreover, prostate cancer cells also 
have osteomimetic properties and produce many osteotropic factors, such as PDGF, IGFs, FGFs, 
TGF-β, VEGF, Wnt1, PTHrP, uPA, PSA, ET-1, and BMPs (Ye et al., 2007) and synthesize and 
deposit bone matrix proteins, such as osteopontin, osteocalcin, osteonectin, and bone sialoprotein 
in the bone matrix (Cher, 2001; Koeneman, Yeung, & Chung, 1999), thus promoting 
predominantly osteoblastic metastases. This bidirectional interaction between the prostate cancer 
cells and the bone microenvironment results in the establishment of a “vicious cycle” that is the 
key for the development of cancer metastasis to bone. 
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Pathophysiological Role of RANKL in Bone Remodeling 
Bone remodeling is a continuous process during adulthood through the resorption of old bone by 
bone-degrading osteoclasts and the subsequent formation of new bone by bone-forming 
osteoblasts (Manolagas & Jilka, 1995). Under normal conditions, bone remodeling continues in 
cycles where osteoclasts adhere to bone and remove it by acidification and proteolytic 
degradation, and once osteoclasts leave the resorption sites, osteoblasts subsequently invade the 
area and begin the process of forming new bone by secreting osteoid (a matrix of collagen and 
other proteins), which is eventually mineralized. After the bone formation finishes, the surface of 
the bone is covered by lining cells, characterized as a distinct type of terminally differentiated 
osteoblasts (Parfitt, 1994). Bone remodeling is a dynamic process that requires coordinated 
cellular activities among osteoblasts, osteocytes, and osteoclasts to maintain bone homeostasis 
(Stains & Civitelli, 2005). Osteoclastic bone resorption is always followed by osteoblastic bone 
formation, which led to the concept that the two processes are mechanistically “coupled” in order 
to maintain a constant, homeostatically controlled amount of bone (Rodan, 1998).  
RANKL, a receptor activator of NF-κB, is a member of the tumor necrosis factor (TNF) super 
family. RANKL exits both as a membrane-bound and a secreted form, for which the latter is a 
result of the proteolytic cleavage by MMPs or alternative splicing (Ikeda, Kasai, Utsuyama, & 
Hirokawa, 2001; Lynch et al., 2005). RANKL is primarily expressed on the surface of 
osteoblasts and bone marrow stromal cells and the soluble form can be released by activated T 
cells (Roodman, 2004; Vela et al., 2007). Moreover, RANKL is also found to be expressed in 
many different tissue types, such as peripheral lymph nodes, bone marrow, thymus, spleen, brain, 
heart, skeletal muscle, kidney, liver, lung, and mammary gland (Kartsogiannis et al., 1999; Lacey 
et al., 1998). RANKL expression can be up-regulated by many hormones and growth factors, 
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such as PTH, PTHrP, prostaglandin E2, vitamin D, and glucocorticoids, as well as by several 
cytokines, such as IL-1, IL-6, IL-7, IL-17, and TNF-α, (Anandarajah, 2009; Theoleyre et al., 
2004). RANKL plays essential roles in multiple aspects of the osteoclastogenesis including 
osteoclast formation, differentiation, maturation, and survival during bone remodeling (Lacey et 
al., 1998; Vela et al., 2007). The predominant role of RANKL in osteoclastogenesis was 
discovered in RANKL knockout mice that developed osteopetrosis with an excess of bone 
formation due to the complete absence of osteoclasts (Kong et al., 1999), and no factor or 
combination of factors has been shown to be capable of restoring bone resorption when RANKL 
is absent (Anandarajah, 2009; Kearns, Khosla, & Kostenuik, 2008). Both membrane-bound and 
soluble forms of RANKL are implicated as important physiological and pathological mediator of 
bone resorption (Kearns et al., 2008). The activity of RANKL in bone remodeling is mediated by 
binding to its cognate receptor RANK on osteoclast precursors in a paracrine manner to promote 
osteoclastogenesis and hence osteoclast-induced bone resorption (Kong et al., 1999; Yasuda et 
al., 1998). RANKL-induced osteoclastogenesis can be blocked by OPG, which acts as a decoy 
receptor of RANKL, leading to suppressed bone resorption and favoring bone formation 
(Schneeweis, Willard, & Milla, 2005). OPG is also expressed by osteoblasts and bone marrow 
stromal cells, and the ratio of RANKL and OPG determines the degree of osteoclastogenesis. An 
imbalance in the ratio of RANKL to OPG is known to be implicated in the pathogenesis of bone 
remodeling with an increase in RANKL level associated with increased bone resorption. Such 
imbalance is associated with accelerated bone remodeling rate and manifests as the basis of 
several bone diseases characterized by bone loss, such as post menopausal osteoporosis, 
inflammatory arthritis, multiple myeloma, and cancer bone metastases. Moreover, studies from 
animal models of rheumatoid arthritis and bone metastasis demonstrate that RANKL inhibition 
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by OPG or RANKL antibody can lead to significantly reduced bone resorption accompanied 
with increased bone volume, density and strength as well as decreased skeletal tumor burden and 
development (Kearns et al., 2008).  
Autocrine and Paracrine RANK-RANKL Signaling in Prostate Cancer Growth, Survival, 
and Bone Metastasis 
RANKL and RANK are essential mediators in regulating both normal and pathological bone 
remodeling, but they also play a pivotal role in mammary epithelial cell proliferation and 
survival during pregnancy as demonstrated by genetic mouse models (Gonzalez-Suarez et al., 
2007; Kim et al., 2006). Recently, RANKL-RANK signaling has been demonstrated to be 
involved in cancer cell proliferation, survival, and metastasis of various cancers, including breast 
and prostate cancers (Brown et al., 2001; Chen et al., 2006; Fili et al., 2009; Jones et al., 2006). 
Expression of RANKL and RANK is not restricted to the surface of osteoblasts and stromal cells 
and on osteoclast precursor cells in the bone environment; emerging evidences from human 
clinical and in vitro studies have shown that both RANKL and RANK are also expressed by 
some malignant cancer cells and cell lines, including breast, prostate, lung, and thyroid cancers 
that have high metastatic potential to bone (Chen et al., 2006; Hanada et al. 2011; Huang, Cheng, 
Chow, Zheng, & Kumta, 2002; Jones et al., 2006). Moreover, prostate cancer-induced bone 
metastases exhibit significantly higher RANKL levels expressed by the tumor cells than non-
osseous metastases or the primary tumors (Brown et al., 2001; Chen et al., 2006). Similarly, the 
primary breast tumors that retained RANKL expression correlated with an estrogen receptor-
negative and high histological tumor grade (Cross et al., 2006). This suggests that RANKL-
RANK signaling may be implicated in cancer malignant progression and bone metastasis.  
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Cancer growth and survival require reciprocal communications through signals or factors 
secreted by the cancer cells and the host cells in the immediate tumor microenvironment. For 
bone metastatic tumors, the cross talk between the tumor cells and the bone microenvironment 
results in disequilibrium of the bone remodeling and promotes the pathologic “vicious cycle”. 
Cancer cells secrete many cytokines and growth factors, such as IL-6, IL-11, and PTHrP, that 
stimulate osteoblasts and stromal cells to produce RANKL, and the cancer cells can also express 
RANKL directly. RANKL produced by both osteoblasts and cancer cells then acts on osteoclast 
precursors to induce osteoclastogenesis and bone resorption. Increased bone turnover releases 
more cytokines and growth factors richly stored in the bone matrix, fueling more cancer cell 
growth and RANKL secretion (Grimaud et al., 2003). Moreover, the increased RANKL may 
autonomously activate RANK-expressing cancer cells in an autocrine manner, or in a paracrine 
manner if RANKL is produced by the accessory cells in the bone microenvironment. Autocrine 
RANKL signaling has been suggested to enhance the malignant progression of breast cancer 
(Cross et al., 2006). Taken together, the autocrine and paracrine RANKL-RANK signaling can 
induce cancer cell growth and survival, leading to cancer progression and metastasis (Boyce & 
Xing, 2007; Schramek, Sigl, & Penninger, 2011). Another possible way RANKL and RANK 
may be involved in the cancer development and metastasis to the bone is based on the rationale 
that RANK- expressing cancer cells might sense RANKL produced in the bone 
microenvironment as a chemoattractant and therefore migrate in a coordinated manner to the 
bone matrix (Schramek et al., 2010). It has been demonstrated that RANKL can trigger directed 
migration of human and mouse mammary epithelial cells, breast and prostate cancer cells, and 
melanoma cells that express RANK (Jones et al., 2006). Reciprocally, RANKL-expressing 
cancer cells can also be attracted towards RANK-expressing osteoblasts and stromal cells in the 
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bone microenvironment. Such bidirectional interaction and chemoattraction between cancer cells 
and the bone microenvironment allows the metastasizing tumor cells, particularly breast and 
prostate tumors, preferentially colonize, proliferate, and survive in the bone.  Moreover, blocking 
RANKL-RANK signaling has been shown to reduce tumor burden in long bones by 50%, but not 
metastases in the other tissues in an in vivo model of melanoma bone metastasis (Jones et al., 
2006). In the MDA-MB-231 breast cancer bone metastasis model, inhibition of RANKL with 
OPG-Fc, which consists of the ligand-binding domain of human OPG fused to the Fc domain of 
human IgG (Morony et al., 1999), demonstrated a reduction in both tumor number and size in the 
bone marrow, leading to a total decrease of tumor burden by 80% (Morony et al., 2001). Mice 
treated with OPG-Fc also exhibited decreased skeletal tumor volume and tumor growth while 
increasing tumor cell apoptosis (Canon et al., 2008).  In several prostate cancer models, RANKL 
inhibition with either OPG-Fc or RANK-Fc prevented tumor growth in the bone and/or reduced 
skeletal tumor burden accompanied with decreased serum PSA level in the bone. However, both 
OPG-Fc and RANK-Fc treatments had no effects on the growth of subcutaneous prostate tumors 
(Kiefer et al., 2004; Yonou et al., 2003; Zhang et al., 2001; Zhang et al., 2003). Furthermore, in 
the colon cancer model, OPG-Fc also showed inhibition of tumor growth in bone (Morony et al., 
2001). Together, these studies further confirmed that RANKL inhibition can reduce bone 
metastases and tumor growth in bone, leading to improved survival in multiple myeloma, breast, 
prostate, and colon cancer models; however, RANKL inhibition cannot directly decrease tumor 
cell proliferation in other tissue metastases. These data strongly support the notion that 
RANKL/RANK interaction may not directly stimulate tumor cell proliferation; however, 
autocrine and paracrine RANKL-RANK signaling can promote tumor cell growth and survival 
through reciprocal feedback and interdependence between tumor cells and the bone 
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microenvironment by creating vicious cycle with tumor cells promoting bone resorption and the 
resorbing bone matrix supporting the growth and survival of tumor cells in return, eventually 
leading to cancer progression and bone metastasis. Targeting the RANKL system with small 
molecule inhibitors not only can inhibit bone resorption but also prevent tumor growth and block 
bone metastasis.  
Epithelial to Mesenchymal Transition in Prostate Cancer Progression and Metastasis 
Epithelial to mesenchymal transition (EMT) is considered a critical and evolutionarily conserved 
process during embryonic development (Thiery, 2003). During EMT, epithelial cells undergo 
profound morphogenetic changes by losing their characteristic cell-cell adhesion structures, 
modulating their polarity, and reorganizing their cytoskeleton switching from cytokeratin- to 
vimentin-based filaments, thus resulting in the formation of isolated and migratory mesenchymal 
cells that have invasive properties and resistance to apoptosis (Klymkowsky & Savagner, 2009; 
Savagner, 2010; Singh & Settleman, 2010). EMT was first recognized in the context of cellular 
remodeling during embryogenesis, including heart morphogenesis, mesoderm and neural crest 
formation in the early 1980s (Savagner, 2001; Thiery, Acloque, Huang, & Nieto, 2009). In adults, 
EMT can occur during wound healing, tissue regeneration, and organ fibrosis to generate repair-
associated mesenchymal cells or fibroblasts. Today, EMT is strongly implicated in tumor 
progression and metastasis (Kalluri, 2009; Kang & Massague, 2004; Thiery, 2002). Even though 
some pathologists remain skeptical whether EMT is apparent in human tumor specimens because 
it cannot be followed in time and space in human tumors, a growing body of evidence strongly 
suggests that EMT, if transient, is an essential step for the progression of many carcinomas to 
give rise to the great diversity of phenotypes and malignant potential, and it may be a permanent 
phenomenon in tumors with mixed carcinoma (epithelial origin) and sarcomas (mesenchymal 
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origin) (Kang & Massague, 2004; Sethi, Macoska, Chen, & Sarkar, 2010; Tarin, Thompson, & 
Newgreen, 2005; Thiery, 2002; Thompson, Newgreen, & Tarin, 2005). Moreover, recently, 
EMT has also been mechanistically linked with stemness of the cancer cells, leading to increased 
resistance to apoptosis, diminished senescence and escape from immune surveillance (Kong et 
al., 2010; Lynch et al., 2010; Mani et al., 2008; Morel et al., 2008), eventually leading to drug 
resistance (Singh & Settleman, 2010; van der Pluijm, 2010).  
The hallmark of EMT is the disruption of intercellular contacts through the loss of E-cadherin 
components, which are essential molecules providing the cell-cell adhesion junctions for the 
formation of epithelia and maintenance of the epithelial homeostasis. Cells with lost E-cadherin 
expression can dissociate from the neighboring cells and gain mesenchymal phenotype with 
enhanced cell motility and invasiveness, allowing them to migrate away from the original tissue 
into the adjacent ones.  Such morphological and behavioral transition can promote the 
progression of many cancer cells, including breast, prostate, and pancreas, from an indolent to a 
malignant state, thus favoring their migration, invasion, dissemination, and metastasis (Guarino, 
Rubino, & Ballabio, 2007; Kang & Massague, 2004; Klymkowsky & Savagner, 2009).  During 
EMT, the loss of the epithelial-specific marker, E-cadherin is accompanied by up-regulation of 
mesenchymal-associated genes, such as N-cadherin, vimentin, or fibronectin. Such changes in 
gene expression with decreased E-cadherin and increased N-cadherin or vimentin expression 
during EMT are consistently observed in various cancers with enhanced tumor growth and 
invasiveness, leading to tumor progression and metastasis (Huber, Kraut, & Beug, 2005; Thiery, 
2002). In the context of tumor progression, EMT has been studied extensively in detail in vitro 
using epithelial cell models and in vivo using transgenic mouse tumor models. Therefore, the 
molecular mechanisms underlying the EMT process have been unraveled and several 
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interconnected transduction pathways and a number of signaling molecules governing the 
initiation of EMT have been elucidated. These include receptor tyrosine kinase (RTK), 
Ras/MAPK, Src, PI3K/Akt, Wnt/β-catenin, Rho-GTPases, TGF-β, NF-κB, and integrins 
pathways (Guarino et al., 2007; Klymkowsky & Savagner, 2009; Thiery, 2003). Most of these 
pathways converge on the repression of E-cadherin expression as an event that is critical for the 
onset of EMT, followed by activation of mesenchymal gene expression through the modulation 
of many transcription factors, contributing to the molecular mechanisms of EMT. The loss of E-
cadherin function during tumor progression can be genetically or epigenetically regulated. E-
cadherin expression is frequently inhibited by various epigenetic mechanisms (Thiery, 2002), 
and the loss of E-cadherin expression through promoter hypermethylation is observed in some 
primary tumors as well as some metastases (Chang, Chow, Lam, Wei, & Yuen, 2002; Machado 
et al., 2001). However, in most cases, E-cadherin expression is inhibited through transcription 
repression by zinc-finger transcription factors Snail or Slug (Bolos et al., 2003; Nieto, 2002) and 
basic helix-loop-helix transcription factors Twist or E47 (Yang et al., 2004), which are all strong 
repressors of E-cadherin transcription and potent inducers of EMT. Other E-cadherin repressors, 
such ZEB1 and SIP1 are also implicated in EMT (Peinado, Portillo, & Cano, 2004). E-cadherin 
repressors negatively regulate E-cadherin transcription by recognizing and binding to the 
common proximal E-boxes in E-cadherin promoter (Nieto, 2002; Yang et al., 2004), and 
presumably display overlapping functional redundancy. Overexpression of Snail, Twist, Slug, or 
SIP1 not only suppresses E-cadherin expression but also up-regulates N-cadherin expression in 
human pancreatic, prostate, and gastric cancer (Alexander et al., 2006; Hotz et al., 2007; Odero-
Marah et al., 2008; Rosivatz et al., 2002). A model of E-cadherin suppressors participated during 
EMT and invasion has been suggested by which Snail and SIP1 may induce the initial 
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invasiveness of EMT, whereas Slug, E47, and perhaps ZEB1 would be involved in the 
maintenance of the migratory and invasive phenotype of EMT (Peinado et al., 2004); Twist is 
likely to play a role in the development of distant metastasis by promoting cancer cells to enter 
the bloodstream (Yang et al., 2004). Moreover, Snail and Twist expression has been reported to 
correlate with prostate and breast cancer progression and metastasis (Karreth & Tuveson, 2004; 
Kwok et al., 2005). 
The process of EMT can be initiated by many growth factors, such as EGF, FGF, HGF, IGF, and 
PDGF binding to their cognate receptors and stimulating the receptor tyrosine kinases that 
mediate the phosphorylation and activation of downstream substrates and signaling, including 
Ras/MAPK, PI3K/Akt, Rho/Rac, NF-κB, Src, and β-catenin. Activation of RTK by growth 
factors is known to be required for cell scattering, therefore contributing to the migratory and 
invasive phenotype implicated in EMT (Boyer, Valles, & Edme, 2000). Ras is a small GTP-
binding protein that activates a cascade of effectors with kinase activity, and each of which 
defines a pathway with specific functions. The best characterized Ras effector is the 
serine/threonine kinase Raf, which can initiate a series of phosphorylations leading to the 
activation of MAPK (ERK), which translocates into the nucleus and phosphorylates various 
transcription factors, such as Ets factors, Jun and Fos, and Slug (Boyer, Roche, Denoyelle, & 
Thiery, 1997). These Ras/MAPK-activated downstream transcription factors are essential 
mediators of EMT. Slug is known as a direct repressor of E-cadherin transcription and an inducer 
of EMT (Thiery, 2003), and AP-1 formed from complex of Jun and Fos, and Ets factors are also 
regarded as inducers of EMT (Davies et al., 2005; Hsu, Trojanowska, & Watson, 2004). Other 
than directly triggering MAPK, Ras can also synergistically activate PI3K and Rho/Rac 
signaling which are also important players in EMT (Guarino et al., 2007).  
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PI3K is fundamentally involved in the regulation of cell growth and apoptosis, and the PI3K/Akt 
pathway plays a central role in tumorigenesis by promoting cell survival and cell proliferation 
and inhibiting apoptosis. Activated Akt can directly up-regulate Snail expression, or it can 
phosphorylate and inhibit GSK-3β in the Wnt/β-catenin pathway and prevent the degradation of 
both β-catenin and Snail, thus leading to an increase in both signaling β-catenin and Snail levels, 
ultimately promoting EMT (Bakin, Tomlinson, Bhowmick, Moses, & Arteaga, 2000; Zhou et al., 
2004).  
Rho and Rac are small GTPases involved in the regulation of the actin cytoskeleton, polarization, 
cell-cell and cell-matrix adhesion, membrane trafficking, and cell proliferation (Burridge & 
Wennerberg, 2004; Jiang, Sha, & Schacht, 2006). Therefore, they are recognized as key 
mediators governing cell dissociation, cell shape changes and migratory ability during EMT and 
invasion process. Growth factor-activated receptor tyrosin kinases and their downstream 
mediators Ras and PI3K, as well as signals from extracellular matrix can all modulate the 
activity of Rho and Rac, and their activation are required for induction of cell motility during 
EMT possibly through the breakdown of the intercellular junctions (Guarino et al., 2007).  
Src is a non-receptor SH2 domain-containing cytoplasmic tyrosin kinase involved in the 
regulation of cell growth, adhesion, and migration. Src can modulate the cell adhesiveness state 
by altering the balance between the cadherin-mediated cell-cell adhesion and integrin-mediated 
cell-matrix adhesion and inducing a more motile phenotype. Src is considered as a potent EMT 
inducer because activated Src can promote an ‘adhesion switch’ through disruption of E-
cadherin-based intercellular contacts and up-regulation of dynamic integrin-mediated cell-matrix 
adhesion, leading to a conversion from a cohesive to a dispersed, migratory phenotype.  The 
underlying mechanism of Src-induced migration is based on the activation and accumulation of 
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phosphomyosin through FAK- and MAPK-dependent activation, which results in the breakdown 
of cell-cell contacts and gain of acto-myosin contractility, leading to a mesenchymal phenotype 
suitable for migration and invasion (Avizienyte, Brunton, Fincham, & Frame, 2005).  
TGF-β is a cytokine expressed in most human cancer and plays a dual role in tumor development. 
In the early phases of tumor formation, TGF-β acts as a strong anti-proliferative, pro-apoptotic, 
and tumor growth inhibiting factor; however, in the later stages it converts to promote tumor 
progression by stimulating EMT, migration, and invasion. Activation of TGF-β signaling results 
in the formation of a Smad complex, which is able to translocate into the nucleus and activate 
transcription factor LEF-1/TCF, which is a crucial mediator of EMT. However, TGF-β can also 
induce EMT in a Smad-independent manner through the activation of Ras/MAPK, PI3K, p38, 
Rho and Rac signaling (Bakin et al., 2000; Bhowmick et al., 2001; Xie et al., 2004). In tumor 
cells, it seems that the cooperation between TGF-β and either RTK or downstream Ras and PI3K 
can overcome the suppressive effects of TGF-β on cell proliferation, thereby allowing EMT to 
take place. Moreover, TGF-β can induce epithelial cells to undergo EMT and become 
mesenchymal-like cells that are capable to produce more TGF-β, thus creating an autocrine feed-
forward loop, allowing the maintenance of the mesenchymal-like phenotype and reinforcing the 
EMT process (Guarino et al., 2007).  
β-catenin has been shown to play central roles in both the cell adhesion complex as well as in 
Wnt signaling; therefore, β-catenin represents a converging point where cadherins intersect and 
modulate the Wnt signaling system in EMT (Nelson & Nusse, 2004). The canonical Wnt 
signaling pathway is initiated by Wnt ligands binding to LRP5 and LRP 6 receptors, which then 
complex with the transmembrane Frizzled receptors and activate Dishevelled protein, leading to 
inhibition of glycogen synthase kinase 3β (GSK-3β)-mediated β-catenin phosphorylation and 
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accumulation of unphosphorylated β-catenin in the cytoplasm. β-catenin can be present in the 
membrane associated to E-cadherin, in cytosol, or in the nucleus. Upon Wnt activation, the 
cytosolic β-catenin can translocate into the nucleus, replace the co-repressors and bind with 
LEF/TCF transcription factors to activate the transcription of downstream genes required for 
EMT, such as Ets, Jun, Slug, fibronectin, and vimentin (Brabletz et al., 2005; Mason & Patterson, 
2003; Nelson & Nusse, 2004).  In the absence of a Wnt-mediated signal, most of the cytosolic β-
catenin is sequestered by E-cadherin at the cell junctions, and the remaining β-catenin is rapidly 
degraded through GSK-3β-mediated phosphorylation. Down-regulation of E-cadherin during 
EMT not only increases cell motility through loss of cell-cell adhesion but also results in an 
increase of free cytosolic β-catenin for nuclear signaling, leading to enhanced EMT induction 
and maintenance. In addition to Wnts and loss of E-cadherin, activation of PI3K/Akt, integrin-
linked kinase (ILK), or Ras/MAPK can also stimulate β-catenin nuclear signaling through 
phosphorylation and inhibition of GSK-3β (Ding et al., 2005). Moreover, GSK-3β is found to be 
highly expressed in the epithelial cells and it can block Snail transcription and promote its 
degradation; conversely, inhibition of GSK-3β through Wnt or other signaling leads to up-
regulation of Snail and promotes EMT (Brabletz et al., 2005;  Zhou et al., 2004). 
Recently, NF-κB has been identified as a central mediator of EMT in a model of breast cancer 
progression, and Ras and TGF-β-mediated EMT and activation of their downstream genes are at 
least in part via NF-κB signaling (Huber et al., 2004). Importantly, the NF-κB family of 
transcription factors can promote EMT progression through activation of E-cadherin repressors, 
such as Snail (Brabletz et al., 2005; Kim et al., 2007), Slug (Belguise et al., 2007), ZEB1/2 
(Chua et al., 2007), and Twist (Pham et al., 2007; Sosic & Olson, 2003; Sosic, Richardson, Yu, 
Ornitz, & Olson, 2003), leading to the up-regulation of mesenchymal markers vimentin, MMP2, 
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and MMP9 (Brabletz et al., 2005; Huber et al., 2004; Kong et al., 2010; Min, Eddy, Sherr, & 
Sonenshein, 2008). Therefore, NF-κB signaling is widely recognized for its pivotal roles in cell 
survival, EMT induction, maintenance of invasiveness, and progression to metastasis in many 
human cancers.   
Molecular Mechanism of RANKL-Activated RANK Signaling  
Binding of RANKL to RANK triggers intricate and distinct signaling cascades that induce the 
differentiation of osteoclast precursor cells and stimulate the resorption function and survival of 
mature osteoclasts. RANK-stimulation induces signaling pathways of NF-κB, MAPKs, MAPK-
P38, Src/PI3K/AKT, and NFATc1 through the initial activation of TNF receptor-associated 
factor (TRAF) adaptor proteins, especially TRAF6 (Galibert, Tometsko, Anderson, Cosman, & 
Dougall, 1998; Wada, Nakashima, Hiroshi, & Penninger, 2006). RANKL-RANK interaction 
induces strong NF-κB activation in osteoclasts through activation of TRAF6. RANK stimulation 
induces phosphorylation and degradation of IκBα and the nuclear translocation and DNA 
binding of the NF-κB proteins of p50, p52, and p65 (Jimi et al., 1999). Genetic ablation of NF-
κB p50 and p52 proteins in mice leads to decreased osteoclastogenesis and osteopetrosis (Iotsova 
et al., 1997). Moreover, NF-κB activation can also mediate cellular proliferation, invasion, 
angiogenesis, and metastasis (Aggarwal, 2004; Bhat-Nakshatri, Sweeney, & Nakshatri, 2002; 
Biswas, Cruz, Gansberger, & Pardee, 2000; Bond, Fabunmi, Baker, & Newby, 1998; Chilov et 
al., 1997; Helbig et al., 2003). MAPK family members of p38-MAPKs, JNK, and ERK are also 
activated by RANK stimulation (Jimi et al., 1999). Activated p38 downstream of RANK leads to 
direct phosphorylation of STAT1, controlling various target genes (Kwok et al., 2005) and might 
be involved in regulation of mRNA stability (Chang & Karin, 2001). Activation of JNK from 
RANK-signaling also up-regulates AP-1 transcription factor family members, including cJun, 
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JunB, c-Fos, and Fra, which are essential for osteoclast differentiation (David, Sabapathy, 
Hoffmann, Idarraga, & Wagner, 2002; Wagner, 2002). ERK is also activated upon RANKL 
activation during osteoclastogenesis (Wada et al., 2006). ERK, p38-MAPK, and JNK MAPK 
pathways are also known to be associated with cancer development, proliferation, differentiation, 
survival and migration (Dhillon, Hagan, Rath, & Kolch, 2007; Wagner & Nebreda, 2009). 
Another downstream target of RANK signaling is nuclear factor of activated T cells, calcineurin-
dependent 1 (NFATc1) (Takayanagi et al., 2002). RANKL-RANK signaling induces increased 
NFATc1 expression to promote osteoclast differentiation through activation of osteoclastic genes, 
such as TRAP and calcitonin receptors in cooperation with c-Fos. NFATc1 can also be activated 
via calcineurin with elevated intracellular Ca+2 levels upon RANK activation (Takayanagi, 2005; 
Takayanagi et al., 2002). Recently, NFATc1 has been shown to promote tumor migration, 
invasion, and metastasis through activation of numerous target genes, including COX2, autotoxin, 
and prostaglandin E2, particularly in breast cancer cells (Mancini & Toker, 2009; Muller et al., 
2010). 
PI3K-AKT signaling is also involved in RANKL-induced osteoclastogenesis mediated through 
Src activation (Nakashima et al., 2000). Among the many molecules downstream of Src, PYK2 
(Protein Tyrosine Kinase-2) and c-Cbl are implicated in osteoclast adhesion signaling and bone 
resorption function (Miyazaki et al., 2004; Walsh & Choi, 2003). Src and PI3K function 
mediates RANK and adhesion signals convergence, transmitting the signals for proper actin 
cytoskeletal organization and facilitating the resorption activity of osteoclasts (Chellaiah, 
Fitzgerald, Alvarez, & Hruska, 1998). Additionally, Src is a proto-oncogene that has been 
strongly implicated in the development, growth, progression, and metastasis of many human 
cancers (Irby & Yeatman, 2000). 
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Activation of RANKL-RANK-signaling pathways also plays an important role in cancer 
progression and metastasis. RANK-mediated signaling might act as a link between 
osteoclastogenesis during bone resorption and cancer progression and metastasis.  
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Overarching Hypotheses and Aims of This Study 
The goal of this thesis is to identify and evaluate the role of prostate cancer cell-derived RANKL 
in EMT progression and bone and soft tissue metastases.  
The overarching hypothesis of this study is that autocrine and paracrine cell signaling 
networks, mediated by RANKL-RANK interaction, promotes EMT progression and 
metastasis of prostate cancer cells.  RANKL-RANK interaction provides a “reawakening” 
signal for the “dormant” non-tumorigenic prostate cancer cells to re-engage in 
tumorigenesis and metastasis cascade through a mechanism mediated by RANKL-induced 
autocrine feed-forward activation in which RANKL induced RANKL and c-MET 
expression.  Responsiveness of RANK and c-MET in prostate cancer cells to external 
converging signals, from RANKL, HGF and or VEGF, are responsible for driving EMT 
and prostate cancer bone and soft tissue metastases.  
The first aim is to examine whether RANKL induces prostate cancer cell EMT in vitro at both 
the biochemical and morphological levels.  
The second aim is to examine whether RANKL promotes in vivo tumorigenesis and metastasis of 
prostate cancer cells.  
The third aim is to investigate whether the presence of RANKL-expressing prostate cancer cells 
confers the ability of RANKL-null and non-tumorigenic prostate cancer cells to grow and 
metastasize.   
The fourth aim is to determine the underlying molecular mechanism that regulates RANKL-
induced RANKL expression in an autocrine manner.  
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CHAPTER 2 MATERIALS AND METHODS 
Cell Culture 
The LNCaP, C4-2, and C4-2B human prostate cancer progression models were established by 
our laboratory as previously described (Thalmann et al., 1994). PC-3, PC-3M and DU145 human 
prostate cancer cells and MG63 human osteosarcoma cells were obtained from ATCC (Manassas, 
VA). LNCaP, C4-2, C4-2B, PC3, PC3-M, DU145, and MG63 were all maintained in RPMI 1640 
supplemented with 5% FBS.  ARCaPE and ARCaPM cells, established by our lab (Xu et al., 2006; 
Zhau et al., 1996), were maintained in T-medium (Invitrogen, Carlsbad, CA) supplemented with 
5% FBS. SaOS-2 and RAW264.7 cells (kindly provided by Dr. Neale Weitzmann, Emory 
University, Atlanta, GA) were maintained in DMEM supplemented by 10% FBS.  
Cloning of RANKL Expression Vectors 
Human RANKL cDNA ORF (NM_003701) was purchased from OriGene (Rockville, MD). 
Human RANKL cDNA was amplified by PCR and subcloned into p3×FLAG- myc-CMV-25 
(Sigma-Aldrich, St. Louis, MO) at the NotI and XbaI restriction enzyme sites. The amplified 
human RANKL cDNA was also subcloned into Plvx-AcGFP-N1 plasmids (Clontech, Mountain 
View, CA) at the XhoI and XmaI restriction enzyme sites. The sequences of both p3×FLAG-
RANKL and Plvx-AcGFP-RANKL were confirmed by DNA sequencing.  
Cell Transfection and Transduction 
ARCaPE or ARCaPM cells were seeded into 6-well plates and transiently transfected with flag-
tagged RANKL or neo plasmid DNA under the regulation of CMV-promoter or 20 pmole 
RANKL siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) with a universal siRNA 
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serving as the control (Invitrogen, Carlsbad, CA).  After 48 h of transfection, cells were 
harvested for western blotting and RT-PCR analyses. For stable transfection, LNCaP cells were 
first transfected with either p3xFlag-tagged RANKL- or neo-control-plasmid (p3×FLAG- myc-
CMV-25) cDNA (Sigma–Aldrich, St. Louis, MO) in a 6-well plate for 48h, and the cells were 
trypsinized and seeded into a 15 cm dish. The cells containing the transfected vectors were 
selected in 400 µg/ml of G418 until individual colonies containing the transfected construct were 
formed.  LNCaP cell colonies expressing flag-tagged RANKL or neo plasmid were picked and 
the cells were amplified from a 48-well plate to a 10 cm dish in the presence of G418.  Stable 
clones were maintained in 200 µg/ml of G418 and routinely checked for flag-RANKL 
expression by western blot analysis. 
ARCaPE-RANKL and ARCaPE-Neo stably transfected cell lines were established by a lentiviral 
infection protocol.  In brief, lentiviral particles containing RANKL-GFP or GFP alone (Neo 
control) were produced by 293FT cells after transfection with Plvx-RANKL-AcGFP or Plvx-
AcGFP-N1 plasmids (Clontech, Mountain View, CA) for 24 to 48 h.  The supernatant containing 
the lentiviral particles was centrifuged at 4000 rpm for 10 min, and the lentiviral particles were 
aliquotted for storage at -80°C until use.  ARCaPE cells were infected with lentiviruses 
containing DMEM media in a 1 to 1 ratio in the presence of 8 µg/ml of polybrene (Sigma-
Aldrich, Inc., St. Louis, MO) for 48h, and the cells were selected, characterized and maintained 
in T Medium containing 4 µg/ml of puromycin.   
In Vitro Osteoclastogenesis Assay 
Osteoclast precursor cells (RAW 264.7 cells) and prostate cancer cells were co-cultured in 48-
well plates containing 500 µl of α-MEM media supplemented with 10% FBS, and were set up in 
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quadruplicates. Osteoclast precursor cells were seeded with prostate cancer cells in an 8:1 ratio 
(15,000 RAW 264.7 cells and 1,875 prostate cancer cells) per well. Recombinant mouse 
RANKL (100 ng/ml, provided by Dr. Xu Feng, (McHugh et al., 2000; Zhang, Feng, & 
McDonald, 2003)) was added to the assay as the positive control.  Additionally, recombinant 
OPG (1 µg/ml) was added to designated wells to block RANKL-mediated increased 
osteoclastogenesis. The cells were checked under the microscope daily from day 4 to day 7.  
Cells were fixed and subjected to tartrate-resistant acid phosphatase (TRAP) staining (Sigma-
Aldrich, Inc., St. Louis, MO). TRAP+ multinucleated cells (≥3 nuclei) in the entire well were 
counted as mature osteoclasts and images were taken under light microscopy.  
In Vitro Osteogenic Assay 
Osteoblast precursor cells (MC3T3-E14 cells) and prostate cancer cells were co-cultured in 24-
well plates in 500 µl of osteogenic media containing α-MEM media supplemented with 10% 
FBS, 10 mM β-glycerophosphate, 50 µg/ml of L-ascorbate, and 10-8 M dexamethasome, and 
were set up in triplicates. Osteoblast precursor cells were seeded with prostate cancer cells in a 
10:1 ratio (20,000 MC3T3 cells and 2000 prostate cancer cells) per well.  The cells were co-
cultured for 14 days with a daily check under the microscope, and the osteogenic media were 
changed every two days.  Cells were washed with PBS, fixed with ice cold 75% ethanol at 4°C 
for 30 min, and subjected to Alizarin Red-S (40 mM) staining for 10 min at RT. Cells were then 
washed with water and air dried before being photographed by a scanner.  For quantification, 
Alizarin Red-S dye was eluted with 200 µl of 10% cetylpyridinium chloride (CPC) at RT for 30-
45 min with continuous rocking, and the eluted dye was transferred to a 96-well plate and 
measured at an absorbance of 570 nm using a microplate reader.   
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In Vitro Migration and Invasion Assays 
Migration and invasion by cancer cells were examined in 24-well plates using collagen I and 
growth factor reduced Matrigel (BD Biosciences, Bedford, MA) coated transwells (8 µm pore 
size), respectively, as previously described (Nomura et al., 2006; Odero-Marah et al., 2008). 
Cells were serum-starved in RPMI 1640 or T-medium (Invitrogen, Carlsbad, CA) overnight and 
dissociated in 10 mM EDTA/HEPES. The lifted cells were washed and counted, and 5x104 cells 
were seeded in 100 µl of serum-free RPMI 1640 or T-medium in the upper chamber of the 
transwells in the presence or absence of 1 µg/ml OPG, and 400 µl of RPMI 1640 or T-medium 
supplemented with 5% FBS was placed in the lower chamber of the transwells. After 24h 
(migration) and 48h (invasion) of culturing at 37 °C, the migrated and invaded cells were fixed 
with 10% formaldehyde, stained with 0.5% crystal violet, and the cells at the upper side of the 
membrane of the chamber were removed and quantified (Gleave, Cancer Res 1991).  
In Vitro Proliferation Assay 
RANKL- or Neo vector-expressing ARCaPE and LNCaP cells were seeded into 96-well plate at 
5,000 cells per well. For R1881 treatment, LNCaP-RANKL or LNCaP-Neo cells were serum 
starved in serum-free RPMI1640 overnight and treated in the presence or absence of 10 nM of 
R1881. Cell proliferation was examined daily by adding 20 µl of CellTiter 96 AQueous One 
Solution Reagent (Promega, Madison, WI) into each well and incubating for 2h. The plate was 
read at absorbance of 490 nm using a 96-well plate reader. The CellTiter 96 AQueous One 
Solution Cell proliferation Assay is a colorimetric method capable of determining cell 
proliferation by assessing the total number of viable cells in each well (Berridge & Tan, 1993).  
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Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) 
Total RNA from cells was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA) according to 
the manufacturer’s instructions. Complementary DNA (cDNA) was generated from 3 µg of total 
RNA using SuperScript® III First-Strand Synthesis System (Invitrogen, Carlsbad CA), and 1 µl 
of cDNA was subjected to PCR analyses using the following primers : RANKL F, 5’-TGG ATC 
ACA GCA CAT CAG AGC AG-3’; RANKL R, 5’-TGG GGC TCA ATC TAT ATC TCG 
AAC-3’; RANK F, 5’-GGG AAA GCA CTC ACA GCT AAT TTG-3’; RANK R, 5’-GCA CTG 
GCT TAA ACT GTC ATT CTC C-3’; OPG F, 5’-GCT AAC CTC ACC TTC GAG-3’; OPG R, 
5’-TGA TTG GAC CTG GTT ACC-3’; E-cadherin F, 5’-GCC AAG CAG CAG TAC ATT CTA 
CAC G-3’; E-cadherin R, 5’-GCT GTT CTT CAC GTG CTC AAA ATC C-3’; N-cadherin F, 
5’-GAT GTT GAG GTA CAG AAT CGT; N-cadherin R, 5’-GGT CGG TCT GGA TGG CGA-
3’; Snail F, 5’-CAG ACC CAC TCA GAT GTC AA-3’; Snail R, 5’-CAT AGT TAG TCA CAC 
CTC GT-3’; Vimentin F, 5’-GGA CTC GGT GGA CTT CTC; Vimentin R, 5’-CGC ATC TCC 
TCC TCG TAG-3’; c-Met F, TGGGAATCTGCCTGCGAA; c-Met R, 
CCAGAGGACGACGCCAAA. The PCR reaction cycles involved an initial denaturation at 
94°C for 10 min, followed by 36 cycles of 94°C,1 min; 55 °C,30 sec for RANKL and RANK 
and 48°C, 1 min for OPG; 72°C, 1 min and a final extension at 72°C for 10 min. For E-cadherin 
and N-cadherin gene amplification, the PCR reactions ran for a total of 32 cycles with annealing 
temperatures of 55°C and 47°C, respectively for 30 sec. For Snail, Vimentin, and GAPDH 
amplification, the PCR reactions ran for a total of 28 cycles with annealing temperatures at 48°C 
for 30 sec. The amplified PCR products were detected and analyzed on 1% agarose gel.  
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Western Blot Analysis 
ARCaPE and LNCaP cells were cultured in 6-well plates. At 70% confluency, the cells were 
serum-starved overnight and then treated with 200 ng/ml of trimerized RANKL in serum-free 
and phenol-red free RPMI-1640 medium for three days before cell harvesting.  ARCaPE-
RANKL and LNCaP-RANKL cells were cultured in 6-well plates and treated with 20 µM of 
LY294002, a PI3K inhibitor, 20 µM of SB203580, an inhibitor of MAP kinase reactivating 
kinase, or 2 µM of PS341 (bortezomib), a proteasome inhibitor, at 90% confluency for four 
hours.  Cells were lysed in RIPA buffer containing 1x protease inhibitor cocktail (Thermo Fisher 
Scientific, Waltham, MA) and centrifuged, and the supernatants were collected and quantified 
using the Bradford Protein Assay (Thermo Fisher Scientific, Waltham, MA). Cell lysates (20-30 
µg) were resolved on a 4-12% Bis-Tris gradient SDS-PAGE (Invitrogen, Carlsbad, CA) under 
reducing conditions, followed by transblotting onto nitrocellulose membrane (BioRad, Hercules, 
CA). The membranes were blocked in 5% non-fat milk in PBST for one hour at room 
temperature (RT) and incubated with diluted primary antibodies in blocking buffer at 4°C 
overnight. The primary antibodies used were RANKL, E-cadherin, vimentin, OPG, c-Met (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA), p-Met (Tyr-1230/34/35) (Invitrogen, Carlsbad, CA), 
RANK (Amgen, Thousand Oaks, CA), N-cadherin (BD Transduction Laboratories, San Jose, 
CA), phospho-Akt (Ser 473), Akt, phospho-p38 (Thr180/Tyr182), p38, phospho-ERK1/2 
(Thr202/Tyr204), ERK, phospho-SAPK/JNK (Thr183/Tyr185), JNK, phospho-NF-κB p65 
(Ser536), and NF-κB p65 (Cell Signaling Technology, Danvers, MA). Production and usage of 
androgen receptor antibody (PG21) were previously reported (Prins, Birch, & Greene, 1991). 
The membranes were washed with PBST three times before incubating with peroxidase-
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conjugated anti-mouse or anti-rabbit secondary antibodies at RT for one hour. After three washes, 
the membranes were visualized using ECL Plus reagent (GE Healthcare, Piscataway, NJ).  
The nuclear extracts of LNCaP, RANKL-treated LNCaP, LNCaP-Neo, and LNCaP-RANKL 
cells were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher 
Scientific, Waltham, MA) and resolved on a 4-12% Bis-Tris gradient SDS-PAGE (Invitrogen, 
Carlsbad, CA) under reducing conditions, followed by transblotting onto nitrocellulose 
membrane (BioRad, Hercules, CA). Membranes were probed with cMyc (D84C12XP), phospho-
Lamin A/C (Ser 22) (Cell Signaling Technology, Danvers, MA), and Max (sc-197X) antibodies 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA). 
Soft Agar Colony Formation 
Six well plates were first coated with 1 ml of 0.5% Agarose mixed in RPMI1640 supplemented 
with 10% FBS and placed at room temperature until they solidified. One thousand prostate 
cancer cells were then mixed in 1 ml of 0.3% agarose in RPMI1640 supplemented with 10% 
FBS and laid over the pre-coated 0.5% agarose layer, and 1 ml feeding media (RPMI1640 
containing 10% FBS) were added into the well after the top agarose layer solidified. Media were 
changed every three days. Once the colonies were formed, the plates were stained with 0.5% 
crystal violet for 30 min at room temperature and washed with distilled water until the crystal 
violet in the agarose became clear and only the colonies were stained blue. The colonies (>100 
um) were then counted and images of each well were taken by camera.  
 
 
 30 
In Vivo Experiments 
All animal procedures were performed according to an approved protocol from the Institutional 
Animal Care and Use Committee. LNCaP-RANKL and LNCaP-Neo cells or ARCaPE-RANKL 
and ARCaPE-Neo cells (1x106 cells/50µl PBS) were inoculated intracardially into 5- to 7-week-
old male athymic nude mice (Charles River, Wilmington, MA), using a 28G1/2 needle (LNCaP-
RANKL n=20; LNCaP-Neo n=15) as described previously (Odero-Marah et al., 2008). For the 
co-inoculation experiment, LNCaP-RANKL and LNCaP-RFP cells were pre-mixed at 1 to 9 or 9 
to 1 ratios in a total of a million cells and intracardially inoculated into 5- to 7-week-old male 
athymic nude mice. A million LNCaP-Neo and LNCaP-RFP cells premixed at a 1 to 1 ratio were 
also intracardially co-inoculated into the nude mice. A million LNCaP-RANKL cells were also 
inoculated intratibially in nude mice a week before the intracardial inoculation of a million 
LNCaP-RFP cells. All mice were constantly monitored for tibial or metastatic tumor formation 
on a weekly basis.  Mice bearing metastatic bone tumors were first observed at 2 months, and 
mice were sacrificed 3 to 4 months after injection. Before euthanasia, all mice were scanned with 
X-ray or µCT analysis to examine the skeleton and determine the types of bone lesions.  All 
metastatic tumors to bone or soft tissues were harvested and processed for histomorphological 
and histochemical analyses. For the co-inoculation experiments, the harvested bone or soft tissue 
tumors were subjected to fluorescent imaging using the Xenogen imaging system for detecting 
the red fluorescent signal (excitation: 570; emission: 620).  
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Immunohistochemical Analysis 
All reagents from the DAKO system were used for immunoperoxidase staining of section slides. 
Paraffin-embedded sections of bone and soft tissue tumors were rehydrated and antigenic 
epitopes were retrieved in citrate buffer using a pressure cooker. After antigen retrieval, slides 
were blocked with dual endogenous enzyme block (DEEB) at RT for 10 min and incubated with 
primary antibodies against Flag (Cell Signaling Technology, Danvers, MA), RANKL IMG-185A 
(Imgenex, San Diego, CA), RANKL NB100-56512 (Novus, Littleton, CO), RANKL FL-317 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), RFP (Antibodies-online, Atlanta,GA), E-
cadherin, N-cadherin, vimentin, c-Met, neuropilin 1, Mcl-1, p-NF-κB p65 (Ser 536), VEGF 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and p-c-Met (pYpYpY1230⁄1234⁄1235) 
(Invitrogen, Carlsbad,CA) at 4°C overnight. The slides were placed at RT for 1 h and rinsed in 
Tris-buffered saline with 0.05% Tween (TBST) and incubated with Envision + Labeled 
Polymer-HRP at RT for 30 min. The slides were incubated with peroxidase substrate buffer with 
a chromogen, diaminobenzidine (DAB) to detect the staining signal, followed by hematoxylin 
counterstaining of nuclei. After dehydration and cover-slipping, the slides were examined by 
light microscopy. The intensity of IHC staining was scored based on a combined intensity and 
percentage positive scoring method as previously reported (De Marzo, Knudsen, Chan-Tack, & 
Epstein, 1999). Strong intensity was scored as 3, intermediate as 2, weak as 1, and negative as 0. 
Each intensity score was then summed with the score of percentage of cells that were stained, 
with >50% of the cells as 2, <50% of the cells as 1, and none as 0. One-way ANOVA was used 
to analyze the population scores between the two stages of cancer progression (Bone vs. benign, 
well-differentiated, or poorly-differentiated, or well-differentiated vs. benign).  
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Tartrate-Resistant Acid Phosphatase Staining 
The osteoclasts in tissue samples were detected by Tartrate-Resistant Acid Phosphatase (TRAP) 
staining. The bone tumors were harvested and decalcified in 10% ethylenediamine tetraacetic 
acid (EDTA)/ PBS for 14 days. The decalcifying solution was changed every other day. The 
decalcified bone tissues were processed, paraffin embedded, and cut into sections. The bone 
tissue sections were deparaffinized and stained with a TRAP staining kit purchased from Sigma 
(St. Louis, MO) according to the manufacturer’s instructions, followed by Orange G staining.  
Goldner’s Trichrome Osteoid Staining 
Paraffin-embedded tissue sections were de-paraffinized and rehydrated in a series of alcohol and 
rinsed in water. The tissue sections were first stained for nuclei in Weigert’s iron hematoxylin for 
20 min and rinsed in water for 1 min. The slides were then differentiated in acid alcohol (1% 
hydrochloric acid in 70% alcohol) for less than 5 sec followed by rinsing in water for 10 min. 
The slides were stained in a sequence of solution A (0.075g Ponceau 2R, 0.025g acid fuchsin, 
0.01g azophloxin, and 0.2ml acetic acid in 100 ml distilled water) for 5 min, rinsed with 1% 
acetic acid, solution B (2g orange G and 4g phosphomolybdic acid in 100 ml water) for 3 min, 
rinsed with 1% acetic acid, solution C (0.2g light green and 0.2 ml acetic acid in 100 ml water) 
for 5 min, and rinsed with 1% acetic acid for 5 min. The slides were blot dried, cleared in 100% 
alcohol and xylene, and mounted (Murphy, Simmons, Kaigler, & Mooney, 2004). 
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP was performed by a ChIP-IT kit (Active Motif, Inc., Carlsbad, CA). LNCaP and LNCaP-
RANKL cells were serum-starved overnight and treated with 200 µg/ml of RANKL, 200 µg/ml 
of RANKL plus 200 µg/ml of OPG, or 1 µg/ml of OPG for LNCaP-RANKL cells for an 
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additional 48h. The cells were formaldehyde-fixed and sheared into 200-1500 bp of DNA 
fragments by enzymatic shearing mixture for 10 min at 37 °C. A portion of the cross-linked 
protein-DNA complexes was reserved as input DNA, and the rest of the protein-DNA complexes 
were subjected to immunoprecipitation with anti-cMyc antibody (Cell Signaling Technology, 
Danvers, MA) and anti-rabbit IgG as a negative control. The precipitated DNA was extracted 
and purified for both semi-quantitative and quantitative real-time PCR analyses. The PCR 
primers 5’-CCTGGTCACTCTTCCTCAAC-3’ (forward) and 5’-
CTCTAGGCAAGATTTGTGAC-3’ (reverse) were used to amplify cMyc DNA from the input 
and anti-cMyc- and anti-rabbit IgG-precipitated DNA. The amplified PCR products were 
detected and analyzed on a 3% agarose gel. Quantitative real-time PCR was also conducted to 
further quantify the PCR products from the ChIP analysis. The purified DNA was mixed with 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and the cMyc primer pair 
and amplified using the ABI 7500 Fast detection system (Applied Biosystems, Foster City, CA). 
The relative expression of each sample was then normalized with that of input to get the fold 
change.  
Electrophoretic Mobility Shift Assay (EMSA)  
Nuclear extracts of LNCaP, RANKL-treated LNCaP, and LNCaP-RANKL cells were prepared 
using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Waltham, 
MA). EMSA was performed using the non-invasive LightShift Chemiluminescent EMSA kit 
according to the manufacturer’s instructions. The double-stranded oligonucleotide of cMyc/Max 
binding motif (underlined) within the RANKL promoter is 5’-
CAATTTAGAACACATGCTTTAATAAC-3’, which was used as biotin-labeled and unlabeled 
probes (and later was used as competitors at 400x) in the binding reactions. For the supershift 
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assay, 2 µg of cMyc (sc-764X) and Max (sc-197X) antibodies (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) were pre-mixed with the nuclear extracts for 30 min on ice before adding the 
binding reaction mixture, which further incubated at RT for 20 min. The samples were subjected 
to electrophoresis on a 5% TBE gel in 0.5x TBE buffer for 1h and transferred onto a nylon 
membrane in 0.5x TBE buffer for 1h. The nylon membrane was UV cross-liked at 120 mJ/cm2 
for 1 min, blocked, and incubated with streptavidin-HRP solution at RT for 15 min. The 
membrane was washed for four times for 5 min each before adding the substrate. The membrane 
was then exposed to X-ray film to detect the biotin-labeled DNA by chemiluminescence.  
PCR Array 
The PCR arrays, Osteogenesis (PAHS-026) and TNF-α ligands and receptors (PAHS-063) were 
purchased from SABiosciences (Qiagen, Frederick, MD). The RNA was extracted from LNCaP 
and LNCaP-RANKL cells and converted to cDNA by reverse transcription PCR using a RT2 
First Strand Kit (C-03) from SABiosciences (Qiagen, Frederick, MD). The mixture of cDNA and 
SYBR Green Master Mix was added to each well of the array plate containing the primer pairs 
for different genes. Quantitative real-time PCR was performed using the ABI 7500 Fast detection 
system (Applied Biosystems, Foster City, CA) at 95°C for 10 min and 40 cycles of 95°C, 15 sec 
and 60 °C, 1 min, and followed by a dissociate curve. The relative expression was analyzed 
using the SABiosciences online analyzing tool based on the ∆∆Ct method.  
Cytokine antibody array 
The data for the cytokine antibody arrays (RayBiotech Inc. Norcross, GA) were kindly provided 
by Dr. Sue-Hwa Lin.  
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Construction of RANKL Promoter-Luciferase Reporter Plasmid and Deletion Mutants 
The 2.5kb human RANKL promoter was constructed by amplifying from the human BAC clone 
RP11-86N24 using primers 5’-GTGCACAGAATTCTTCAGGGGGCAAGTC-3’ (forward) and 
5’-GCGAAGCTTCATGGCGCTCGGCCCTCTCG-3’ (reverse). The amplified fragment was 
subsequently subcloned into a firefly luciferase expression vector pGL3-basic (Promega, 
Madison, WI). The authenticity of the 2.5kb RANKL promoter region was confirmed by DNA 
sequencing. A series of deletion mutants of the RANKL promoter were generated from the 2.5kb 
RANKL promoter using QuikChange II XL Site-Directed Mutagenesis Kit following the 
manufacturer’s instructions (Stratagene, Santa Clara, CA). 
Transient Transfection and Luciferase Reporter Assay 
The RANKL promoter and deletion mutants plus the β-galactosidase plasmid (for transfection 
efficiency control) were transiently transfected into prostate cancer cells using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) for 48h. In the treatment experiments, after the 48h transfection 
the cells were serum-starved for 24h before treatment with RANKL, OPG, or RANKL plus OPG 
for another 48h. For cMyc inhibition, the cells were pre-treated with 20 µM cMyc inhibitor, 
10058-F4 for 4h before treatment with RANKL for LNCaP cells. The cells were then harvested 
and extracted for protein lysate using 1X passive lysis buffer (Promega, Madison, WI). The 
lysate was centrifuged at 13,200 rpm at 4°C for 10 min, and the supernatant was collected for 
luciferase assay by mixing 20 µl of protein lysate with 100 µl of substrate (luciferin). The 
luciferase activity of each sample was measured by a BD Monolight 3010 luminometer (BD-
Pharmingen, San Diego, CA). The rest of the protein lysate was used for measuring β-gal activity, 
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and the relative luciferase activity of each sample was calculated by normalizing to the β-gal 
activity.  
Prostate Cancer Tissue Specimens   
Formalin-fixed and paraffin-embedded (FFPE) human prostate cancer specimens were obtained 
from Department of Pathology of the Cedars-Sinai Medical Center (IRB# Pro 00021228).  
Additional clinical prostate cancer tissue specimens were obtained from Dr. Fouad Habib at the 
University of Edinburgh, Scotland, and Dr. Hua Yang at the Jilin University, China.  Usage of 
clinical specimens was approved by the human tissue institutional review committees at the 
respective institutions. 
CRPC Xenografts   
To establish working protocols for single and sequential multiple QD labeling, we chose to  use a 
LTL-313 CRPC xenograft model since it mimics castration-resistant prostate cancer and  
provides consistent and readily available multiple tissue specimens critical for the development 
and establishment of a new MQDL protocol.  FFPE tissues from a castration resistant prostate 
cancer (CRPC) LTL-313 (Living Tumor Laboratory, www.livingtumorcentre.com) xenograft 
model were obtained from Vancouver Cancer Center, BC Cancer Agency, Vancouver, Canada.  
The LTL-313 tumor line was developed from prostate needle biopsy specimen from an 80-year 
old patient diagnosed with Gleason Score 8 prostate cancer with a serum PSA level of 17 ng/ml 
at the time of diagnosis (Andersen et al., 2010).  The tumor line development protocol was 
approved by the Clinical Research Ethics Board of the University of British Columbia, in 
accordance with the Laboratory Animal Guidelines of the Institute of Experimental Animal 
Sciences (Human specimen use was with approvals from University of British Columbia, 
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Canada (IRB# UBC BCCA REB #H04-60131).  Briefly, to establish castration-resistant prostate 
cancer, fresh LTL-313 tumor tissues from the 5th generation of grafting were cut into 3 × 3 × 1 
mm pieces and re-grafted into the subrenal capsules of male NOD-SCID mice.  The animals 
were maintained for tumor formation for two months before castration to remove androgens.  
Three weeks after castration, when the tumor volume was significantly reduced, the remaining 
tumor tissues were harvested and prepared as FFPE tissue blocks.  Xenongraft tissues used in 
this study were derived from 9 tumors from castrated mice and 5 tumors from 5 intact mouse 
hosts supplemented with testosterone that had undergone sham operation. 
Single QD Labeling (SQDL)   
The IHC staining protocol was modified for single QD labeling.  Streptavidin-conjugated QDs 
(565-, 585-, 605-, 625-, 655- and 705 nm) were prepared as 10 nM in PBS with 6% IgG-free, 
protease-free BSA (Jackson Immunoresearch; West Grove, PA).  Antigen retrieved tissues or 
fixed cell samples were incubated in PBS containing 2.5% horse serum (Vector Laboratories) 
and 20% Streptavidin Block Reagent (Invitrogen) for 20 minutes, followed by treatment with 
primary Abs as described above in the above immunoreagents section in PBS plus 1% horse 
serum and 20% Biotin Block Reagent (Invitrogen) at 4oC overnight.  After a 3 × 5 min PBST 
(PBS+ 0.4% Triton X-100) rinse specimens were incubated with the secondary Ab cocktail at 
room temperature for 30 min and then incubated with the respective streptavidin-QD at 37oC for 
60 min.  At the end of each incubation, the specimens were subjected to routine 3 x 5 min PBST 
(PBS+ 0.4% Triton X-100) rinse.  After the final rinse, the slides were mounted in aqueous 
mounting media containing 4'6-diamidino-2-phenylindole (DAPI) (Vector Laboratories) for 
imaging.  The Ab dilutions were described in the IHC section above. 
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Multiplexed QD Labeling (MQDL)   
The single QD labeling protocol was modified for MQDL, in which a single tissue section was 
subjected to staining for multiple markers in a sequential manner.  For each biomarker test, 
labeling started with a streptavidin blocking, followed by primary Ab reaction and biotinylated 
secondary Ab incubation, and reaction with streptavidin-conjugated QD at a specified 
wavelength.  Sections were incubated sequentially (with a 3 x 5 min PBST rinse after each 
incubation).  Primary Abs and dilutions in MQDL were identical to those used for SQDL.  The 
immunoreaction sequences were: 1) Anti-Neuropilin-1 Ab, 2 hours, room temperature; 
biotinylated horse anti-goat IgG, at room temperature, 30 min; streptavidin-QD705, at 37°C, 1 
hour.  2) Anti- p-c-Met Ab, at 4oC, overnight; biotinylated horse anti-rabbit IgG, at room 
temperature, 30 min; streptavidin-QD655 at 37°C, 1 hour.  3) Anti-VEGF Ab, at room 
temperature, 2 hours; biotinylated horse anti-rabbit IgG, at roomtemperature, 30 min; 
streptavidin-QD625 at 37°C, 1 hour.  4) Anti- p-p65-NFκB Ab at 4oC, overnight; biotinylated 
horse anti-rabbit IgG at room temperature, 30 min; streptavidin-QD565 at 37°C, 1 hour.  5) Anti- 
RANKL Ab at room temperature, 2 hours;  biotinylated horse anti-mouse IgG at room 
temperature, 30 min; streptavidin-QD585 at 37°C, 1 hour.  6) Mounting in aqueous mounting 
media containing DAPI.  Ab concentrations were described in the IHC section.  Sections of 
FFPE LNCaP-RANKL human prostate cancer cells were used as a positive control.  For negative 
control, primary Abs were replaced with isotype- and species-matched control Abs and applied 
to an immediately adjacent tissue section, and MQDL was performed in parallel with the tissue 
slide labeled with the testing primary Abs. 
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Spectral imaging 
Image acquisition   
A CRi spectral imaging system (Caliper Life Sciences, Hopkinton, MA) with built-in Nuance 
v3.1 software was used to document multispectral images following the manufacturer’s 
recommended protocol.  For each field of cancer tissue, serial images were acquired at a 10 nm 
wavelength interval from 450 to 800 nm, a range chosen corresponding to the active fluorescent 
QDs.  It generates an unprocessed image “cube” as a stack of 36 separate images with each 
image containing the complete spectral information for every pixel at that given wavelength.  All 
images were acquired at 400 × magnification, with a 50 milliseconds exposure.  To avoid 
variations in labeling due to cell heterogeneity, five images from different cancerous tissue sites 
were taken for each tissue specimen for subsequent quantification. 
Image deconvolution   
Image deconvolution or unmixing protocol was used to extract specific labeling by a specified 
QD.  A spectral library for 565, 585, 605, 625, 655, and 705 nm was built for deconvolution by 
performimg multiple SQDLs using androgen receptor (AR) antibody without final DAPI 
counterstaining on serially adjacent tissue sections.  The positive labeling of AR was confirmed 
by parallel IHC staining on adjacent tissues.  The spectrum of DAPI was obtained by mounting 
the adjacent tissue in the aqueous mounting medium containing DAPI.  Spectra of tissue 
autofluorescence were acquired for each tissue from a negative control slide (see MQDL section) 
prepared by IHC without fluorescent markers.  Autofluorescence reduction was performed using 
Real Component Analysis plug-in software.  The spectral library was then used to unmix the 
cube.  The separate spectral contributions to the data ‘cube’ are outputted as designated colored 
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intensity maps.  These images represent the distribution of each of the QDs and autofluorescence 
in the tissue.  After the deconvolution of the images, the background labeling was filtered and 
only the true positive signals were shown on the images of the Figures presented. 
Signal quantification   
The spectral library was used to deconvolute the imaging cube to extract labeling of individual 
QD using inForm v1.3 software (Caliper) following the recommended strategy.  First, a training 
set comprising two classes of tissue was created: ‘cancer’ and ‘non-cancer’.  The software was 
trained on these areas using the spectra of both the DAPI counterstain and the multiplexed QD 
immunolabeling and tested on 50 randomly selected cells from each image to determine the 
accuracy of differentiating the two classes.  This process was repeated until further iterations no 
longer improved the accuracy.  Histological H/E images were then used to localize cancer cells 
based on nuclear DAPI labeling.  A built-in algorithm was then used to define the cytoplasmic vs. 
nuclear subcellular regions.  Based on an analysis of images at 400 × magnification, the optimal 
threshold settings approximated: fixed scale 200, minimum blob size 20, maximum blob size 
10,000, circularity threshold 0, edge sharpness 0, fill hole enabled (nuclear parameters); inner 
distance to nucleus 1, outer distance to nucleus 7, minimum cytoplasm sample size 1, minimum 
signal range 0, maximum signal range 65535 (cytoplasmic parameters).  To eliminate non-
specific signals at the specified spectrum, an acellular area within the field being analyzed was 
used as background labeling.  QD fluorescence intensity in each cell was exported to an Excel 
spreadsheet (Microsoft, Seattle, WA) and subjected to statistical analysis (Ghazani et al., 2006; 
Liu et al., 2010). 
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Statistical Analysis 
Student’s t-test was used for statistical analysis between most of the experimental groups and 
control groups. Significance (P value) between the experimental and the control smaple smaller 
than 0.05 is annotated as * ,and  if P value smaller than 0.005 is annotated as **.  
One-way ANOVA was used to analyze the population scores between the two stages of cancer 
progression (Bone vs. benign, well-differentiated, or poorly-differentiated, or well-differentiated 
vs. benign) for RANKL IHC scoring (*** = P<0.001; ** = P<0.05 over the benign tumors).  
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CHAPTER 3 AUTOCRINE AND PARACRINE CELL SIGNALING MEDIATED BY 
RANKL-RANK INTERACTION PROMOTES EPITHELIAL TO MESENCHYMAL 
TRANSITION AND PROGRESSION OF HUMAN PROSTATE CANCER CELLS 
Introduction 
Epithelial to mesenchymal transition (EMT), an essential process during embryonic development, 
is an event where epithelial cells lose their polarity and cell-cell contacts and undergo extensive 
cytoskeleton remodeling at the migration and invasion front (Kang & Massague, 2004). EMT is 
also known to play an important role in tumor progression and metastasis (Boyer et al., 2000; 
Hotz et al., 2007). Cells undergoing EMT are characterized by loss of intercellular contacts and 
gain of mesenchymal phenotype with enhanced motility and invasiveness, and such 
morphological and behavioral switches allow the transition of cancer cells from an indolent state 
to a malignant state, leading to tumor invasion, dissemination, and metastasis. This 
morphological transition is accompanied by the loss of the epithelial-specific marker E-cadherin, 
which is the first and most critical event during EMT, followed by up-regulation of 
mesenchymal-associated genes such as N-cadherin, vimentin, or fibronectin. Such changes in 
gene expression with decreased E-cadherin and increased N-cadherin or vimentin expression 
during EMT are consistently observed in various cancers with enhanced tumor growth and 
invasiveness leading to tumor progression and metastasis (Huber et al., 2005; Thiery, 2002).  
The process of EMT can be triggered by many growth factors, such as TGF-β, EGF, IGF, and 
FGF, leading to the activation of multiple interrelated signaling pathways and various signaling 
molecules, including tyrosine kinsases (RTK), Ras/MAPK, Src, PI3K/AKT, Wnt/β-catenin, and 
NF-κB-, Notch-, and Hedgehog-dependent signaling (Boyer et al., 2000; Guarino et al., 2007; 
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Huber et al., 2005; Thiery & Sleeman, 2006).  Most of these pathways converge on the 
repression of E-cadherin expression and the activation of mesenchymal gene expression through 
the modulation of many transcription factors, contributing to the molecular mechanisms of EMT. 
The loss of E-cadherin function during tumor progression can be genetically or epigenetically 
regulated. In most cases, E-cadherin expression is down-regulated at the transcriptional level by 
zinc-finger transcription factors Snail or Slug (Bolos et al., 2003; Nieto, 2002) and a basic helix-
loop-helix transcription factor Twist (Yang et al., 2004), which are both strong repressors of E-
cadherin transcription and potent inducers of EMT. Snail and Twist negatively regulate E-
cadherin transcription by binding to E-box motifs in E-cadherin promoter (Nieto, 2002; Yang et 
al., 2004), and they are capable of increasing N-cadherin expression in human prostate and 
gastric cancer (Alexander et al., 2006; Hotz et al., 2007; Rosivatz et al., 2002). Moreover, their 
expression has been reported to be correlated with prostate and breast cancer progression and 
metastasis (Karreth & Tuveson, 2004; Kwok et al., 2005). 
Prostate cancer is the most commonly diagnosed cancer and the leading cause of death among 
men in the United States. Advanced and metastatic prostate cancer frequently causes bone 
metastases (Y. Li et al., 2006), and about 80% of prostate cancer patients (Landis, Murray, 
Bolden, & Wingo, 1999) will have bone metastasis, which is usually incurable. The bone 
microenvironment particularly serves as a growth-factor and extracellular-matrix-rich site for 
prostate cancer cells to colonize. Two major cell types in bone, the bone-resorbing osteoclasts 
and the bone-forming osteoblasts, are known to interact with prostate cancer cells contributing to 
the subsequent mixed osteosclerotic and osteolytic lesions found in clinical human prostate 
cancer bone metastatic specimens (Boyce & Xing, 2007; Roato et al., 2008; Roodman, 2004; 
Rosivatz et al., 2002).  
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RANKL, a receptor activator of NF-κB ligand, is a member of the tumor necrosis factor (TNF) 
superfamily and a master regulator of bone remodeling. RANKL exits in both a membrane-
bound and a secreted form. The latter is a result of proteolytic cleavage by MMPs or alternative 
splicing (Ikeda et al., 2001; Lynch et al., 2005). RANKL is primarily expressed on the surface of 
osteoblasts and marrow stromal cells and is released by activated T cells (Roodman, 2004). 
RANKL exerts its action by binding to its receptor RANK on osteoclasts in a paracrine manner 
to promote osteoclast maturation and hence osteoclast-induced bone resorption (Kong et al., 
1999; Yasuda et al., 1998). Osteoblasts also express and secrete OPG, which is a decoy receptor 
of RANKL, to regulate or fine-tune the RANKL activity. RANKL has recently been shown by 
our laboratory (Odero-Marah et al., 2008; Zhau et al., 2008) and others (Boyce & Xing, 2007; 
Chen et al., 2006; Huang et al., 2002; Jones et al., 2006) to be expressed in malignant prostate 
cancer cells, which also express its receptor, RANK.  Our previous data also showed that 
RANKL was up-regulated along with other mesenchymal markers in Snail- or EGF plus TGF-β-
induced EMT of prostate cancer cells, therefore indicating RANKL as a novel EMT marker 
during prostate cancer progression (Odero-Marah et al., 2008; Zhau et al., 2008).  
In this study, we further examined whether RANKL could be a mediator of EMT in human 
prostate cancer cells. Using the ARCaPE/ARCaPM prostate cancer progression model and non-
metastatic LNCaP cells, we demonstrated that RANKL was capable of inducing EMT 
progression, migration, and invasion of prostate cancer cells. Moreover, RANKL stimulated its 
own expression in an autocrine fashion in prostate cancer cells, and the increased RANKL 
expression by prostate cancer cells could further activate osteoclast precursors in a paracrine 
fashion to induce osteoclastogenesis and subsequently increase bone resorption, leading to 
osteolytic lesions. Together, RANKL promoted survival, EMT progression, and bone metastasis 
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in human prostate cancer cells. Therefore, it is essential to understand the cellular mechanisms 
and the downstream targets by which RANKL promotes prostate cancer survival, EMT 
progression, and bone metastasis, which can be exploited for the future development of potential 
therapeutic treatments for the prevention of prostate cancer-induced bone metastasis.  
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Results 
RANKL Expression Is Correlated with Human Prostate Cancer Progression  
We previously identified RANKL as a novel marker for prostate cancer EMT progression 
(Odero-Marah et al., 2008). To further confirm the significance of RANKL in human prostate 
tumor progression, we examined RANKL expression in clinical prostate cancer tissue specimens 
of differing Gleason grade and tumor stage using an established IHC protocol. We took special 
steps including the use of multiple anti-RANKL antibodies from commercial sources, 
immunoadsorption of these antibodies by recombinant RANKL protein, and validation of 
RANKL expression in experimental human prostate cancer cells and xenograft tissues by RT-
PCR and western blots. Using the well-characterized anti-RANKL monoclonal antibody, we 
assessed RANKL expression on one commercial TMA of benign and prostate cancer specimens 
and two custom-made TMAs containing well- and poorly-differentiated and bone metastatic 
prostate cancer specimens. We observed low levels of staining for RANKL in benign prostate 
tumor (N=20) but positive staining in both the nucleus and cytoplasm in well- and poorly-
differentiated human prostate cancer specimens (Fig.1A, well differentiated N=18; poorly 
differentiated N=39). Significantly stronger immunostaining for RANKL was observed in the 
bone metastases (Fig.1A N=43). Statistical analysis (one-way ANOVA) further confirmed the 
significantly higher expression of RANKL in the bone metastatic specimens over benign, well-
differentiated (P<0.001), and poorly-differentiated prostate cancers (P=0.035) (Fig. 1B). 
RANKL expression in primary tumor was also higher compared to benign tumor (P=0.023).  
These immunohistochemical results support a positive correlation between the level of RANKL 
expression and the progression of clinical prostate cancer specimens with increased RANKL 
expression from benign to locally invasive status, and to skeletal metastases.  
 47 
We next examined RANKL, RANK, and OPG expression at both the mRNA and protein levels 
in several pairs of isogenic human prostate cancer cell lines with differential propensity for bone 
and soft tissue metastases. Two osteosarcoma cell lines, MG-63 and SaOS-2, served as positive 
controls. Differential expression at mRNA and protein levels of RANKL, RANK, and OPG was 
observed in each pair of these isogenic cell lines (Fig. 1B and 1C).  Positive correlations of 
RANKL expression and the aggressiveness of human prostate cancer cell lines were observed 
with higher expression in ARCaPM, C4-2/C4-2B, and PC-3M cells than the corresponding 
parental, ARCaPE, LNCaP, and PC-3 cells. Higher levels of RANKL expression were found in 
more aggressive osteosarcoma MG-63 than in indolent SaOS-2 cells. The RANKL receptor, 
RANK, was expressed by all of the prostate cancer cell lines, and strong expression was 
observed in ARCaPM and PC3M cells.  RANK mRNA expression is not always correlated with 
RANK protein expression in LNCaP cells.  While an inverse relationship of protein expression 
was observed between RANKL and OPG, there was no correlation between RANKL and OPG 
mRNAs. In the ARCaP EMT prostate cancer progression cell model (Xu et al., 2006), we 
demonstrated consistently that the more invasive and metastatic ARCaPM cells had stronger 
expression of the RANKL/RANK/OPG triad than the less invasive ARCaPE cells. Among these 
isogenic prostate cancer cell line pairs, ARCaPE and LNCaP cells showed the lowest expression 
level of RANKL, RANK, and OPG. Collectively, these results indicated that RANKL, RANK, 
and OPG were expressed by most of the human prostate cancer cell lines we examined, and their 
levels of expression generally correlated with the virulence of these cells.  
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Figure 1. RANKL expression is expressed in clinical prostate cancer and cancer bone 
metastasis.  RANKL, RANK, and OPG are differentially expressed in human prostate cancer 
cell lines. A, RANKL expression was examined in clinical human prostate cancer specimens by 
immunohistochemical (IHC) staining. RANKL expression is negative or low in benign tumors 
but positively stained in well- and poorly- differentiated primary human prostate tumors and in 
prostate tumors metastasized to the skeleton.  RANKL expression may be correlated with human 
prostate cancer progression and bone metastasis. B, Relative score of RANKL IHC staining in 
benign (N=20), well-differentiated (N=18), poorly-differentiated (N=39), and bone metastatic 
prostate tumors (N=43). (*** = P<0.001; ** = P<0.05 over the benign tumors). C, 
RANKL/RANK/OPG expression was examined in different human prostate cancer (ARCaPE, 
ARCaPM, LNCaP, C4-2, C4-2B, PC-3, PC-3M) and human osteoblastic tumor cell lines (MG-63 
and SaoS-2).  The expression was shown by both RT-PCR (left panel) and western blot (WB, 
right panel).    
C. 
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RANKL Induces EMT Progression of Prostate Cancer 
Given our early observation that RANKL expression increased corresponding to EMT induced in 
ARCaPE cells upon addition of soluble growth factors (Odero-Marah et al., 2008; Zhau et al., 
2008), we examined if exogenously added recombinant RANKL, or forced RANKL expression 
genetically in prostate cancer cells, may contribute directly to their mesenchymal transition.  We 
used two cell models for this study, the ARCaP EMT cell model (Xu et al., 2006) and the 
LNCaP cell model (Thalmann et al., 2000).  Our previous investigations revealed that ARCaP 
cells when provoked to assume EMT by soluble growth factors underwent morphologic, 
biochemical and behavioral changes, whereas the LNCaP cell model when provoked to undergo 
EMT by soluble growth factors only exhibited biochemical and behavioral but not morphologic 
transition (Josson et al., 2011). ARCaPE cells exposed to 200 ng/ml recombinant RANKL 
protein gradually changed their morphology from cobble-stoned clusters to more dispersed and 
fibroblastic-like appearance over the 8-day period (Fig. 2A). RANKL treatment down-regulated 
E-cadherin but up-regulated N-cadherin expression, reflecting a ‘cadherin switch’ with a 
replacement of E-cadherin by N-cadherin during EMT (Fig. 2B-1) (Maeda, Johnson, & 
Wheelock, 2005; Voulgari & Pintzas, 2009).  RANKL also induced up-regulation of Snail, 
vimentin, and RANKL expression, consistent with the previous observation that these markers 
are associated with EMT (Zhau et al., 2008). The ability of recombinant RANKL to induce its 
own expression is restricted to such cancers as prostate (ARCaP and LNCaP) and osteosarcoma 
(MG-63 and Saos-2) cells but not normal prostate (PrEC and RWPE-1) or bone (RAW264.7) 
cells (data not shown).  OPG, a decoy receptor of RANKL, was found to antagonize RANKL-
RANK interaction and block RANKL-induced EMT and cadherin switch in ARCaPE cells (Fig. 
2B-2).  Further, Figure 2B-3 shows that by exposing ARCaPM to OPG, EMT was reversed, both 
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morphologically (reversal to epithelial morphology) and biochemically (expression of 
mesenchymal cell associated genes and reversal of cadherin switch).  These results were 
confirmed by a genetic approach where depleting endogenous RANKL by RANKL siRNA 
induced mesenchymal to epithelial transition (MET) (Fig. 2B-4).  The functional role of 
exogenously added RANKL in the induction of EMT was also confirmed in the LNCaP cell 
model (Fig. 2B-5).  
The functional role of RANKL in provoking EMT in the ARCaP cell model is also supported by 
the in vitro migration and invasion behaviors of ARCaP
 
and LNCaP cells. Recombinant RANKL 
treatment increased the migration and invasion of ARCaPE and LNCaP cells, and these changes 
were abrogated by the presence of OPG (Fig. 2C).  Likewise, ARCaPM and LNCaP-RANKL 
cells expressed higher intrinsic levels of RANKL and also gained increased migratory and 
invasive phenotypes, which were antagonized by OPG treatment.  These results are consistent 
with the presence of an autocrine loop involving RANKL-RANK that is capable of driving the 
morphologic, biochemical and/or behavioral transition of ARCaP and LNCaP cells from their 
lesser invasive epithelial phenotype to a more aggressive mesenchymal phenotype.  
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Figure 2. RANKL treatment induces morphological and biochemical changes wherein prostate 
cancer cells undergo EMT progression, leading to increased in vitro migration and invasion in 
ARCaPM cells. Addition of OPG can prevent the RANKL-induced EMT transformation of 
prostate cancer cells. A, ARCaPE cells were serum-starved overnight and treated with 200 ng/ml 
of trimerized recombinant RANKL protein (rRANKL) for 8 days. Cell morphological changes 
were observed at day 2, 5, and 8. Images were taken with light microscopy (20x magnification). 
B1, B2, and B5, Prostate cancer progression model; ARCaP and LNCaP cells were treated with 
200 ng/ml of rRANKL proteins alone or in the presence of OPG, a decoy RANK receptor, and 
biochemical changes of EMT-specific markers were examined by RT-PCR and Western blot 
analyses. RANKL decreased the epithelial marker E-cadherin and increased the mesenchymal 
markers vimentin, N-cadherin, and Snail. RANKL also increased its own expression. Addition 
of OPG abolished RANKL-induced biochemical EMT changes. B3 and B4, mesenchymal 
ARCaPM cells when treated with 1 µg/ml of OPG or transiently knocked down RANKL showed 
increased expression of epithelial marker but decreased expression of mesenchymal markers, 
indicating a reversal of EMT phenotype. C, RANKL protein treatment enhanced the migration 
and invasion of ARCaPE and LNCaP cells, which could be diminished in the presence of OPG. 
Consistently with these findings, ARCaPM cells when treated with 1 µg/ml of OPG, showed 
decreased migration and invasion potential. 
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Ectopic RANKL Expression Promotes EMT in Human Prostate Cancer Cells 
To establish a genetic basis defining the autocrine roles of RANKL in the promotion of EMT and 
prostate cancer progression, ectopically RANKL, tagged with either GFP or Flag, was enforced 
respectively in ARCaPE and LNCaP human prostate cancer cell lines. Clones stably expressing 
RANKL were isolated, characterized and in vivo tumorigenic and metastatic potential 
determined. Western blot analysis demonstrated the expression of RANKL with slightly shifted 
molecular weight corresponding to the sizes of GFP or Flag tag (Fig. 3A).  ARCaPE-RANKL 
showed morphologic transition to a mesenchymal phenotype, from a cobblestone to a more 
dispersed spindle-shaped appearance, when compared to the neo transfected controls (Fig. 3B).  
A lesser morphologic change was seen in LNCaP-RANKL cells, from their original spindle- and 
neuron-like morphology to a more round and oval shape morphology, when compared to neo-
transfected LNCaP cells.  These morphologic features induced by increased RANKL expression 
were also reflected in their biochemical properties, i.e. a switch of E-cadherin to N-cadherin, 
vimentin, Snail, and RANKL expression. Moreover, RANKL overexpression in both ARCaPE 
and LNCaP cells also stimulated endogenous RANKL expression at both transcript and protein 
levels (Fig. 3A), supporting earlier results where adding exogenous recombinant RANKL to 
these human prostate cancer cells induced RANKL expression (see Fig. 2B).   The functional 
roles of RANKL in ARCaPE and LNCaP cells were determined in vitro. Enforced RANKL 
exerted no growth effects on either ARCaPE or LNCaP cells (Fig. 3D). ARCaPE-RANKL and 
LNCaP-RANKL transfectants, however, displayed enhanced migration and invasion compared 
to the Neo control cells (Fig. 3E). The increase in cell migration and invasion were suppressed 
by OPG, suggesting increased autocrine RANKL-RANK interaction upon enforced RANKL 
expression. Moreover, ARCaPE-RANKL and LNCaP-RANKL also promoted in vitro soft agar 
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colony formations, implying an enhanced tumorigenic potential of these cells conferred by 
RANKL expression. The enhanced tumorigenicity of ARCaPE-RANKL and LNCaP-RANKL 
cells can be attenuated upon the addition of OPG, lowering the number of colony formations in 
soft agar (Fig. 3F).   
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Figure 3. RANKL overexpression also promoted EMT progression of prostate cancer cells 
and increased their migration and invasion potential. A, Characterization of RANKL 
overexpression in ARCaPE and LNCaP cells by Western blot analysis. RANKL expression 
constructs were tagged with GFP or Flag proteins, and RANKL overexpression was detected 
by RANKL, GFP, or Flag antibodies. B, RANKL overexpression changed the morphology of 
ARCaPE and LNCaP cells detected under light microscopy (10x and 20x magnification). 
Since the RANKL expression construct introduced into the ARCaPE cells had a GFP tag, 
RANKL overexpression was also detected using fluorescent microscopy. RANKL was shown 
to be expressed on the membrane, cytosol and nuclei of the genetically tagged cells (10x and 
20x magnification). Progressive morphological changes in LNCaP cells were induced by 
RANKL expression, but LNCaP-Neo cells demonstrated no morphological change. C, 
RANKL overexpression also induced EMT changes at the molecular level. D, Stable clones 
overexpressing RANKL or Neo constructs were established in both ARCaPE and LNCaP 
cells, and their proliferation rates were examined by MTS assay. RANKL was found not to 
affect the basal cell proliferation rate of ARCaPE and LNCaP cells. E, RANKL 
overexpression, however, increased cell migration and invasion of ARCaPE and LNCaP cells, 
which were antagonized upon addition of OPG. F. RANKL increased the tumorigenic 
potential of both LNCaP and ARCaP cells by inducing increased anchorage-independent 
colony formation compared to LNCaP-Neo and ARCaPE-Neo cells, and such induction could 
be attenuated upon addition of OPG.  
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RANKL Expression in ARCaPE and LNCaP Cells Induces In Vitro Osteoclastogenesis 
To determine if the enforced RANKL is biologically functional, we compared the ability of both 
the Neo controls and RANKL-expressed ARCaPE and LNCaP cells to induce osteoclast 
maturation in an in vitro osteoclastogenesis assay to quantify the numbers of matured osteoclasts 
(Lacey et al., 1998; Yasuda et al., 1998). Mouse macrophage RAW264.7 cells, known to be 
osteoclast precursors, were co-cultured with ARCaPE-RANKL or LNCaP-RANKL cells; stably 
Neo-expressed ARCaPE and LNCaP cells served as controls. Ectopically expressed RANKL in 
ARCaPE and LNCaP cells induced significantly increased numbers of large and matured 
osteoclasts (no. of nuclei >3), which were equivalent to that induced by 100 ng/ml of trimerized 
RANKL protein; ectopically Neo-expressed ARCaPE and LNCaP cells induced only a few 
mature osteoclasts (Fig. 4).  Addition of OPG decreased by approximately two-fold the 
formation of mature osteoclasts induced by ARCaPE-RANKL and LNCaP-RANKL cells, but 
had very minimal blocking effects against osteoclastogenesis induced by Neo-transfected control 
cells. These results further confirmed that RANKL produced by ARCaPE-RANKL or LNCaP-
RANKL cells is biologically functional and capable of mounting an enhanced osteoclastogenesis 
reaction in vitro. 
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Figure 4. RANKL expressed in ARCaPE and LNCaP cells was found to be biologically active 
driving the maturation of cancer cell-adjacent osteoclast precursor cells in a paracrine fashion. 
A, RANKL-expressing ARCaPE and LNCaP cells were co-cultured with osteoclast precursor 
RAW-264.7 cells in the presence or absence of OPG for five days, and TRAP+ multinucleated 
mature osteoclasts were stained and counted under light microscopy. Addition of 100 ng/ml of 
RANKL protein to RAW264.7 cells served as positive control. RANKL overexpressed by 
ARCaPE and LNCaP cells induced five-fold more TRAP+ mature osteoclasts than Neo control 
cells, indicating that RANKL expressed by ARCaPE and LNCaP cells was functional. B, 
Representative images of TRAP+ multinucleated mature osteoclasts induced by RANKL 
protein in ARCaPE-RANKL and LNCaP-RANKL as well as Neo control cells in the presence 
or absence of OPG (20x magnification).  
B. 
A. 
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RANKL Promotes EMT by Activation of NF-κB through an Akt and P38 Dependent 
Mechanism in Prostate Cancer Cells 
The autocrine action of tumor cell-derived RANKL on the cell surface receptor RANK in 
prostate cancer cells was studied. RANKL expressed in both ARCaPE and LNCaP cells 
significantly activated the PI3K-Akt, P38 MAPK, and NF-κB signaling pathways by increasing 
the phosphorylated levels of Akt on serine 473, P38 on tyrosine 180, and P65 on serine 536. 
Nevertheless, RANKL did not activate other MAPKs, such as Erk1/2 and JNK/SAPK (Fig. 5A).  
RANKL-RANK interaction is therefore capable of inducing multiple downstream signaling 
pathways in prostate cancer cells similar to RANK activation in osteoclasts (Boyle, Simonet, & 
Lacey, 2003; Wada et al., 2006). Subsequently, we examined the effect of kinase inhibitors 
specific for Akt, P38, and NF-κB on RANKL-induced EMT. We treated both ARCaPE-RANKL 
and LNCaP-RANKL cells with 20 µM of a PI3K inhibitor, LY294002, 20 µM of a P38 inhibitor, 
SB203580, and 2 µM of NF-κB or proteasome inhibitor, PS341 respectively for 4h followed by 
western blot analysis.  As can be seen in Fig. 5B, PI3K and NF-κB inhibitors both increased E-
cadherin and decreased vimentin and RANKL expression in ARCaPE-RANKL cells, leading to a 
reversal of EMT, and similar results were observed in LNCaP-RANKL cells treated with either a 
P38 or a NF-κB inhibitor. This result shows that direct inhibition of NF-κB signaling prevented 
RANKL-induced EMT in both ARCaPE-RANKL and LNCaP-RANKL cells. Moreover, we 
observed that PI3K inhibitor also reduced the phosphorylated level of P38, and subsequently P38 
inhibitor resulted in a reduction in phosphorylated level of P65 in both cell types, thus suggesting 
transactivation of cell signaling axes in the sequence of Akt, P38, and P65 stimulation by 
RANKL in prostate cancer cells. These findings are consistent with previous studies showing 
that PI3K-Akt transactivates P38, which further activates NF-κB transcriptional activity through 
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phosphorylation of P65 upon TNF-α stimulation (Madrid, Mayo, Reuther, & Baldwin, 2001; 
Viatour, Merville, Bours, & Chariot, 2005). Therefore, we conclude that RANKL promoted 
EMT by activation of the NF-κB pathway through an Akt and P38 dependent mechanism in 
prostate cancer cells.  
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Figure 5. RANKL induced EMT in prostate cancer cells by activating NF-κB signaling 
through AKT and p38 dependent pathways. A, RANKL activated PI3K-AKT, p38, and NF-κB 
by increasing their phosphorylation levels in ARCaPE and LNCaP cells as detected by Western 
blot analysis. B, ARCaPE-RANKL and LNCaP-RANKL cells were treated with PI3K (20 µM 
LY294002), p38 (20 µM, SB203580), and NF-κB (2 µM, PS341) inhibitors for 4 hours, and 
the cells were harvested for cell lysis followed by Western blot analysis. 
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Discussion 
Apart from the major role of RANKL in regulating bone remodeling in osteoclasts, there is a 
growing body of evidence to support the idea that RANKL-RANK signaling also exerts 
important functions in other tissue types, such as mammary gland development during pregnancy 
(Fata et al., 2000; Kong et al., 1999), lymph node organogenesis (Kong et al., 1999), and 
monocyte function and inflammatory responses (Seshasayee et al., 2004). However, how 
RANKL-RANK interaction might be involved in cancer development and progression has not 
yet been clearly elucidated. We previously showed that RANKL was expressed by malignant 
prostate cancer cells and its expression was up-regulated during prostate cancer EMT 
progression, serving as a novel EMT marker. In this study, we further show that RANKL is 
directly involved in driving the EMT progression and bone metastasis of prostate cancer cells. 
Moreover, blocking RANKL with OPG can reduce prostate cancer-induced osteolytic lesions.  
Our data first demonstrated that RANKL expression was closely associated with clinical human 
prostate tumor progression where RANKL expression is significantly elevated in bone 
metastases and poorly-differentiated prostate cancer compared to a low level of expression in 
benign and a moderate level in well-differentiated prostate cancer specimens. 
RANKL/RANK/OPG triad was found to be expressed by various prostate cancer cell lines at 
different levels (Fig 1). Importantly, we further demonstrated that RANKL treatment or 
overexpression induced indolent human prostate cancer cells, such as ARCaPE and LNCaP cells, 
to undergo EMT, leading to increased migration and invasion in vitro (Fig. 2 and 3). In 
agreement with other studies, activation of RANK can enhance cell migration and invasion of 
prostate cancer cells as well as other epithelial cancer cells (Armstrong et al., 2008; Jones et al., 
2006; Sabbota et al.). Blocking RANKL with its decoy receptor OPG not only prevented 
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RANKL-induced EMT of ARCaPE and LNCaP cells, but also converted the mesenchymal 
phenotype and behavior of ARCaPM cells to become more epithelial-like with decreased levels 
of mesenchymal markers and reduced migration and invasion, a phenomenon known as EMT 
reversal (Fig. 2). RANKL expression is stimulated by many osteotropic and growth factors, such 
as TGF-β, PTHrP, and prostaglandin E2 (Roodman, 2004; Virk & Lieberman, 2007). To our 
knowledge, we are the first to demonstrate that RANKL treatment or overexpression triggered 
auto-induction of RANKL expression in prostate cancer cells (Fig. 2B and 3A). Increased levels 
of RANKL can therefore activate RANK on prostate cancer cells in an autocrine manner to 
further substantiate their EMT progression and malignancy. Since our data showed that RANKL 
produced by prostate cancer cells is functional in inducing in vitro osteoclastogenesis (Fig. 4), 
one can further speculate that increased RANKL expression by prostate cancer cells can 
simultaneously bind to RANK on the surrounding osteoclast precursors in a paracrine manner to 
activate osteoclast maturation and bone resorption in the bone microenvironment. 
Since prostate cancer cells are well-known for their osteomimetic properties, which allow them 
to imitate the gene expression and behavior of the bone cells, we speculated that RANK 
activation in prostate cancer cells during EMT transformation might share similar signaling 
transductions with the differentiating osteoclast precursors. During osteoclastogenesis, RANKL-
RANK interaction activates multiple downstream signaling cascades, such as the NF-κB, P38, 
ERK, JNK, and Src-Akt pathways (Boyle et al., 2003; Jones et al., 2006). We therefore 
examined these signaling molecules in RANKL-overexpressing LNCaP and ARCaPE cells. We 
observed that only the NF-κB, P38, and PI3K-Akt pathways were activated in ARCaPE- and 
LNCaP-RANKL cells as well as RANKL-treated ARCaPE cells, but not the ERK or JNK 
pathways (Fig. 5A). We further asked which one of the three pathways is predominantly 
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activated and responsible for the RANKL-induced EMT progression and RANKL auto-induction 
in prostate cancer cells. We inhibited each of the three pathways with their specific inhibitors and 
examined the EMT markers as well as RANKL expression. Our data indicated that RANKL-
induced EMT was abrogated by inhibiting NF-κB signaling in both ARCaPE- and LNCaP-
RANKL cells; however, P38 or PI3K inhibitors also partially reverted the EMT markers and 
decreased RANKL expression in ARCaPE- or LNCaP-RANKL cells. Moreover, we observed 
that both p38 and PI3K inhibitors diminished the level of p65 phosphorylation, and p38 inhibitor 
had a stronger inhibitory effect on NF-κB activation than PI3K inhibitor, and in addition, PI3K 
inhibitor significantly reduced the phosphorylated level of p38 in both cells (Fig. 5B). Our results 
are therefore in agreement with several studies which have shown that activation of p38 MAPK 
is required for p65 phosphorylation and transcription function (Bergmann, Hart, Lindsay, Barnes, 
& Newton, 1998; Kuphal, Poser, Jobin, Hellerbrand, & Bosserhoff, 2004; Wesselborg, Bauer, 
Vogt, Schmitz, & Schulze-Osthoff, 1997), and AKT can transactivate the p65 subunit of NF-κB 
through the activation of p38 MAPK (Madrid et al., 2001; Viatour et al., 2005). Furthermore, 
studies using malignant melanoma also showed that the ERK pathway is not involved in NF-κB 
activation (Kuphal et al., 2004; Wang & Richmond, 2001). These results suggested that RANKL 
induces a sequential activation of signaling cascades from PI3K-AKT, p38, and then to NF-κB in 
ARCaPE- and LNCaP-RANKL cells. Therefore, RANKL mediates EMT transformation of 
prostate cancer cells by transactivating NF-κB signaling through AKT and P38 dependent 
pathways which are known to be involved in cancer cell survival, progression, and metastasis.  
In summary, RANKL expressed by prostate cancer cells or other cell types in the 
microenvironment binds to RANK on prostate cancer cells to drive EMT progression through the 
transactivation of NF-κB signaling in a p38 and/or PI3K-AKT dependent mechanism, and 
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RANKL-RANK interaction can further stimulate RANKL expression in prostate cancer cells, 
forming an auto-induction signaling loop. Furthermore, increased RANKL expression by 
prostate cancer cells can also activate osteoclast precursors in the bone microenvironment in a 
paracrine fashion to induce osteoclastogenesis and increase bone resorption, which subsequently 
releases growth factors richly stored in the bone. Together, the autocrine and paracrine signaling 
mediated by RANKL-RANK interaction creates a vicious cycle that steadily promotes the 
survival, EMT progression, and bone metastasis of human prostate cancer cells.  Targeting of 
RANKL and its downstream molecules may be a potential new therapeutic strategy for 
preventing prostate cancer progression and bone metastasis. 
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CHAPTER 4 RANKL EXPRESSING PROSTATE CANCER CELLS PROMOTE BONE 
METASTASIS AND TRANSFORM NON-TUMORIGENIC AND NON-METASTATIC 
PROSTATE CANCER CELLS TO CO-COLONIZE AT METASTATIC SITES 
Introduction 
Advanced prostate cancer, such as CRPC, has a propensity to metastasize to bone, and more than 
80% of CRPC patients will develop bone metastases with a high level of morbidity (Bubendorf 
et al., 2000; Horwich, 2004; Loberg et al., 2005) for which there is presently no cure. Bone 
metastasis is also associated with hypercalcemia, anemia, bone pain, recurrent infection, spinal 
cord compression, fractures and paralysis (Coleman, 1997, 2001; Ye et al., 2007). Although 
tumor genetic constituents and behavioral anomalies are now shown to be regulated by 
interactions between cancer cells and their microenvironment (Josson et al., 2011 ; Mundy, 
1997), the molecular mechanism of PCa bone colonization still remains elusive. Moreover, it is 
now well established that prostate cancer cells can home to bone but not necessarily colonize 
bone successfully; prostate cancer cells must interact reciprocally with bone cells by promoting 
bone resorption and new bone formation (Coleman, 1997; Mundy, 1997; Roodman, 2004).  
Even though emerging evidence has recently suggested the importance of RANKL-RANK 
interaction in breast and prostate cancer progression and metastasis (Jones et al., 2006; Josson et 
al., 2011 ; Odero-Marah et al., 2008; Zhang et al., 2001; Zhau et al., 2008), there is no animal 
model available depicting the role and behavior of RANKL-overexpressing prostate cancer cells 
in vivo. We have demonstrated that RANKL exogenous treatment or endogenous overexpression 
can induce EMT progression of prostate cancer cells such as LNCaP and ARCaPE at both the 
biochemical and morphological levels and enhance their in vitro migration, invasion, and 
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tumorigenic potential. In this study we investigated the in vivo role of RANKL in prostate cancer 
growth and metastases using RANKL-overexpressing LNCaP and ARCaPE cell models and 
examined their in vivo tumorigenic and metastatic potential through interaction with the 
microenvironments.  
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Results 
RANKL Facilitates Tumor Formation and Bone Metastasis of Human Prostate Cancer 
Cells In Vivo 
Though we showed the in vitro EMT progression of prostate cancer cells induced by RANKL, it 
is crucial to determine the in vivo effect of RANKL in terms of tumor formation and metastases. 
Therefore, we inoculated LNCaP-RANKL or LNCaP-Neo and ARCaPE-RANKL or ARCaPE-
Neo cells intracardially into male athymic nude mice to determine their tumorigenic and 
metastatic potentials. We found that RANKL expression significantly enhanced the metastatic 
potential of LNCaP and ARCaPE cells. LNCaP-RANKL and ARCaPE-RANKL cells induced 
100% and 70% incidence of gross bone metastases to various anatomical sites, including the legs, 
skull, ribs and spine, and an average of 72% and 65% incidence of gross soft tissue metastases to 
lymph nodes, adrenal glands, and lungs over a three-month observation period (Table 1; Fig. 6A).  
LNCaP-Neo cells, in contrast, failed to produce any tumor or metastasis, consistent with the 
known indolent nature of LNCaP cells (Wu et al., 1998).  ARCaPE-Neo cells also failed to 
induce any bone metastasis but showed 20% metastatic incidence to adrenal glands. Mice 
bearing LNCaP-RANKL and ARCaPE-RANKL cells also developed serious cachexia with 
extensive tumor burden mostly in the skeleton. We inspected mice with bone lesions using µCT 
analysis to determine the type of bone lesions induced by LNCaP-RANKL and ARCaPE-
RANKL cells. Previous studies by our laboratory (Thalmann et al., 1994; Wu et al., 1998) and 
others (Corey et al., 2002) showed that intratibial or orthotopic injection of LNCaP lineage-
derived C4-2, and C4-2B cells in immune-compromised mice produced mixed osteolytic and 
osteoblastic bone lesions. LNCaP or LNCaP-Neo cells, when injected intrafemorally or 
orthotopically in immune-compromised mice, however, failed to form tumors (Wu et al., 1994; 
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Wu et al., 1998), Table 1). Figure 6B shows 3D µCT scans of skeletons of mice bearing the 
LNCaP-Neo, LNCaP-RANKL, ARCaPE-Neo, and ARCaPE-RANKL cells.  Extensive bone 
destruction at femoral, pericranial, jaw, and spinal sites was observed in most of the mice bearing 
the LNCaP-RANKL and ARCaPE-RANKL cells with gross skeletal metastases but not in mice 
bearing the Neo control cells. These results indicated that LNCaP-RANKL and ARCaPE-
RANKL cells induced severe osteolytic bone lesions where the bones were heavily resorbed 
compared to the bone structure of the Neo control mice.  
We next sought histochemical evidence of RANKL expression and EMT phenotype in metastatic 
tumors from mice bearing the LNCaP-RANKL cells using IHC staining against flag-tagged 
RANKL and EMT markers. We observed that RANKL expression when detected with either 
Flag or RANKL antibody showed a stronger signal in the bone tumor at the bone/tumor interface 
compared to lymph node tumor. Both bone and lymph node metastatic tumors expressed high 
levels of N-cadherin and vimentin but low levels of E-cadherin expression, demonstrating the 
EMT progression of the tumor cells. Interestingly, we demonstrated that E-cadherin expression 
in both bone and lymph node metastatic tumors appeared to be in clusters or subsets of the tumor 
cells, showing a heterogeneous tumor cell population/clone. This phenomenon can be explained 
as the re-expression of E-cadherin during mesenchymal-to-epithelial transition (MET) to allow 
the establishment of metastatic tumor cells in the microenvironment at distant sites, following the 
metastases of disseminated tumor cells resulting from EMT. Such re-expression of E-cadherin 
during MET of metastatic tumor cells has been well demonstrated in many breast and prostate 
cancer metastases to bone and liver, indicating the epithelial plasticity of tumor cells (Chao, 
Shepard, & Wells, ; Kowalski, Rubin, & Kleer, 2003; van der Pluijm, 2010; Wells, Yates, & 
Shepard, 2008; Yates, Shepard, Stolz, & Wells, 2007). Since RANKL expressed by LNCaP cells 
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was biologically functional in inducing in vitro osteoclastogenesis, we further examined the 
osteoclastic activity in the bone tumors induced by LNCaP-RANKL cells intracardially 
inoculated in nude mice using TRAP staining. We observed an increased number of TRAP-
positive mature osteoclasts at the bone/tumor interface compared to normal bone from mice 
bearing the LNCaP-Neo cells (Fig 6D), which further confirms the biological functionality of 
RANKL produced by LNCaP cells in activating osteoclastogenesis in vivo.  
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Table 1. Metastatic incidence of LNCaP-RANKL and ARCaPE-RANKL vs LNCaP-Neo and 
ARCaPE-Neo cells in nude mice. RANKL- and Neo-expressing  LNCaP and ARCaPE cells were 
intracardially inoculated into male athymic nude mice. Mice were sacrificed three months after 
injection, and the tumors metastasized to the soft tissues and bone were harvested and evaluated 
for the metastatic incidence. Mice inoculated with LNCaP-Neo cells failed to form any visible 
metastatic tumor.  
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Figure 6. RANKL increased the metastatic potential of both LNCaP and ARCaPE cells and 
induced osteolytic lesions in bone. RANKL-induced tumors expressed mesenchymal phenotype 
and exhibited increased osteoclastic activity in bone. A, Representative images of metastatic 
tumors in bone and soft tissues induced by LNCaP-RANKL and ARCaPE-RANKL cells 
inoculated in nude mice (Metastatic sites are labeled and indicated by arrows). B, Representative 
3D µCT scans demonstrate osteolytic lesions in mouse femur, spine, skull, and tibia (outlined in 
red) induced by the LNCaP-RANKL and ARCaPE-RANKL cells inoculation in nude mice. C, 
Immunohistochemical (IHC) staining of RANKL and EMT marker expression in bone and soft 
tissue (lymph nodes) tumors induced by LNCaP-RANKL cells inoculated in nude mice. Using 
LNCaP-RANKL cells as a model, we showed that a small number of LNCaP-RANKL cells are 
sufficient to induce bone metastases in the presence of bystander RANKL non- or low-
expressing cells.  Importantly, histomorphology showed that both RANKL-expressing and low-
expressing cells reside in the bone metastasis tumors, suggesting the important function of 
RANKL in contributing to the overall bone metastases irrespective of the basal steady-state level 
of RANKL expression. D, TRAP staining of mature osteoclast lining (red) in bone tumor 
induced by the inoculation of LNCaP-RANKL cells in nude mice compared to the normal bone 
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RANKL Expressing Prostate Cancer Cells Promote Tumorigenesis of RANKL Non-
Expressing Prostate Cancer Cells in the Bone 
We further examined if there is cross-talk between RANKL-expressing and RANKL-non-
expressing prostate cancer cells to mimic the heterogeneous population of cancer cells in the 
bone microenvironment. We co-inoculated a thousand, ten thousand, and a hundred thousand 
LNCaP-RANKL cells and a million RANKL-low-or-non expressing LNCaP cells labeled with 
red fluorescent protein (LNCaP-RFP) intratibially and examined whether RANKL-expressing 
prostate cancer cells are capable of inducing neighboring RANKL-non-expressing prostate 
cancer cells to form tumors in the bone. We demonstrated that as few as a thousand LNCaP-
RANKL cells can promote the non-tumorigenic, RANKL-non-expressing LNCaP-RFP cells to 
grow tumors in mice tibia (Fig 7). We detected the presence of LNCaP-RFP cells using 
fluorescent imaging of the harvested tumors. We also found that as the number of LNCaP-
RANKL cells increased, the tibial tumors were bigger and the red fluorescent signal detected 
was stronger, implicating RANKL-expressing LNCaP cells augmentation of the tumorigenic 
potential of RANKL-non expressing LNCaP-RFP cells in the tumor microenvironment.  
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 Figure 7. Small numbers of RANKL-expressing PCa cells conferred tumorgenicity of RANKL-
non-expressing PCa cells in bone. One thousand, ten thousand, and a hundred thousand 
RANKL-expressing LNCaP (LNCaP-RANKL) cells were co-inoculated with a million RANKL 
non-expressing LNCaP cells tagged with red fluorescent protein (LNCaP-RFP) in both tibia of 
nude mice. Tibial and soft tissue tumors were harvested and subjected to fluorescent imaging for 
detection of the red fluorescent signal using the Xenogen imaging system at an excitation of 535 
nm and emission of 620 nm. Spleens were also harvested and used as controls. 
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RANKL-expressing PCa Cells Promote Co-colonization of Non-metastatic and RANKL-
non-expressing PCa Cells to the Metastatic Sites 
We next used the bone metastatic LNCaP-RANKL cell model plus indolent LNCaP-RFP cells to 
examine if RANKL-expressing prostate cancer cells are capable of promoting RANKL-low-or-
non-expressing and non-metastatic prostate cancer cells to proliferate and metastasize in vivo. 
We co-inoculated LNCaP-RANKL and LNCaP-RFP cells intracardially at a ratio of 1 to 9 and 9 
to 1, respectively. We also intratibially inoculated the LNCaP-RANKL cells first, followed by 
intracardial inoculation of the LNCaP-RFP cells. Mice bearing the LNCaP-RANKL plus 
LNCaP-RFP at a 9 to 1 ratio demonstrated 100% metastases to bone and an average of 65% 
metastases to soft tissues such as adrenal glands and lymph nodes. However, when co-
inoculation of LNCaP-RANKL and LNCaP-RFP cells at a 1 to 9 ratio, metastases to bone and 
soft tissues occurred only at a 60% and 30% incidence, respectively. When inoculating LNCaP-
RANKL cells intratibially followed by intracardial inoculation of LNCaP-RFP cells, all of the 
mice (n=5) demonstrated 100% tumor growth in the tibial bone as well as metastases to either 
adrenal glands or lymph nodes. When inoculating non-tumorigenic LNCaP-RFP cells 
intratibially followed by intracardial inoculation of LNCaP-RANKL cells, 50% of the mice (n=4) 
developed tibial tumors but we observed no soft tissue metastasis (Table 2). 
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Table 2. Metastatic incidence of LNCaP-Neo or LNCaP-RANKL plus LNCaP-RFP cells in 
nude mice. LNCaP-RANKL and LNCaP-RFP cells were intracardially co-inoculated into 
male athymic nude mice at a ratio of either 1 to 9 or 9 to 1 in a total of a million cells. Half a 
million of LNCaP-Neo plus half a million of LNCaP-RFP cells were also intracardially co-
inoculated into nude mice but failed to form any tumor or metastasis. A million LNCaP-
RANKL or LNCaP-RFP cells were also inoculated intratibially followed by intracardiac 
implantation of a million LNCaP-RFP or LNCaP-RANKL cells. Tumors metastasized to the 
soft tissues and bone were harvested and evaluated for the metastatic incidence.  
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We further examined the red fluorescent signals of the metastatic tumors harvested from the 
mice of all three groups using fluorescent imaging ex vivo to detect any presence of the LNCaP-
RFP cells in the tumors. Interestingly, we found that the metastatic bone and soft tissue tumors 
from all three groups exhibited the red fluorescent signals, especially the bone tumors compared 
to the normal organs such as spleen, bone, and kidney acting as negative controls.  In addition, 
red fluorescent signal was also detected in the tibia of mice bearing intratibial LNCaP-RFP cells 
plus intracardial LNCaP-RANKL cells, but not if the LNCaP-Neo cells were injected 
intracardially instead (Fig. 8A). Moreover, we also detected red fluorescent signals from frozen 
as well as paraffin-embedded tissue sections of the metastatic tumors under the fluorescent 
microscope (Fig. 8B and 8C). Alternatively, we stained the RFP on the paraffin-embedded tumor 
sections with antibody and further confirmed the presence of LNCaP-RFP cells in the bone 
tumors (Fig. 8C). We also performed multiplexed quantum dot (QD) labeling of RANKL and 
RFP on paraffin-embedded tumor sections to confirm the co-presence of LNCaP-RANKL and 
LNCaP-RFP cells in the bone tumor as well as to examine the level of RANKL expression by 
the bone-colonizing LNCaP-RFP cells (Fig. 8D).  We found that the number of colonizing 
LNCaP-RFP cells corresponds with the number of co-inoculated LNCaP-RFP cells in mice. We 
also observed that RANKL expression in the LNCaP-RANKL induced bone tumors is 
heterogeneous, suggesting the possibility that RANKL expression can be switched on/off by the 
prostate cancer cells depending on the surrounding microenvironment. Moreover, we discovered 
that the colonized LNCaP-RFP cells in the bone tumors also express high or moderate level of 
RANKL indicated by the co-localization (yellow) of RANKL (green) and RFP (red) labeling 
(Fig. 8D). This result further indicated that RANKL-expressing LNCaP-RFP cells lead to 
transformation from an indolent state to become metastatic. RANKL expression in LNCaP-RFP 
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cells may be induced by a mechanism of RANKL autocrine induction through a paracrine 
interaction with LNCaP-RANKL cells. Together, these results suggested that LNCaP-RFP cells 
co-colonized with the LNCaP-RANKL cells in the metastatic sites. LNCaP cells are known to be 
non-tumorigenic and non-metastatic; however, the co-existence of LNCaP-RANKL cells might 
transform and convey metastatic potential to the indolent LNCaP-RFP cells, allowing their co-
colonization to the bone and soft tissues with LNCaP-RANKL cells. Moreover, tumors induced 
by LNCaP-RANKL cells in the tibial bone also promoted homing of the LNCaP-RFP cells to the 
tumor sites. This observation might be well explained by the ‘seed and soil’ theory where the 
disseminated LNCaP-RANKL cells initially created a favorable environment by inducing 
osteolytic lesions in the bone, leading to the release of growth factors and cytokines that 
subsequently allowed the circulating LNCaP-RFP cells to colonize and grow in the bone lesions. 
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Figure 8. RANKL-expressing PCa cells promote co-colonization of non-metastatic and 
RANKL-non-expressing PCa cells at metastatic sites. A. Representative images and 
corresponding red fluorescent signal intensity of bone and soft tissue tumors harvested from 
nude mice bearing tumors with LNCaP-RANKL plus LNCaP-RFP cells at 1 to 9 and 9 to 1 
ratios and intratibial inoculation of LNCaP-RANKL cells followed by intracardiac inoculation 
of LNCaP-RFP cells. Representative in vivo X-ray and fluorescent images (Ex: 740; Em: 840) 
of intratibial inoculation of LNCaP-RFP cells followed by intracardiac inoculation of LNCaP-
RANKL cells. B. Representative red fluorescent microscopy detected from frozen sections of 
bone and soft tissue tumors harvested from each group (20x magnification).  Parts of the 
tumors were fixed in OCT and sectioned using Cryostat at -25 ºC and the red fluorescent 
signals of the frozen sections were detected using fluorescent microscopy. C. Representative 
images of red fluorescent microscopy and corresponding immunohistochemical staining of 
RFP and hematoxylin and eosin (H&E) staining from paraffin-embedded tumors of each 
group detected by light and fluorescent microscopy (25x magnification). D. Representative 
images of multiplexed quantum dot (QD) labeling of RANKL (green) and RFP (red) as well 
as merged QD labeling of paraffin-embedded tumor sections counterstained with DAPI 
nuclear staining (blue). Individual QD labeled protein expression is presented alone in 
pseudocolor, followed by a composite of the superimposed QD signals overlaid with nuclear 
DAPI staining. Images were acquired using the Cri spectral imaging system at 40x 
magnification. 
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Co-culture of RANKL-expressing and RANKL-non-expressing PCa Cells Induces 
Increased Osteoblastic Activity In Vitro and Mixed Osteolytic and Osteoblastic Lesions In 
Vivo 
We next sought to determine in vitro osteoblastic and osteoclastic activity in a co-culture of 
LNCaP-Neo or LNCaP-RANKL cells with LNCaP-RFP cells. We performed in vitro 
osteoclastogenesis and osteogenic assays by incubating the osteoclast (RAW 264.7 cells) and 
osteoblast (MC3T3 cells) precursors with LNCaP-RANKL, LNCaP-Neo, and LNCaP-RFP cells 
as well as with the co-culture of LNCaP-RANKL or LNCaP-Neo with LNCaP-RANKL cells at a 
1 to 9 ratio. We demonstrated that LNCaP-RANKL cells induced high levels of osteoclast 
differentiation but low levels of osteoblast mineralization compared to LNCaP-Neo or LNCaP-
RFP cells (Fig. 9A and 9B). Nevertheless, upon co-culture with LNCaP-RFP cells, the number of 
mature osteoclasts formed decreased and the osteoblast mineralization increased significantly 
compared to the LNCaP-RANKL cells alone. The levels of osteoclast maturation and osteoblast 
mineralization were comparable between the LNCaP-Neo, LNCaP-RFP cells and co-culture of 
both cell types (Fig. 9A and 9B). These results suggested that the presence of LNCaP cells can 
switch predominantly osteoclastic LNCaP-RANKL cells to become more osteoblastic-like.   
Furthermore, µCT scans demonstrated that mice bearing either a 1 to 9 or 9 to 1 ratio of LNCaP-
RANKL and LNCaP-RFP cells or intratibial LNCaP-RANKL plus intracardial LNCaP-RFP cells 
all displayed mixed osteolytic and osteoblastic lesions in the bone (Fig. 9C). Intratibial co-
inoculation of a thousand, ten thousand, and a hundred thousand LNCaP-RANKL cells plus 
LNCaP-RFP cells also led to mixed osteolytic and osteoblastic lesions (Fig. 9C). Next, we 
sought to examine the histological evidence of the mixed osteoyltic and osteoblastic phenotype 
in paraffin-embedded tumor sections. We combined TRAP (red staining of multinucleated 
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osteoclasts) as well as orange G (yellow orange staining of new bone formation) staining and 
demonstrated that the bone tumors from all three groups exhibited osteolytic as well as 
osteoblastic activities at the bone and tumor interface. Higher osteoblastic but lower osteolytic 
activity was observed in the bone tumors induced by a 1 to 9 ratio of LNCaP-RANKL and 
LNCaP-RFP cells as well as by the intratibial LNCaP-RANKL plus intracardial LNCaP-RFP 
cells (Fig. 9D). We alternatively demonstrated the increased level of osteoblastic activity in the 
tumors induced by the co-inoculation of LNCaP-RANKL and LNCaP-RFP cells by detecting the 
osteoid formation/thickness using Trichrome staining (Fig. 9E). The osteoid stained in red, and 
the mineralized bone stained in turquoise. The level of osteoid formation and thickness can 
reflect the level of bone formation (Ott, 2008). Together, these results indicated that the level of 
osteoblastic and osteoclastic phenotype displayed in the bone lesions seemed to be correlated 
with the number of LNCaP-RFP and LNCaP-RANKL cells, respectively, during the co-
inoculation.  
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Figure 9. Co-culture of RANKL-expressing and non-expressing PCa cells induces increased 
osteoblastic activity in vitro and mixed osteolytic and osteoblastic lesions in vivo. A. LNCaP-
RANKL and LNCaP-Neo cells were cultured alone or co-cultured with LNCaP-RFP at a 1 to 9 
ratio in the presence of pre-osteoblast MC3T3-E1-14 cells for 14 days, and the cells were stained 
with Alizarin Red, which was then extracted and quantitated by measuring at an absorbance of 
450 nm. B. LNCaP-RANKL and LNCaP-Neo cells were cultured alone or co-cultured with 
LNCaP-RFP at a 1 to 9 ratio in the presence of osteoclast precursor RAW264.7 cells for 7 days, 
and TRAP+ multinucleated mature osteoclasts were stained and counted under light microscopy. 
Addition of 100 ng/ml of RANKL protein to RAW264.7 cells served as positive control. C. 
Representative 3D µCT scans demonstrate a mix of osteolytic and osteoblastic lesions in mouse 
tibia induced by the LNCaP-RANKL and LNCaP-RFP tumor cell inoculation in nude mice. D. 
TRAP staining of mature osteoclast lining (red) and orange G staining of new bone formation 
(yellow orange) in bone tumor induced by the co-inoculation of LNCaP-RANKL and LNCaP-
RFP cells in nude mice. Images were taken by light microscopy at 12.5x and 25x magnification. 
E. Trichrome staining of osteoids and active bone formation (red), mineralized bone (green), and 
cartilage (purple) in bone tumor induced by the co-inoculation of LNCaP-RANKL and LNCaP-
RFP cells in nude mice (Magnification 25x).  
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RANKL Induced Expressional Changes of Soluble Factors Associated with Prostate 
Cancer Progression and Mixed Bone Metastasis 
We further examined the changes of gene expression associated with osteoblastic regulation and 
prostate cancer progression upon RANKL expression of LNCaP cells as well as the co-culture of 
LNCaP-RANKL and LNCaP-RFP cells in vitro. We first analyzed the transcriptional expression 
of osteoblastic markers such as OPG (Gori et al., 2000; G. H. Thomas, 2001), Runx2 (Komori et 
al., 1997; Otto et al., 1997), activating transcription factor 4 (ATF4) (Yang et al., 2004), and 
alkaline phosphatase (ALP) (Szulc, Garnero, Marchand, Duboeuf, & Delmas, 2005) in LNCaP-
RANKL, LNCaP-Neo, and LNCaP-RFP cells alone or a co-culture of both cells at a 1 to 9 ratio. 
Figure 10A shows that co-culture of LNCaP-RANKL and LNCaP-RFP cells significantly 
induced OPG, Runx2, and ALP expression but only a moderate level of ATF4 expression 
compared to LNCaP-Neo/LNCaP-RFP and LNCaP-RANKL cells or LNCaP-Neo plus LNCaP-
RFP cells. We also observed that LNCaP-RANKL cells have a higher expression of OPG and 
Runx2 but not ATF4 or ALP compared to LNCaP-Neo/LNCaP-RFP cells. We previously 
identified that OPG and RANK expression was up-regulated along with RANKL overexpression 
in LNCaP and ARCaPE cells (data not shown). It is also interesting to find that the Runx2 
expression level is higher in LNCaP-RANKL than in LNCaP-Neo even though Runx-2 is an 
important transcriptional factor involved in osteoblastic differentiation (Komori, 2006; K. 
Nakashima & de Crombrugghe, 2003). These results explain the increased level of osteoblastic 
activity observed in bone lesions induced by the co-inoculation of LNCaP-RANKL and LNCaP-
RFP cells in vivo, likely through the up-regulation of these osteoblastic regulatory genes.  
We next examined various cytokine, chemokine, and growth factor expressions using cytokine 
antibody arrays probed with conditioned media (CM) from parental LNCaP, LNCaP-RANKL, 
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and co-cultured LNCaP and LNCaP-RANKL cells (Fig. 10B) as well as qRT-PCR array for 
LNCaP and LNCaP-RANKL cells to indicate the differential production of the soluble factors. 
Interestingly, the cytokine array revealed an induction of MCP-2 protein, a chemotaxis factor, 
specifically in the mixed cell co-culture but not in the LNCaP or LNCaP-RANKL CM (Fig. 10C). 
Its induction may be a result of the inter-reactive cross-talk between LNCaP and LNCaP-
RANKL cells. Furthermore, the results from both cytokine antibody and qRT-PCR arrays 
indicated five categories of soluble factors involved in mediating chemotaxis, bone resorption, 
bone formation, proteolytic cleavage, and angiogenesis that were up-regulated in LNCaP-
RANKL cells (Table 3).  
Taken together, these results demonstrate that an increased RANKL level in prostate cancer cells 
can alter both the production and secretion of chemokines, cytokines and growth factors. These 
alterations could affect the balance of osteolytic/osteoblastic activities when prostate cancer cells 
colonize bone. The secreted factors will be further refined, validated and developed as predictive 
biomarkers for prostate cancer progression. We will also further investigate the role of MCP-2 in 
osteoblast/osteoclast differentiation. 
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Figure 10. RANKL induced expressional changes of soluble factors associated with prostate 
cancer progression and mixed bone metastasis. A. Co-culture of LNCaP-RANKL and LNCaP-Neo 
cells with LNCaP-RFP cells at a ratio of 1 to 9 in vitro. The total RNA was extracted for RT-PCR 
analysis of osteoblastic markers OPG, Runx2, ATF4, and ALP. B. Representative RayBio antibody 
arrays probed with parental LNCaP, LNCaP-RANKL, and LNCaP and LNCaP-RANKL co-
cultured conditioned media indicated altered soluble factor production in LNCaP-RANKL as well 
as co-cultured conditioned media. Red circles indicate a unique MCP-2 induction upon co-culture 
with the parental LNCaP cells. C. Quantification of the increased MCP-2 induction in co-culture. 
Asterisks indicate statistical significance (P<0.01).  
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Table 3. A selected list of soluble factor production up-regulated in LNCaP-RANKL cells 
compared to LNCaP-Neo cells. The altered expression was confirmed at the protein level, 
which is shown in black, and differential expression at the mRNA level is shown in red. 
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RANKL Induces Functional cMet Expression and Leads to HGF-Induced cMet 
Phosphorylation in Prostate Cancer Cells 
Interestingly, we further discovered that EMT-inducing RANKL and scatter factor HGF (Chang, 
Kao, Way, Ho, & Fu, ; Hung et al.) are capable of inducing cMet expression as well as activating 
downstream cMet signaling through increased levels of phosphorylated cMet in prostate cancer 
cells. As shown in Figure 11A, exogeneous RANKL and HGF treatments significantly increased 
cMet expression as well as the phosporylated level of cMet in both LNCaP and ARCaPE cells, 
and such induction can be abrogated upon the addition of OPG or anti-HGF antibody. Similarly, 
RANKL overexpression in LNCaP cells also up-regulated cMet and phosphorylated cMet 
expression at both the RNA and protein levels (Fig. 11B). As demonstrated by single quantum 
dot labeling (SQDL), LNCaP-RANKL cells expressed high levels of membrane-bound and 
cytoplasmic cMet and phosphorylated cMet compared to RANKL-low and cMet-null expressing 
LNCaP-Neo cells (Fig. 11C). As shown in Fig. 11D, multiplexed QD labeling (MQDL) further 
illustrated strong co-expression and co-localization of RANKL, c-Met, and p-c-Met on the 
membrane as well as in the cytoplasm of LNCaP-RANKL cells but was not observed in LNCaP-
Neo cells. Moreover, the induced c-Met is biologically functional since the p-c-Met expression 
increased upon the addition of HGF, and this activation of p-c-Met can be antagonized by anti-
HGF monoclonal antibody (Fig. 11E). Promoter reporter assay further confirmed that RANKL 
treatment or overexpression induced up-regulation of cMet transcriptional activity (Fig. 11F). 
Up-regulation of cMet and p-c-Met expression level was also observed in histological sections of 
bone and soft tissue tumors induced by LNCaP-RANKL cells in vivo (Fig. 11G). 
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Figure 11. RANKL and HGF induce c-MET expression and phosphorylated levels of c-Met. 
A. RANKL and HGF treatments induced c-Met and p-c-Met expression in LNCaP and 
ARCaPE cells detected by western blot analysis. Such induction can be attenuated upon the 
addition of OPG and HGF neutralizing antibody. B. LNCaP-RANKL cells expressed high 
levels of cMet and phosphorylated cMet at both the RNA and protein levels as detected by 
RT-PCR and western blot analyses. C. Representative images of DAPI and single quantum 
dot labeling (SQDL) of RANKL, c-Met, and p-c-Met in LNCaP-Neo and LNCaP-RANKL 
cells as well as overlaid images (40x magnification). D. Representative images of multiplexed 
quantum dot (QD) labeling of RANKL (green), c-Met (red), and p-c-Met (yellow) of LNCaP-
RANKL and LNCaP-Neo cells counterstained with DAPI nuclear staining (blue). Individual 
QD labeled protein expression is first presented alone in pseudocolor followed by a composite 
image of the superimposed QD signals overlaid with nuclear DAPI staining. Images were 
acquired using the Cri spectral imaging system at 40x magnification. E. RANKL-induced 
cMet is functional in responding to HGF treatment with increased cMet as well as 
phosphorylated cMet at protein levels as detected by western blot analysis. F. RANKL 
treatment or overexpression up-regulated cMet transcriptional activity, which can be 
attenuated by OPG treatment. *, P<0.05; **,P<0.005 G. Representative images of c-Met and 
p-c-Met IHC staining of LNCaP-RANKL-induced bone and adrenal gland tumors. 
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Discussion 
We examined the metastatic and osteolytic potential of LNCaP-RANKL and ARCaPE-RANKL 
cells in vivo following intracardial inoculation to male athymic nude mice. We observed that 
both LNCaP-RANKL and ARCaPE-RANKL cells induced a high incidence of both bone and 
soft tissue metastases, which could be observed at two months after the injections, while LNCaP-
Neo cells failed to produce any tumor or metastasis and ARCaPE-Neo cells failed to form any 
bone metastasis (Table 1 and Fig. 6A). Mice bearing either LNCaP-RANKL or ARCaPE-
RANKL cells demonstrated extensive osteolytic lesions in the skeleton but not mice bearing 
LNCaP-Neo and ARCaPE-Neo cells (Fig. 6B). Both bone and soft tissue metastases dissected 
from mice bearing the LNCaP-RANKL cells expressed the EMT phenotype with high expression 
of the mesenchymal markers N-cadherin and vimentin and low expression of the epithelial 
marker E-cadherin (Fig. 6C). Moreover, RANKL expression exhibited heterogeneity in subsets 
of the metastatic tumor cells, indicating a mixed population of LNCaP-RANKL cells and 
RANKL non- or low-expressing cells residing in the metastatic tumors. Importantly, the 
histomorphology suggested that a small number of RANKL-expressing cells may be sufficient to 
induce bone metastases in the presence of bystander RANKL non- or low-expressing cells, 
implicating the important function of RANKL in contributing to overall bone and soft tissue 
metastases irrespective of the basal steady-state level of RANKL expression. With RANKL 
overexpression, all of the bone metastases were expected to be highly osteolytic with severe 
degradation of the bones shown by both µCT demonstrations (Fig. 6B) as well as the high level 
of TRAP-positive staining of dissected tumors (Fig. 6D). Several studies showed that LNCaP 
cells are highly indolent and non-metastatic for both intracardial and intraosseous inoculations in 
the nude mice model, but they are capable of inducing osteoblastic or mixed lesions in the SCID 
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mouse model after intratibial injection (Corey et al., 2002; Fisher et al., 2002; Wu et al., 1998). 
Therefore, our animal model is to our knowledge the first to show that intracardial inoculation of 
LNCaP cells overexpressing RANKL can promote EMT progression and bone metastases. 
RANKL confers the malignant and metastatic potential of LNCaP cells to home to the bone, 
leading to predominantly osteolytic lesions. Even though the majority of prostate cancer patients 
develop osteoblastic bone metastasis, there is also considerable evidence of tumor-induced 
osteoclastic bone resorption as an initial and a constant event, leading to overall elevated bone 
remodeling, since these two processes are mechanistically coupled. In our animal models where 
RANKL is overexpressed by the prostate cancer cells, the balance is completely tilted towards to 
the osteolytic phenotype of bone metastases.  
However, the underlying mechanism of RANKL-induced bone metastasis is not yet clear. One 
potential mechanism may be explained by the ‘seed and soil’ theory where RANK expressing 
osteoclast precursors present in the bone microenvironment attract the circulating RANKL 
expressing tumor cells in the bloodstream to land in bone, resulting in the activation of osteoclast 
maturation followed by increased resorption. This results in the release of a plethora of growth 
factors richly stored in the bone, which can further activate the surrounding prostate cancer cells 
to express more RANKL in a paracrine fashion. Subsequently, increased RANKL expression can 
further stimulate RANKL expression by the prostate cancer cells in an autocrine manner, leading 
to a vicious cycle.  
Since LNCaP-RANKL cells provoked osteoclastogenesis in mouse skeleton, we further tested 
the hypothesis that these characteristics of LNCaP-RANKL cells may facilitate the growth and 
colonization of otherwise non-tumorigenic, non-metastatic and RANKL-null LNCaP cells. We 
provided evidence that small numbers of RANKL-expressing prostate cells are capable of 
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conferring tumorigenicity to RANKL-low or-null expressing prostate cancer cells in vivo. As 
low as one thousand LNCaP-RANKL cells are sufficient to facilitate the growth of LNCaP-RFP 
tumors in mouse skeleton and soft tissues.  Bigger tibial tumors with more intensified RFP 
signals were detected in chimeric tumors consisting of an increasing number of LNCaP-RANKL 
cells. This further implies that the RANKL-expressing LNCaP cells augmented the tumorgenic 
potential of RANKL-non expressing LNCaP-RFP cells in the tumor microenvironment (Fig. 7).  
We also discovered that RANKL-expressing prostate cancer cells promoted co-colonization of 
RANKL-non-expressing and non-metastatic prostate cancer cells to metastatic sites. Intracardial 
co-inoculation of LNCaP-RANKL cells and LNCaP-RFP at a ratio of 9 to 1 or 1 to 9 
significantly increased the metastatic incidence compared to intracardial co-inoculation of 
LNCaP-Neo plus LNCaP-RFP cells, which failed to form any metastasis in vivo (Table 2).  Ex 
vivo imaging of bone and soft tissue tumors as well as histological examinations of frozen and 
paraffin-embedded tumor sections all displayed red fluorescent signals, revealing the presence of 
LNCaP-RFP cells at the metastatic sites. Similar observations were also made in bone and soft 
tissue tumors when LNCaP-RFP cells were injected intracardially in mice harboring LNCaP-
RANKL cells in the skeleton. Interestingly, fluorescent imaging also showed that intracardial 
inoculation of LNCaP-RANKL cells in mice harboring LNCaP-RFP cells in the tibial bone 
induced skeletal tumor formation by these non-tumorigenic LNCaP-RFP cells, as a strong 
intensity of red fluorescent signaling was detected in the tibial tumor (Fig. 8). These experiments 
together demonstrated unequivocally the ability of non-tumorigenic or “dormant” LNCaP-RFP 
cells to participate in tumorigenesis and metastases to bone and soft tissues in the presence of 
LNCaP-RANKL cells. In addition, QD labeling results revealed that the number of LNCaP-RFP 
cells colonized to the bone corresponds with the proportion of co-inoculated LNCaP-RFP cells in 
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mice. We also observed that RANKL expression in LNCaP-RANKL induced bone tumors is 
heterogeneous, indicating the possibility that RANKL expression can be switched on/off by the 
prostate cancer cells depending on the surrounding microenvironment. Moreover, we discovered 
that the colonized LNCaP-RFP cells in bone tumors also express high or moderate levels of 
RANKL as indicated by the co-localization (yellow) of RANKL (green) and RFP (red) labeling 
(Fig. 10D), suggesting the induction of RANKL expression in RFP-tagged LNCaP cells by 
RANKL-expressing LNCaP cells, which do not express RFP. Since co-inoculation of LNCaP-
Neo plus LNCaP-RFP cells failed to form tumor or metastasis in mouse skeleton, this result 
further implies that the RANKL-expressing LNCaP cells can “reawaken” dormant LNCaP-RFP 
cells, leading to their participation in tumorigenesis and metastasis possibly through the 
induction of RANKL expression. Such an observation might also be well explained by the ‘seed 
and soil’ theory where the disseminated LNCaP-RANKL cells initially create a favorable 
environment by inducing osteolytic lesions in the bone, leading to the release of growth factors 
and cytokines that subsequently allow the circulating and presumably dormant LNCaP-RFP cells 
to colonize and grow at the bone sites.  
We further observed that co-culture of RANKL-expressing and RANKL-low-expressing prostate 
cancer cells induced increased osteoblastic activity in vitro and mixed osteolytic and osteoblastic 
lesions in vivo. Since LNCaP-RANKL cells induced predominately osteolytic reactions in mouse 
skeleton, we examined whether mixed osteolytic/osteoblastic reactions can be provoked by the 
co-presence of RANKL-high-expressing and –low-expressing LNCaP cells.  Osteoblastogenesis 
and osteoclastogenesis assays in vitro showed that LNCaP-RANKL cells induced predominately 
osteoclast differentiation with low levels of osteoblast mineralization while LNCaP-Neo or 
LNCaP-RFP cells either cultured alone or together with LN-RANKL cells produced 
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substantially increased osteoblast mineralization (Fig. 9A).  These results are in agreement with 
the 3D µCT scans of representative chimeric tumors composed of intracardial 1 to 9 or 9 to 1 
ratios of LNCaP-RANKL and LNCaP-RFP cells, intratibial LN-RANKL plus intracardial LN-
RFP cells, or intratibial LNCaP-RANKL plus LNCaP-RFP cells, which all displayed mixed 
osteolytic and osteoblastic lesions in the bone (Fig. 9C). TRAP staining of mature osteoclast 
lining (red) and orange G staining of new bone formation (yellow orange) in bone tumor were 
observed in the chimeric tumors co-inoculated with LN-RANKL and LN-RFP cells in nude mice 
(Fig. 9D).  Alternative evidence of the increased level of osteoblastic activity in the tumors 
induced by the co-inoculation of LN-RANKL and LN-RFP cells is illustrated by detecting the 
osteoid formation/thickness using Trichrome staining (Fig. 9E). The osteoid stained in red, and 
the mineralized bone stained in turquoise. The level of osteoid formation and thickness can 
reflect the level of bone formation (Ott, 2008). Moreover, co-culture of LNCaP-RANKL and 
LNCaP-RFP cells in vitro further demonstrated elevated expression of important osteoblastic 
regulatory genes, such as OPG, Runx2, ALP, and ATF4, as well as a chemotactic factor, MCP-2, 
which is specifically induced in the mixed cell co-culture (Fig. 10A-C). Analyses from Cytokine 
Antibody array as well as qRT-PCR array generated an expression profile of regulatory factors 
involved in chemotaxis, bone resorption, bone formation, proteolytic cleavage, and angiogenesis 
that are elevated in RANKL-expressing LNCaP cells (Table 3). These results demonstrated that 
increased RANKL levels in prostate cancer cells can alter the production of chemokines, 
cytokines, and growth factors, and such alterations can directly affect the progression of prostate 
cancer cells as well as the balance of osteolytic and osteoblastic activities when prostate cancer 
cells colonize the bone.  
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We further discovered a previously unrecognized forward feedback loop in which RANKL-c-
Met signaling converges. RANKL expression induced both RANKL and c-Met expression by 
prostate cancer cells (Fig. 11).  RANKL or HGF treatment of LNCaP and ARCaPE cells 
demonstrated an up-regulated expression of cMet as well as phosphorylated level of p-c-Met. 
Similar results were also observed in LNCaP-RANKL cells at both the RNA and protein levels. 
The RANKL and c-Met expressed by prostate cancer cells are both biologically functional as 
evidenced respectively by increased osteoclastogenesis (Fig. 4) and phosphorylation of c-Met 
when RANKL-expressing prostate cancer cells are exposed to mononuclear osteoclasts in co-
culture or exogenous recombinant HGF (Fig. 11). 
We observed that the extent of osteolysis can be switched from osteolytic to osteoblastic 
depending on the proportion of RANKL-positive and RANKL-negative prostate cancer cells 
used in the mixed populations.  For example, using LNCaP-RANKL cells as a model, we 
showed that a small number of LNCaP-RANKL expressing cells are sufficient to induce bone 
metastases in the presence of bystander RANKL non- or low-expressing cells.  Importantly, 
histology showed that both RANKL-expressing and low-expressing cells reside in the bone 
metastasis tumors, suggesting the important function of RANKL in contributing to overall bone 
metastases irrespective of the basal steady-state level of RANKL expression.  Since RANKL low 
and non-expressing LNCaP cells failed to form tumors in mice without the co-presence of 
RANKL-positive LNCaP cells, we believe that RANKL is an important factor activating the 
“dormancy” of prostate cancer cells to form tumors in mouse bone.  This well explains the 
clinical observation of cancer dormancy in which prostate cancer cells are often found in the 
bone but fail to colonize the bone (Aguirre-Ghiso, 2007).  In the presence of RANKL-positive 
LNCaP cells, RANKL low or non-expressing prostate cancer cells participated in bone 
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colonization.  RANKL-c-Met signaling converges, whereby RANKL expression induces both 
RANKL and c-Met expression by prostate cancer cells, further committing them to EMT 
progression and metastasis. These results have important clinical implications in which further 
justify the targeting of RANKL as an effective therapeutic approach for human prostate cancer 
bone metastasis targeting not only existing tumors but also preventing the activation of tumor 
dormancy.  
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CHAPTER 5 RANKL STIMULATED AN AUTOCRINE FEED-FORWARD 
INDUCTION OF RANKL EXPRESSION MEDIATED BY C-MYC/MAX 
TRANSACTIVATION IN PROSTATE CANCER CELLS 
Introduction 
RANKL expression can be positively and negatively regulated by many hormones and growth 
factors, such as PTH, PTHrP, prostaglandin E2, estradiol, glucocorticoids, testosterone, vitamin 
D3 (1α,25(OH)2D3), and progesterone/progestin as well as by several cytokines, such as IL-1, 
IL-6, IL-7, IL-17, and TNF-α, (Anandarajah, 2009; Theoleyre et al., 2004) through various 
molecular mechanisms. These RANKL-stimulating factors can be secreted by bone cells and 
certain tumor cells, including breast and prostate cancer cells, which have high propensity to 
invade bone and cause skeletal complications and metastases (Mundy, 2002). Recently, we have 
identified that both exogenous and endogenous RANKL can induce RANKL expression in an 
autocrine feed-forward manner in prostate cancer cells but not in normal cells. Blocking the 
source of RANKL using RANKL natural decoy receptor, OPG, can attenuate the up-regulated 
RANKL expression at both the RNA and protein levels. The augmented RANKL has been 
shown to be biologically functional in increasing in vitro osteoclastogenesis. Moreover, since 
prostate cancer cells express both RANKL and its receptor RANK (Armstrong et al., 2008; Chen 
et al., 2006; Jones et al., 2006; Odero-Marah et al., 2008; Zhang et al., 2001), the autocrine 
induction of RANKL in prostate cancer cells allows EMT progression and enhanced metastatic 
potential, demonstrated by increased in vitro migration, invasion, and tumorigenic activities as 
well as enhanced in vivo bone and soft tissue metastases. Therefore, it is crucially important to 
unravel the molecular mechanism of RANKL-induced autocrine regulation. In this study, we 
investigated the transcriptional regulation of RANKL expression using a 2.5kb RANKL 
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promoter reporter to identify the important transcription factor(s) involved in RANKL-induced 
autocrine feed-forward activation. 
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Results 
Validation of 2.5kb Human RANKL Promoter Activity in Human Osteosarcoma and 
Prostate Cancer Cells 
We previously determined that RANKL is capable of inducing its own expression in prostate 
cancer cells through an autocrine feed-forward regulation. In order to study the transcriptional 
regulation of RANKL gene expression, we constructed a 2.5kb human RANKL promoter 
amplified from a BAC clone containing the 5’ upstream promoter region of RANKL using PCR. 
We first sought to validate the 2.5kb RANKL promoter reporter activity in human osteoblastic 
osteosarcoma, SaOS-2 cells stimulated with osteotropic factors, such as PTH and vitamin D3 
(Anandarajah, 2009; Theoleyre et al., 2004), which are known to stimulate RANKL expression 
in osteoblasts. The RANKL promoter activity was increased in SaOS-2 cells by approximately 3 
fold upon treatment with 10 nM of PTH or 20 nM of vitamin D3 (Fig. 12A). We further 
examined the RANKL transcriptional activity in prostate cancer ARCaPM, ARCaPE, LNCaP, C4-
2, and PC3 cells as well as in SaOS-2 cells as a positive control. We found that RANKL 
promoter activity was much higher in PC3 and ARCaPM cells, which are known to express high 
levels of RANKL, compared to RANKL-low expressing ARCaPE, LNCaP, or C4-2 cells (Fig. 
12B). This finding therefore correlates with the endogenous level of RANKL expression in these 
prostate cancer cells detected by either RT-PCR or by western blot analyses in the previous 
results (Fig. 1B).  
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Figure 12. RANKL promoter (2.5Kb) activity in human osteosarcoma and prostate cancer 
cells. A. The 2.5Kb RANKL promoter was introduced into human osteosarcoma SaOS-2 
cells to examine RANKL basal promoter activity as well as the stimulated promoter activity 
by exogenous treatments with PTH and vitamin D3. B. RANKL promoter activity was 
examined in prostate cancer ARCaPE, ARCaPM, LNCaP, C4-2, and PC3 cells and compared 
to osteosarcoma SaOS-2 cells as a positive control. * , p<0.05  
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RANKL Induced an Autocrine Feed-forward Induction of RANKL Expression in Prostate 
Cancer Cells 
We discovered that exogenous RANKL treatment can induce endogenous RANKL expression in 
prostate cancer cells, such as ARCaPE and LNCaP cells, which express low levels of RANKL. 
Treatment of ARCaPM cells with OPG can decrease the RANKL production by ARCaPM cells at 
both the RNA and protein levels (Fig. 13A). We also introduced the RANKL promoter to the 
ARCaP cell model to examine RANKL transcriptional activity upon treatment with RANKL, 
OPG or RANKL plus OPG. We found that RANKL promoter activity is consistent with the 
biochemical data where RANKL treatment induced a significant induction of RANKL 
transcriptional activity in both ARCaPE and ARCaPM cells. Such increased RANKL promoter 
activity can be attenuated upon exposure to OPG. Furthermore, treating ARCaPM cells with OPG 
resulted in a reduction in RANKL promoter activity, but OPG treatment has minimal effect on 
RANKL transcription in ARCaPE cells (Fig. 13B). Similarly, RANKL promoter activity was 
greatly activated upon RANKL treatment but addition of OPG decreased the RANKL-induced 
RANKL transcriptional activity in LNCaP cells (Fig. 13C).  
We also examined the RANKL promoter activity in RANKL-overexpressing LNCaP and 
ARCaPE cells to further confirm the RANKL autocrine activation. As shown by Figure 13D and 
13E, endogenous RANKL overexpression greatly up-regulated RANKL promoter activity by 
approximately 8 fold compared to Neo controls in both LNCaP and ARCaPE cells, and exposure 
to OPG decreased the RANKL promoter activity in these cells. RANKL promoter activity was 
not affected by OPG treatment in LNCaP-Neo and ARCaPE-Neo cells. 
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Figure 13. RANKL induced an autocrine feed-forward induction of RANKL expression in 
prostate cancer cells. A. RANKL treatment up-regulated RANKL expression at both mRNA 
and protein levels in ARCaPE and LNCaP cells, which can be attenuated upon addition of 
OPG. RANKL expression in ARCaPM cells can be down-regulated by the addition of 1 ug/ml 
of OPG. B. Corresponding results were also observed using a RANKL promoter reporter assay 
in which RANKL promoter activity was induced by RANKL treatments in ARCaPE and 
ARCaPM cells. OPG treatment could dampen the RANKL promoter activity in ARCaPM cells 
and abolish the RANKL autocrine induction. C. RANKL autocrine induction was also 
observed in LNCaP cells as demonstrated by RANKL promoter reporter assay. RANKL 
promoter activity was significantly up-regulated in D. LNCaP-RANKL and E. ARCaPE-
RANKL cells compared to Neo controls of both cell types, and OPG treatment attenuated the 
increased RANKL promoter activity in both LNCaP-RANKL and ARCaPE-RANKL cells * , 
p<0.05; **, p<0.005.  
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Identification of the cMyc Binding Motif within the -1884 and -1384 Region of RANKL 
Promoter that Mediates the RANKL Autocrine Feed-forward Induction by RANKL 
We discovered that RANKL is capable of inducing its own expression in prostate cancer cells. 
We next further identified the cis-acting element(s) in the RANKL promoter region that are 
responsible for RANKL autocrine transcriptional regulation using a promoter deletion study. We 
first generated five deletion mutants of the 2.5 kb RANKL promoter: D1 (deletion from -2383 to 
-1884), D2 (deletion from -1884 to -1384), D3 (deletion from -1384 to -884), D4 (deletion from -
884 to -384), and D5 (deletion from -384 to -101) (Fig. 14A). We transfected these five deletion 
constructs as well as the full-length promoter into RANKL-expressing LNCaP-RANKL cells and 
RANKL-low or –non-expressing LNCaP-Neo cells. As shown in Figure 14B, full-length 
RANKL promoter activity was significantly induced in LNCaP-RANKL cells but not in the 
LNCaP-Neo cells, and among the five deletion constructs only the D2 deletion construct (-1884 
to -1384) abolished RANKL promoter activity in LNCaP-RANKL cells. However, the basal 
promoter activity was very minimal and remained unchanged for these RANKL deletion mutants 
in the LNCaP-Neo cells. These results suggested that the potential cis-acting element mediating 
the RANKL-induced autocrine regulation might reside at region D2 between -1884 and -1384 of 
the RANKL promoter.  
We next tried to characterize the precise cis-acting element(s) within the 500-bp D2 region (-
1884 and -1384) of the RANKL promoter. Database searching revealed two putative cis-acting 
elements in the D2 region: the CRE binding site (-1177~-1184) and the cMyc/Max binding site 
(-1372~-1384) (Fig. 14C). We subsequently generated the respective CRE and cMyc deletion 
mutants, and we transfected the D2, CRE, and cMyc deletion mutants as well as the full-length 
promoter to examine their luciferase reporter activities in LNCaP-RANKL and LNCaP-Neo cells. 
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Consistently, RANKL overexpression greatly induced RANKL promoter activity in LNCaP cells 
but such induction was abolished upon deletion of the 500-bp D2 region of the promoter (Fig. 
14D). The cMyc/Max deletion construct completely abolished RANKL basal promoter activity 
in LNCaP-RANKL cells but not by the CRE deletion mutant. Similar results were also observed 
for the promoter activities of the CRE and cMyc/Max deletion mutants in LNCaP cells treated 
with RANKL (Fig. 14E). The RANKL promoter activity was not significantly changed by the 
deletion mutants in LNCaP-Neo and LNCaP cells. Taken together, these data demonstrated that 
the cMyc/Max binding site within the RANKL promoter region is important for RANKL 
promoter activity regulated by RANKL autocrine induction.  
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Figure 14. Identification of the cMyc binding motif within the -1884 and -1384 region of 
RANKL promoter that mediates the RANKL autocrine feed-forward induction by RANKL. A. 
Diagram of RANKL full promoter construct and deletion mutants, D1 deleted from -2383 to -
1884, D2 deleted from -1884 to -1384, D3 deleted from -1384 to -884, D4 deleted from -884 to 
-384, and D5 deleted from -384 to -101. B. The transcriptional activities of these RANKL 
promoter deletion mutants were examined in LNCaP-RANKL and LNCaP-Neo cells. D2 
mutant showed a significant reduction of RANKL transcriptional activity to a minimal level in 
LNCaP-RANKL cells, and all deletion mutants showed minimal responsiveness in LNCaP-Neo 
cells. C. The DNA sequence of D2 region (500bp) within the RANKL promoter (-1884~-1384). 
CRE (-1177~-1184) and cMyc/Max (-1372~-1384) binding sites were identified within the D2 
region (underlined). D. The full length RANKL promoter and D2, CRE, and cMyc/Max 
deletion mutants were examined for their RANKL transcriptional activity in LNCaP-RANKL 
and LNCaP-Neo cells or E. in LNCaP cells treated with or without RANKL. The RANKL 
transcriptional activity was significantly inhibited with the cMyc/Max deletion mutant in 
LNCaP-RANKL and RANKL-treated LNCaP cells. **, p<0.005.  
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RANKL Autocrine Activation Is Mediated through Direct Interaction of cMyc to Its cis-
acting Binding Element within the RANKL Promoter Region in Prostate Cancer Cells 
We next wanted to further validate whether cMyc transcription factor is the key protein 
mediating RANKL-induced autocrine gene regulation in prostate cancer cells. We therefore 
conducted ChIP analysis to investigate the in vivo interaction between nuclear cMyc and its 
binding cis-acting elements in RANKL-treated and RANKL-overexpressing LNCaP cells in the 
presence or absence of OPG. The binding of cMyc to the chromatin was detected by PCR 
amplification of the cMyc binding region within the RANKL promoter using the original 
protein-DNA complexes (input) and anti-cMyc- or anti-rabbit IgG immunoprecipitated DNA-
protein complexes as templates. As shown in Fig. 15A, no cMyc amplified PCR product was 
detected in either LNCaP or LNCaP-Neo cells whereas the levels of cMyc PCR product were 
greatly increased in LNCaP cells treated with RANKL or in LNCaP-RANKL cells, and the level 
of cMyc amplification was decreased upon OPG treatment of these cells.  In addition, using 
quantitative real-time PCR as readouts, we observed that RANKL significantly increased the 
binding of cMyc transcription factor to its binding site within the RANKL promoter region by 
20-fold and 8-fold in LNCaP-RANKL and RANKL-treated LNCaP cells, respectively. OPG 
treatment attenuated the interaction of cMyc with its binding site by 13-fold in LNCaP-RANKL 
cells and by 4-fold in LNCaP cells treated with RANKL (Fig. 15B). Furthermore, activation of 
the cMyc target gene requires direct binding of cMyc/Max heterodimers to the consensus 
binding sites containing the E-box box sequence (CACGTG) within the promoter sequence 
(Walhout, Gubbels, Bernards, van der Vliet, & Timmers, 1997).   
To further determine whether there is a direct binding of cMyc/Max heterodimer to its binding 
motif within the RANKL promoter, we performed an electrophoretic mobility shift assay 
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(EMSA) using non-invasive biotin-labeled cMyc/Max oligonucleotides as probes and detecting 
the formation of DNA-protein complexes. One band indicating the DNA-protein complex was 
detected on gel after the nuclear extracts from LNCaP-RANKL or RANKL-treated LNCaP cells 
were incubated with the probes. The band was absent in the presence of a 400-fold excess of 
unlabeled probes as competitors, suggesting that the binding of cMyc/Max oligonucleotides to 
the nuclear proteins in LNCaP-RANKL or RANKL-treated LNCaP cells is specific (Fig. 15C).  
Furthermore, the band of the DNA-protein complex was supershifted when anti-cMyc or anti-
Max antibodies were incubated with the DNA-protein binding reaction due to retardation of the 
DNA-protein-antibody complex, but the shift was not observed with incubation with anti-rabbit 
IgG. Moreover, no DNA-protein binding complex was observed for LNCaP cells. Together, 
these results suggest that RANKL promotes the direct binding of cMyc/Max heterodimers to the 
corresponding binding sequence within the RANKL promoter and activates RANKL expression, 
leading to cMyc-mediated RANKL autocrine feed-forward induction.  
Moreover, we examined the level of nuclear cMyc and Max in RANKL-treated LNCaP and 
LNCaP-RANKL cells, and we found significant up-regulation of nuclear cMyc and Max levels 
compared to LNCaP cells (Fig. 15D). This suggests that RANKL treatment or overexpression 
also induced cMyc and Max expression levels, leading to the subsequent activation of RANKL 
transcription through increased cMyc/Max heterodimer binding to the RANKL promoter. We 
further examined RANKL promoter activity in LNCaP-RANKL and RANKL-treated LNCaP 
cells in the presence of a cMyc inhibitor, 10058-F4, which disrupts cMyc and Max interaction 
and prevents transactivation of c-Myc target gene expression. We observed that the cMyc 
inhibitor induced a significant decrease in RANKL transcriptional activity in both RANKL-
treated LNCaP and LNCaP-RANKL cells but had no effect on RANKL promoter activity in 
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LNCaP or LNCaP-Neo cells (Fig. 15E). Moreover, cMyc inhibitor also greatly decreased 
RANKL expression in LNCaP-RANKL or RANKL-treated LNCaP cells at protein levels, 
further suggesting that disruption of the cMyc/Max heterodimer inhibits the transactivation of 
RANKL expression (Fig. 15F). 
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Figure 15. RANKL autocrine activation is mediated through direct interaction of cMyc to its 
cis-acting binding element within the RANKL promoter region in prostate cancer cells. A. 
ChIP analysis of LNCaP cells treated with 200 µg/ml of RANKL or RANKL plus OPG as 
well as LNCaP-RANKL cells and LNCaP-RANKL cells treated with OPG. The chromatin 
and nuclear proteins were cross-linked with formaldehyde, sheared by enzymatic shearing 
mixture and subjected to immunoprecipitation (IP) using anti-cMyc antibody or anti-rabbit 
IgG as a negative control. The input and cMyc antibody- and IgG-pull-downed cMyc-DNA 
complex was subjected to semi-quantitative RT-PCR for cMyc DNA amplification. B. 
Quantitative real-time PCR was also performed for cMyc amplification in the ChIP analysis. 
C. EMSA analysis demonstrating nuclear cMyc/Max heterodimer binding to cMyc 
oligonucleotides in RANKL-treated LNCaP and LNCaP-RANKL cells in vitro. Nuclear 
extract from both cells was incubated with biotin-labeled cMyc/Max probe (lanes 2-6). An 
excess of unlabeled probe (400x) as competitor (lane 3), anti-cMyc antibody (lane 4), anti-
Max antibody (lane 5), and anti-rabbit IgG as negative control (lane 6) were added to the 
binding reaction. Arrows indicate free probe, cMyc/Max-DNA complex, and supershifted 
cMyc/Max-DNA complex conjugated with anti-cMyc or anti-Max antibodies. D. The nuclear 
protein levels of cMyc and Max in LNCaP cells treated with RANKL and LNCaP-RANKL 
cells were examined by Western blot analysis, and lamin A/C was used as the internal 
control. E and F, RANKL treated LNCaP cells and LNCaP-RANKL cells were treated with 
20 µM of cMyc inhibitor, 10058-F4 and examined for the RANKL promoter reporter activity 
as well as protein expression level. cMyc inhibitor significantly decreased RANKL 
transcriptional activity (E) and protein expression (F) in LNCaP-RANKL cells or in LNCaP 
cells treated with RANKL. * , p<0.05; **, p<0.005.  
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Discussion 
We demonstrated for the first time that RANKL can induce autocrine feed-forward induction of 
RANKL expression at both the transcriptional and translational levels. To study the 
transcriptional regulation of RANKL autocrine induction, we constructed a 2.5kb RANKL 
promoter reporter using a BAC clone containing RANKL 5’ upstream promoter regions. The 
promoter was functional in RANKL-producing osteosarcoma SaOS-2 cells, and upon stimulation 
with RANKL-stimulating or osteotropic factors, such as PTH and vitamin D3, RANKL promoter 
activity was significantly induced (Fig. 12A). RANKL promoter activity was also examined in 
prostate cancer cells, and the level of RANKL transcriptional activity was correlated with the 
endogenous level of RANKL expression and paralleled the aggressiveness and malignancy of the 
cells (i.e. RANKL promoter activity was high in aggressive ARCaPM and PC3 cells but low in 
indolent cells, such as ARCaPE and LNCaP (Fig. 12B). RANKL treatment and overexpression 
both induced up-regulation of RANKL expression in prostate cancer cells at both the RNA and 
protein levels (Fig. 13A). RANKL-induced autocrine activation was further demonstrated by 
RANKL promoter reporter assay. RANKL promoter activity was augmented in ARCaPE, 
ARCaPM, and LNCaP cells when treated with RANKL, and the induced activity was abrogated 
upon exposure to OPG (Fig. 13B and 13C). Furthermore, overexpression of RANKL in LNCaP 
and ARCaPE cells also significantly activated the RANKL promoter activity compared to the 
Neo-transfected cells (Fig. 13D and 13E).  
Our RANKL promoter deletion study identified the region from -1884 to -1384 within the 
RANKL promoter as responsible for the RANKL-mediated autocrine induction since deletion of 
that region abolished the RANKL basal promoter activity (Fig. 14A and 14B). Within that region 
of RANKL promoter, we predicted two potential cis-acting elements, including CREB and 
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cMyc/Max motifs that might be potentially involved in RANKL autocrine transcriptional 
regulation (Fig 14C). Further characterization of these two binding sites by a deletion study 
revealed that cMyc/Max binding to RANKL promoter is required for RANKL-induced RANKL 
transcription in LNCaP-RANKL as well as RANKL-treated LNCaP cells (Fig. 14D and 14E). 
ChIP and EMSA analyses further confirmed that RANKL treatment or overexpression induced 
direct and specific binding of nuclear cMyc/Max heterodimer to its binding site within the 
RANKL promoter to activate RANKL transcription, and such binding can be attenuated upon 
OPG treatment (Fig. 15A, 15B, and 15C). RANKL also greatly increased both cMyc and Max 
nuclear protein levels in LNCaP cells (Fig.14D). Disruption of cMyc and Max interaction by 
cMyc inhibitor (10058-F4) prevented transactivation of RANKL promoter, leading to a 
significant reduction in RANKL transcription as well as protein expression in both RANKL-
treated or overexpressing  LNCaP cells (Fig.15E and 15F).  
Together, these results demonstrate a novel regulatory mechanism of RANKL-induced RANKL 
autocrine gene expression via cMyc/Max heterodimer transactivation. Such auto-induction of 
RANKL expression promotes EMT progression and metastasis by prostate cancer cells and also 
leads to the establishment of the “vicious cycle” between prostate cancer cells and their 
surrounding microenvironment, especially in the bone.  
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CHAPTER 6 THE USE OF ENGINEERED HUMAN PROSTATE CANCER CELL LINE 
AND XEONGRAFT MODEL FOR THE STUDY OF CELL SIGNALING NETWORK IN 
CASTRATION-RESISTANT PROSTATE CANCER: A MULTIPLEX QUANTUM DOT 
LABELING APPROACH (PLOS ONE 2011 IN PRESS) 
Introduction 
Semi-conductor quantum dots (QDs) fluorescent nanoparticles have been recognized as one of 
the great recent advances for our ability to detect relevant biomarkers expressed by cells, tissues 
and sera (Hu et al., 2010; Leung, 2004; Shi et al., 2008; Sweeney et al., 2008; Wagner, Li, Li, Li, 
& Le, 2010).  The unique optical and electronic properties of QDs include their narrow and 
symmetrical emission bands, size- and material-tunable light emission, high surface to volume 
ratio, photostability, signal brightness and sensitivity, and simultaneous excitation of multiple 
fluorescence colors making it possible to detect multiple targets simultaneously at the single cell 
level (Shi et al., 2008; Xing et al., 2007).  Quantum dot labeling, QDL, is superior to 
conventional organic dyes for cell and tissue staining, especially since the latter yield broad 
bandwidth with overlapping signal emissions and are highly susceptible to photobleaching.  
Multiplexing biomarkers with different colors provides significant advantages over traditional 
organic or fluorescent dyes for the detection and analysis of dynamic changes in proteins and 
nucleic acids in cells or tissues under pathophysiologic conditions.  QDL has been applied 
successfully to detect the levels of expression of genes in situ associated with important biologic 
processes such as epithelial to mesenchymal transition (Xing et al., 2007) in cancer metastasis 
(R. Li et al., 2009), protein biomarkers in the blood, the presence of nucleic acids, microRNA 
and DNA methylation in sera or tissue extracts with samples barcoded for rapid processing by 
automated protocols (Bailey, Puleo, Ho, Yeh, & Wang, 2009; Kong et al., 2010; Liang et al., 
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2005).  In the present study, we employed multiplexed quantum dot labeling (MQDL) to detect 
the activated c-Met-mediated cell signaling pathway leading to EMT, cancer growth and bone 
and soft tissue metastasis in a novel prostate cancer metastasis model (Thalmann et al., 1994; 
Thalmann et al., 2000; van Leenders et al., 2003).  We confirmed the levels of gene expression 
assessed by MQDL with gene expression as determined by RT-PCR and western blots.  We then 
applied the MQDL protocol to determine if the c-Met cell signaling pathway and EMT are 
activated in a castration-resistant prostate cancer (CRPC) animal model and in clinical prostate 
cancer specimens obtained from patients with high Gleason scores and bone metastasis.  We 
observed that activation of c-Met is closely linked to EMT in cancer cells and their subsequent 
increased migration, invasion and metastasis (Chung et al., 1992; Pisters et al., 1995; Zhang et al., 
2010).  c-Met signal activation in human prostate cancer has important clinical implications: 1) 
c-Met downstream signaling drives EMT and cancer cell migration, invasion, metastasis and 
survival in several human solid tumor models including prostate cancer (Lengyel et al., 2005; 
Torres et al., 2011; Zhang et al., 2010; Zhou et al., 2011).  2) Since targeting c-Met and VEGFR2 
downstream signaling with a synthetic multiple tyrosine kinase inhibitor, cabozantinib (XL-184), 
resulted in remarkable resolution of bone and soft tissue metastases in a large number of patients 
with solid tumors including CRPC patients (Smith et al., 2010; Zhang, Guessous, Kofman, Schiff, 
& Abounader, 2010), it would be important to show if these cell signaling pathways might be 
activated in clinical specimens and in relevant tumor xenograft models.  We used a human 
prostate cancer cell line to demonstrate that c-Met activation confers EMT and prostate cancer 
bone and soft tissue metastases and investigated in depth the c-Met signaling activation by 
molecular analyses with results confirmed by MQDL.  We then employed MQDL to evaluate c-
Met signaling activation in clinical prostate cancer tissue specimens and correlated the results 
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with a castration-resistant human prostate cancer xenograft model.  We showed that MQDL, 
coupled with Vectra Image Analysis, enhances the quantitative profiling capability of individual 
biomarkers at the single cell level.  A series of biomarkers associated with EMT, such as 
decreased expression of EpCAM, and increased expression of N-cadherin, vimentin and RANKL, 
and c-Met signal activation, including VEGF, neuropilin 1, p-c-Met and phospho(p)-NF-κB p65 
(Tobar, Villar, & Santibanez, 2010; Zhang et al., 2010), were analyzed.  The results of these 
studies showed a remarkable parallelism of EMT and c-Met activation between the prostate 
cancer cell model, the CRPC xenograft model and clinical prostate cancer specimens.  The 
methodologies established in the present study could be of significant value in the near future to 
characterize other activated signaling pathways in clinical specimens, interrogate molecular 
mechanisms underlying cancer progression, identify druggable targets, and follow up the clinical 
response of patients to therapeutic intervention. 
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Results 
Development of a quantitative QD labeling protocol for the assessment of gene expression 
associated with the activation of c-Met signaling and EMT in cultured human LNCaP cells 
stably tansfected with RANKL  
LNCaP bone and soft tissue metastases model 
A novel LNCaP bone metastasis model was developed by stable transfection of this cell line with 
RANKL (LNCaP-RANKL), which drives EMT in the transfected cells. When RANKL 
overexpressing LNCaP cells were injected intracardially in mice they exhibited an increased 
incidence of bone and soft tissue metastases (Table 4). 
 
Table 4.  RANKL overexpressing LNCaP cells induced high incidences of bone and 
soft tissue metastases. LNCaP-RANKL and LNCaP-neo cells (1x106 cells/50µl PBS) 
were inoculated intracardially into 5- to 7-week-old male athymic nude mice (LNCaP-
RANKL n=20; LNCaP-neo n=15).  Metastatic lesions were observed between 2 - 3 
months after injection.  * Micro-CT tomography detected bone lesions in limbs, ribs, 
jaw, and skull determined by X-ray radiography and confirmed by histopathologic 
staining (H&E). 
 Lymph nodes Bones* Adrenal glands Lung 
LNCaP-neo        0/15        0/15        0/15        0/15 
LNCaP-RANKL      18/20 (90%)      20/20 (100%)      17/20 (85%)        8/20 (40%) 
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Validation of Activated c-Met Signaling Components That Lead to EMT by RT-PCR, 
Western Blot and Single Quantum Dot Labeling, SQDL 
Comparison of gene expression between stable LNCaP-neo control and LNCaP-RANKL cells 
using RT-PCR and Western blot showed evidence of activated c-Met signaling through increased 
expression of c-Met, p-c-Met, and p-NFκB p65 (Fig. 16).  The cells underwent morphologic 
(Panel A) and biochemical (Panels B and C) epithelial to mesenchymal transition, with decreased 
intercellular adhesion mediated by E-cadherin and EpCAM, and increased N-cadherin, vimentin 
and RANKL.  These assessments of c-Met signaling activation and EMT were subjected to 
SQDL analyses with a specific effort to confirm if c-Met activation and EMT occurred in this 
cell model of prostate cancer progression.  SQDL confirmed that in comparison to control 
LNCaP-neo cells (Fig. 17A), LNCaP-RANKL cells (Fig. 17B) had activated c-Met signaling as 
revealed by an elevated expression of RANKL, c-Met, p-c-Met and p-NFκB p65 and evidence of 
EMT, a cadherin switch of elevated expression of N-cadherin, vimentin and RANKL but 
decreased expression of E-cadherin and AR.  Quantitative analyses (Fig. 18) of 1,000 randomly 
selected cancer cells by inForm software (Caliper) supported the imaging data in which both AR 
and E-cadherin expression was drastically decreased and activated c-Met signaling components 
led to EMT, such as elevated expression of c-Met, p-c-Met, p-NFκB p65, N-cadherin, vimentin, 
and RANKL were observed in LNCaP-RANKL, when compared to LNCaP-neo cells.  This 
quantitative SQDL protocol was adopted for gene expression analyses of an established CRPC 
LTL-313 xenograft model. 
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Figure 16.  RANKL-transfected LNCaP cells induced epithelial to mesencymal transition in 
histomorphology (A) and gene expression in mRNA (B) and protein (C).  Data represent one of 
3 RANKL-stably transfected and 2 neo-stably transfected LNCaP cell clones. 
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Figure 17.  RANKL overexpression activated c-Met signaling components detected by single 
quantum dot labeling, SQDL.  Differential QD labeling of proteins was performed in LNCaP-
neo (A) and LNCaP-RANKL (B) cells using DAPI nuclear staining as reference.  For each 
analysis, QD labeled protein expression is presented in pseudocolor, with the overlaid image of 
DAPI and QD signals (Merged).  ×400. 
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Figure 18. Quantification of differential gene expression subsequent to RANKL overexpression 
in LNCaP cells.  Cell-based average intensity counts from 1,000 each of neo- and RANKL-
transfected LNCaP clones were quantified using inForm software.  Statistically significant 
changes in protein expression were observed (P < 0.05). 
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Validation of c-Met signaling activation and EMT in the CRPC LTL-313 model with 
results confirmed by IHC and SQDL 
To understand the clinical significance of c-Met signaling activation and EMT in the LNCaP-
RANKL model and the associated increases in prostate cancer metastases, we defined the c-Met 
signaling pathway and EMT in a CRPC LTL-313 xenograft model obtained from the Living 
Tumor Laboratory (livingtumorcentre.com).  We included additional c-Met signaling associated 
genes such as neuropilin-1, VEGF, p-Akt, VEGFR2, Mcl-1 and AR, which were characterized as 
mediators of c-Met downstream survival signaling (Coloff et al., 2011; Huynh et al., 2009; D.C 
Smith et al., 2010; Zhang et al., 2010).  Figure 19 shows that increased c-Met signaling-
associated genes and decreased AR expression in CRPC LTL-313 xenografts maintained in 
castrated male hosts, as assessed by IHC (Panel A) and SQDL (Panel B) compared to the 
xenografts maintained in intact mice with androgen supplementation. 
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Figure 19.  Detection of c-Met activated and EMT associated proteins in the CRPC LTL-313 
xenograft model by conventional IHC (A) and SQDL (B).  Castration increased a panel of genes 
in LTL-313 xenograft prostate cancer and decreased AR expression compared to xenografts 
obtained from intact hosts by both IHC and SQDL.  ×400. 
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MQDL Analysis Demonstrated Activated c-Met and EMT in a CRPC LTL-313 Xenograft 
Model and Primary and Metastatic Human Prostate Cancer Tissue Specimens 
A series of human prostate cancer xenografts obtained from the Living Tumor Laboratory was 
used to test the quantitative MQDL protocol.  We selected the LTL-313 model for this task 
because this model exhibits CRPC characteristics with a propensity for primarily lymph node, 
lung and liver metastases with infrequent bone metastasis, when the tumors are implanted and 
grown under the renal capsules.  We tested the hypothesis that tumors grown in castrated mice 
would develop castration resistance and have activated c-Met signaling leading to EMT, when 
compared to tumors grown in mice supplemented with exogenous androgen (Fig. 20A).  Three 
approaches were taken: 1) to establish a robust MQDL protocol to detect and quantify a panel of 
gene expressions on the CRPC LTL-313 model tissue specimen with results compared with 
SQDL; 2) to use this established quantitative MQDL protocol to confirm if activation of c-Met 
and EMT occur in the CRPC LTL-313 tissues maintained in the castrated hosts; and 3) to 
demonstrate by the standardized MQDL protocol the activation of c-Met and EMT induction in 
both primary and skeletal metastatic human prostate cancer tissues.  Figure 20B shows the 
quantitative MQDL analyses of neuropili-1, p-c-Met, VEGF, p-NFκB p65, and RANKL, 
previously reported to be associated with c-Met signal activation (Tobar et al., 2010; Zhang et al., 
2010) and EMT (Odero-Marah et al., 2008; H. E. Zhau et al., 2008) in human prostate cancer 
cells and in the CRPC LTL-313 model.  We showed activated c-Met signaling and EMT, as 
exhibited by increased expression of neuropilin-1, VEGF, and RANKL protein and activation of 
p-c-Met and p-NFκB p65 in the CRPC LTL-313 tumor model with higher expression and 
activation of these genes in LTL-313 tumor xenografts maintained in castrated compared to 
intact mice.  As an internal control for minimizing the possible fluorescence interference of 
 138 
multiple QD probes, we performed MQDL side by side with the SQDL protocol (see above).  
The elevated expression of the 5 studied genes was found to be statistically significant by inFom 
quantitative analyses (Fig. 20B).  We determined this panel of 5 genes in primary prostate cancer 
specimens with different Gleason scores and found that expression of neuropilin-1, VEGF, p-c-
Met, RANKL, and p-NFκB p65 were more elevated in poorly differentiated (Gleason score 10) 
than moderately differentiated (Gleason score 7, 3+4) prostate cancer (Fig. 21).  These results, 
taken together, confirmed that QD labeling is highly sensitive and versatile and can be used for 
multiplexing gene expression profiles in experimental models at the single cell level. 
Furthermore, we showed that some clusters of LTL-313 tumor cells grown as xenografts in 
castrated male hosts underwent EMT (marked as M in Fig. 22A, Composite panel) and others 
only partially transitioned to express both E and M markers (marked as E/M in Fig. 22A, 
Composite panel).  Decreased expression of EpCAM, an epithelial biomarker, with concomitant 
increased expression of mesenchymal markers, such as N-cadherin and RANKL, was observed 
(Fig. 22A, Deconvoluted panels).  These data support the conclusion that castration promotes 
EMT in prostate cancer cells in situ.  Similar EMT was detected by MQDL in clinical primary 
prostate cancers (Fig. 22B).  A cluster of prostate cancer cells underwent EMT (M) while the 
other clusters of cells underwent partial EMT (E/M) (Fig. 22B, Composite panel).  Furthermore, 
Figure 23 demonstrates the co-expression of epithelial EpCAM and mesenchymal RANKL, and 
vimentin biomarkers in a metastatic bone tissue specimen. 
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Figure 20.  Multiplexed quantum dot labeling (MQDL) simultaneously detected c-Met activated 
and EMT genes in a CRPC LTL-313 xenograft model.  Single tumor tissue sections from intact 
and castrated hosts were subjected to sequential MQDL.  Enhanced expression of c-Met 
activated genes was detected in tumor tissues from castrated hosts.  A, A stack of multiple 
images (Cube), nuclear staining (DAPI), and individual gene expression (in pseudocolors) are 
shown.  Gene expression signals were superimposed with DAPI nuclear signals to yield a 
composite image for analysis.  ×400.  B, Significant differences in gene expression were found 
by quantification analysis of 1,000 cells in each tumor specimen using inForm software (P < 
0.05). 
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Figure 21.  MQDL assesses differential gene expression in clinical primary prostate cancer 
specimens.  C-Met-activated and EMT protein expressions in 5,000 cells of each representative 
prostate cancer tissues of Gleason scores 7 (3+4) and 10 (5+5) were compared.  Expression 
intensities were quantified with the inForm software and statistically compared (P < 0.05). 
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Figure 22.  MQDL detects EMT biomarkers in CRPC LTL-313 prostate tumors harvested from 
castrated hosts and from clinical prostate cancer.  A, The CRPC LTL-313 model showed 
androgen deprivation induced more abundant expression of EMT markers in a cluster of cells 
within the tumor region, as revealed by QD labeling of EpCAM, N-Cad, and RANKL.  B, 
Similar EMT biomarkers were detected in a clinical primary prostate cancer specimen (Gleason 
score 6; 3+3) with documented bone metastasis.  M denotes cells that completed EMT and E/M 
indicates cells undergoing partial EMT.  ×400. 
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Figure 23. MQDL detects EMT biomarkers in clinical bone tissue specimens. A representative 
specimen of human prostate cancer bone metastasis co-expressed high levels of epithelial 
EpCAM, and mesenchymal RANKL and vimentin proteins.  ×400. 
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Discussion 
Understanding the underlying molecular signaling pathway in CRPC and prostate cancer bone 
and soft tissue metastases could benefit patient care through improved disease surveillance and 
selection of patients for more effective targeting.  Considering the limited amount of tissues and 
cells available from biopsies and needle aspirates, and the challenges of tumor cell heterogeneity, 
MQDL offers a valuable multiplexing capability to analyze changes in cell signaling network 
components, at the single cell level during prostate cancer progression in both preclinical models 
and clinical specimens.  The advantages of quantitative MQDL over conventional IHC are: 1) 
Data obtained by quantitative MQDL could contain spatial and temporal information on the 
tissue specimens at the single cell level that can be easily integrated into the already-known 
histomorphometric and immnohistochemical information obtained from the tumor tissues or cells.  
2) The cell signaling network defined in tissue specimens could have predictive value for 
assessing the progression and therapeutic responsiveness of the prostate cancer.  3) Quantitative 
MQDL is highly efficient for tissue and cell utilization and can be further developed to monitor 
simultaneously multiple cell signaling networks in human cancer cells in situ.  The results of our 
studies using quantitative MQDL suggest that activation of c-Met signaling is responsible for 
driving prostate cancer cells to undergo EMT, with prostate cancer cells acquiring increased 
capability for cell migration, invasion and metastasis.  The quantitative aspect of the MQDL 
protocol is supported by a preclinical animal model in which LNCaP-RANKL cells, shown to 
overexpress RANKL, had activated c-Met signaling (Table 1, Figures 1 - 3), and underwent 
EMT by acquiring increased ability to metastasize to mouse skeleton and soft tissues, compared 
to parental LNCaP-neo cells.  In parallel, we presented evidence of activated c-Met and EMT in 
a preclinical CRPC LTL-313 tumor xenograft model (Figures 4, 5, and 7A).  Using the 
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established and validated MQDL protocol, we consistently observed activated c-Met with 
evidence of EMT in poorly differentiated (high Gleason score) and bone metastatic clinical 
prostate cancer specimens (Figures 6 and 8) (Zhang et al., 2011; Zhang et al., 2010; Zhau et al., 
2008).  Taken together, we suggest that activation of c-Met signaling and subsequent induction 
of EMT is probably a common feature of prostate cancer cells, xenograft models and clinical 
prostate cancer specimens exhibiting an increased propensity for lethal progression.  These 
results suggest the possible link between c-Met-mediated signaling activation, EMT and prostate 
cancer aggressiveness developed in a castration-resistant state.  This increased c-Met signaling 
network in prostate cancer cells could be considered as one of the reasons why targeting c-Met 
and VEGFR2  kinases with a small molecule, cabozantinib (XL-184), resolved bone and soft 
tissue metastases in a broad spectrum of solid tumors in patients (Smith et al., 2010; Zhang et al., 
2010).  Because of the small sample size used for the determination of c-Met signal activation in 
clinical prostate cancer specimens, a large scale of evaluation using clinical prostate cancer 
specimens with known status of c-Met activation (e.g. sensitive vs. resistant to cabozantinib) is 
warranted. 
Several technical issues with MQDL deserve special attention.  1) Conjugation non-covalently of 
streptavidin-coated QD to biotinylated secondary whole Ab is preferred to the direct conjugation 
of QD to secondary Ab fragments via reduced sulfhydryl-amine coupling.  The former non-
covalent method of QD detection through the biotin-avidin complex in our practice provides 
high labeling specificity and intensity.  2) Florescence interference and florescence resonance 
energy transfer can present a challenge for designing a suitable protocol to assess gene 
expression in cells.  Sweeney (Sweeney et al., 2008) provided earlier evidence that order of the 
addition of antibodies and QDs could affect cell labeling read-outs.  We suggest conducting a 
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series of combinational tests to determine the optimal reaction sequence and using matched 
primary Abs and QDs, a parallel set of negative control Ab IgGs, and when possible confirming 
the MQDL results with SQDL, IHC and Western blots.  3) The quality of the tissues and cells 
and non-specific labeling should be carefully determined in the immediately adjacent tissue 
sections to the actual sections used for data acquisition and analyses.  4) For internal controls, β-
actin and EF1-α, two routinely used internal protein loading controls for western blotting, were 
assessed in our current protocol.  We found that β-actin and EF1-α expression levels fluctuated 
depending on the QD-conjugates used and the levels were different between prostate tissues 
obtained from intact and castrated hosts in preclinical models.  These results are in agreement 
with the report of Yurube T et al. (Yurube et al., 2011) using β-actin as a control gene for 
immunofluorescence detection of gene expression in a rat tail disc degeneration model and found 
that β-actin was significantly down-regulated rather than staying unchanged.  Before establishing 
a well-accepted internal control for MQDL, we used stringent negative subtype matched 
antibodies as controls. 
In summary, MQDL is demonstrated to be a highly dynamic technique for assessing multiple 
gene expression at the single cell level in formalin-fixed cell and tissue specimens.  This protocol 
could be of great value for assessing cell signaling network in tissues and cells obtained from the 
clinic or from the laboratory.  Because of the unique photo-physical properties of QDs, MQDL 
could provide a sensitive method to determine levels of gene expression relevant to cell signaling 
networks or special biomarker expression even when clinical materials are limited. 
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CHAPTER 7 GENERAL DISCUSSION AND FUTURE DIRECTIONS 
Understanding the biology and targeting of prostate cancer bone metastasis holds promise for 
improving the survival of patients with castration-resistant and lethal progressive disease 
(Beltran et al., 2011; Lee, Saylor, & Smith, 2010; Sturge et al., 2011).  Among the many biologic 
processes studied, we and others found that the induction of EMT by soluble growth factors can 
provoke increased cancer cell growth, invasion, migration and ultimately metastasis to distant 
organs (Josson et al., 2011; Odero-Marah et al., 2008; Xu et al., 2006; Zhau et al., 2008).  
Previous elegant studies have demonstrated the paracrine roles of tumor-derived PTHrP which 
promotes RANKL expression by osteoblasts, increasing bone turnover through a “vicious cycle”, 
and linked cellular interactions among cancer (which expresses PTHrP), osteoblasts (which 
express RANKL) and osteoclasts (which express RANK) (Guise et al., 2010 ; Roodman, 2004; 
Vela et al., 2007; Ye et al., 2007; Yin, Pollock, & Kelly, 2005). Potential paracrine roles of 
RANKL in mediating hormone-induced stromal-epithelial interaction in mammary gland 
development (Fata et al., 2000; Fernandez-Valdivia et al., 2009; Gonzalez-Suarez et al., 2007; 
Gonzalez-Suarez et al., 2010; Schramek et al., 2010; Schramek et al., 2011), and expansion of 
the “stem cell niche” providing an escape route for cancer cells to gain altered behaviors such as 
increased EMT and resistance to hormone-, chemo- and/or radiation-therapy (Al-Ejeh et al., 
2011; Gangemi et al., 2009; Ghotra, Puigvert, & Danen, 2009; Nicolini et al., 2011; Schwarz-
Cruz-y-Celis & Melendez-Zajgla, 2011) have also been proposed.  The present study added to 
our understanding of the roles of tumor cell-derived RANKL in EMT, and further defined the 
converging RANKL-c-Met forward feedback loop to explain the roles of prostate cancer cell-
derived RANKL in bone and soft tissue metastases.  The significance of these observations 
includes: 1) RANKL derived from tumor cells or the microenvironment could amplify RANKL 
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downstream growth and survival signaling by promoting RANKL and c-Met expression.  Both 
RANKL (Chu, 2010; Odero-Marah et al., 2008; Zhau et al., 2008) and HGF (Chang et al., 2011; 
Hung et al., 2011) have been shown to induce EMT in prostate cancer cells and activation of a 
downstream signaling network involving c-Met which is activated primarily by VEGF in the 
ARCaP cell model through its co-receptor, neuropilin-1, to promote survival by activating an 
anti-apoptotic gene, Mcl-1 (Zhang et al., 2010). 2) The expressed RANKL and c-Met in cancer 
cells are biologically functional and participate in enhanced osteoclastogenesis and increased c-
Met phosphorylation and downstream survival signaling (Eder, Vande Woude, Boerner, & 
LoRusso, 2009; Sutherland, Rogers, Tosh, & Rogers, 2009; Zhang et al., 2010). 3) A small 
number of RANKL-expressing prostate cancer cells are sufficient to facilitate the growth and 
colonization of RANKL-null cells in mouse skeleton suggesting that RANKL can serve as a 
factor in “reawakening” cancer dormancy in mouse bone.  Based on the trafficking of LNCaP-
RFP cells, we observed that prostate cancer bone metastasis contributed directly to its secondary 
soft tissue metastases. 4) The feed-forward RANKL autocrine induction is mediated by 
activation of an oncogenic transcription factor, cMyc, that regulates RANKL expression as well 
as a wide spectrum of downstream genes involved in cancer cell growth, progression, and 
metastasis (Grandori, Cowley, James, & Eisenman, 2000; Gustafson & Weiss, 2010; Wolfer et 
al., 2010; Xu, Chen, & Olopade, 2010). Our findings support the significant clinical insights 
gained from targeting RANKL and c-Met/VEGF based signaling by an anti-RANKL monoclonal 
antibody, denosumab (Adler & Gill, 2011; Bishr et al., 2011; Fizazi et al.,2011 ; George & Moul, 
2011; Scott & Muir, 2011), and the small molecule cabozantinib (XL-184, (Smith, 2011)) which 
were shown to delay or prevent the progression of castration-resistant prostate cancer (CRPC) in 
patients with bone metastasis.    
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The functional roles of RANKL derived from prostate cancer and its contribution to bone and 
soft tissue metastases have not been investigated previously in part due to the lack of evidence of 
a predominant expression of RANKL by prostate cancer cells found to colonize to bone. Our 
results showing RANKL amplifying RANKL and c-Met expression and the facilitating roles of a 
small number of RANKL-expressing prostate cancer cells to promote RANKL-null cells to co-
colonize bone reaffirmed the potential dynamic role of RANKL in prostate cancer bone and 
secondary soft tissue metastases.  Our evidence is further supported by the facts that: 1) RANKL, 
RANK and OPG are expressed by clinical human prostate cancer tissues and also by a wide-
spectrum of isogenic human prostate cancer cell lines (Fig. 1A and 1B).  The steady-state level 
of RANKL expression in these cell lines seems to correlate with the increased invasiveness and 
bone metastatic potential of prostate cancer tissues and cells (Fig. 1B). 2) Interrupting RANKL-
RANK interaction with denosumab in men with clinical progressive prostate or breast cancers 
reduced their skeletal related events and improved patients’ survival (Lee et al., 2010; Lipton, 
2011; Stopeck et al., 2010; Sturge et al., 2011). 3) Using human prostate, breast, lung and renal 
cancer cell lines as experimental models for the study of the underlying mechanisms driving 
cancer bone metastasis, we found a consistent elevation of RANKL that was provoked by 
soluble factors (Zhau et al., 2008) which drove EMT and cancer bone and soft tissue metastases 
and induced lethality in experimental mice (Odero-Marah et al., 2008). 4) Previous studies have 
focused on the sources of RANKL from normal cells, such as osteoblasts B- or T-cells 
(Kartsogiannis et al., 1999; Manolagas & Jilka, 1995; Roodman, 2004; Vela et al., 2007), which 
often activate their receptor RANK in the neighboring normal cells in a paracrine manner (Boyce 
& Xing, 2007; Hanada et al., 2011; Tripodo et al., 2011). Results of this study support a model in 
which prostate cancer cell-derived RANKL plays a pivotal role in conferring the ability of tumor 
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cells to metastasize to bone by induction of EMT driven by PI3K-Akt, P38-MAPK and NF-κB 
signaling (Fig 9A).  This model, however, does not exclude the important functional roles of 
paracrine RANKL-RANK interaction.  The positive feedback loop of RANKL regulation of its 
own expression in prostate and bone cancer but not normal cells (Fig. 2B, 3A, 3C) mediated by 
cMyc transactivation (Fig. 15) makes possible a “vicious cycle” in cancer but not normal cells in 
which autocrine RANKL-RANK signaling is amplified in prostate cancer bone metastasis. 
RANKL-RANK signaling, however, also occurs with paracrine interaction between osteoblasts 
and osteoclasts during bone remodeling (Kearns et al., 2008; Lemaire, Tobin, Greller, Cho, & 
Suva, 2004; Sims & Gooi, 2008) as well as with neighboring cancer cells, conferring the ability 
to grow and metastasize. RANKL autocrine and paracrine signaling can initiate the reactivation 
or reawakening of tumor cells from dormancy (Fig. 8).  RANKL also serves as a paracrine 
mediator in steroid hormone action in mammary gland development and stem cell renewal 
during pregnancy (Fata et al., 2000; Kong et al., 1999), and is also involved in lymph node 
organogenesis (Kong et al., 1999), monocyte function and inflammatory responses (Seshasayee 
et al., 2004).  
Autocrine RANKL-RANK interaction within prostate cancer cells was shown to modulate a 
“cadherin switch” which controls EMT and its reversal MET.  EMT is considered as an 
important early invasive step in prostate cancer bone metastasis but once tumor cells reach 
distant organs a reversal of EMT, called MET, occurs (Chao et al., 2010; Kowalski et al., 2003; 
van der Pluijm, 2010; Wells et al., 2008; Yates et al., 2007).  Data obtained from the ARCaP 
EMT model support this suggestion since by antagonizing RANKL-RANK interaction 
genetically by RANKL siRNA (Fig. 2B-4) or blocking downstream signaling by pathway-
specific inhibitors (Fig. 9B), we have observed a reversal of EMT, or MET.  The reversal could 
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offer an explanation of why the bulk of prostate cancer cells in circulating blood and in bone 
appear epithelial in morphology and express E-cadherin and EpCAM (Armstrong et al., 2011; 
Klymkowsky & Savagner, 2009; Saha et al., 2008; van der Pluijm, 2010; Wells et al., 2008; 
Yates et al., 2007).  The exact mechanisms for how this occurs remain speculative at this time 
but understanding the RANKL-RANK switch in EMT and its reversal to MET could offer such 
an explanation.  Clinical prostate cancer bone metastasis is predominately osteoblastic, yet our 
animal models revealed primarily osteolytic bone reactions (Fig. 8B).  We suggest that factors 
yet to be identified within the tumor microenvironment could play a pivotal role in attenuating 
autocrine RANKL-RANK signaling in prostate cancer cells.  For example, elevated OPG or 
decreased osteoclast activating factors such as IL-11, MIP-1α, and secreted factors that control 
the shedding of activated RANKL by cathepsins and MMPs could dampen RANKL-RANK 
signaling. Attenuating RANKL expression by downregulating osteotropic growth factors, such 
as TGF-β, PTHrP, and prostaglandin E2 (Roodman, 2004; Virk & Lieberman, 2007) could play 
a role. These factors secreted in the tumor microenvironment could be responsible for fine-tuning 
the RANKL-RANK signaling which ultimately determines the cadherin and EMT/MET switches, 
cancer cell growth, survival and therapeutic responsiveness (Zhau et al., 2008).  Since stem cell 
properties have been observed in cancer cells undergoing EMT and RANKL-RANK signaling 
could be responsible for the expansion of the stem cell niche, an appropriate balance of RANKL-
RANK signaling could have profound implications in determining the status of malignancy of 
cancer cells.  Additionally, RANKL-RANK interaction and downstream signaling could also 
convey the ability of cancer bone colonization and the coupling between osteolytic versus 
osteoblastic responses observed in clinical prostate cancer bone metastasis (Keller & Brown, 
2004). Consistent with other studies, activation of RANK can enhance cell migration and 
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invasion of prostate and non-prostate cancer epithelial cells (Armstrong et al., 2008; Jones et al., 
2006; Sabbota et al.2010).  
Prostate cancer cells have been shown to exhibit osteomimetic properties, allowing them to 
imitate the gene expression and functions of bone cells (Keller, 2002; Koeneman et al., 1999; 
Lecrone, Li, Devoll, Logothetis, & Farach-Carson, 2000; Thomas, True, Bassuk, Lange, & 
Vessella, 2000; Zhang et al., 2001).  We found that one of the factors controlling prostate cancer 
cell synthesis and deposition of osteocalcin and bone sialoprotein is β2-microglobulin (Huang et 
al., 2006).  Interestingly, β2-microglobulin expression in human prostate, breast, lung and renal 
cancers increased RANKL expression (Josson et al., 2011) and promoted EMT and cancer 
skeletal and soft tissue metastases resulting in increased lethality in mice (Josson et al., 2011).  
We speculated that RANKL expression by these cancer cells might be responsible, in an 
autocrine manner, for the morphologic, biochemical and behavioral transition of prostate cancer 
cells to express their migratory, invasive and metastatic behaviors through EMT.  Since RANKL 
expressed by prostate cancer cells is functional in the induction of osteoclastogenesis in vitro, 
this suggests RANKL-RANK interaction in prostate cancer cells must be involved also with the 
host microenvironment.  We examined the role of three RANKL-RANK downstream signaling 
networks, PI3K-Akt, P38-MAPK, and NF-κB, in EMT by the use of appropriate pathway-
specific metabolic inhibitors.  Results indicate that RANKL-induced EMT was abrogated by 
inhibiting NF-κB signaling in both the ARCaPE-RANKL and LNCaP-RANKL cell models. 
However, inhibition of P38-MAPK or PI3K-Akt also partially reverted the EMT marker and 
decreased RANKL expression in both ARCaPE-RANKL and LNCaP-RANKL cells (Fig. 9B).  
We observed significant pathway “cross-talk” since both P38 and PI3K inhibitors diminished the 
level of P65 phosphorylation, and P38 inhibitor had a stronger inhibitory effect on NF-κB 
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activation than PI3K inhibitor (Fig. 9B).  Additionally, PI3K inhibitor significantly reduced the 
phosphorylated level of P38 in both cells (Fig. 9B). Our results are therefore in agreement with 
several studies showing that activation of P38 MAPK is required for P65 phosphorylation and 
transcription function (Bergmann et al., 1998; Kuphal et al., 2004; Wesselborg et al., 1997), and 
that Akt can transactivate the P65 subunit of NF-κB through the activation of P38-MAPK 
(Madrid et al., 2001; Viatour et al., 2005). Furthermore, studies using malignant melanoma also 
showed that the ERK pathway is not involved in NF-κB activation (Kuphal et al., 2004; Wang & 
Richmond, 2001). These results suggested that RANKL induced a sequential activation of 
signaling cascades from PI3K-Akt, P38, and then to NF-κB in ARCaPE-RANKL and LNCaP-
RANKL cells. Therefore, RANKL mediates the EMT transformation of prostate cancer cells by 
transactivating NF-κB signaling through Akt and P38 dependent pathways, which are known to 
be involved in cancer cell proliferation, survival, and distant metastasis.  
In summary, our study identified an important role for prostate cancer cell derived RANKL in 
prostate cancer bone and soft tissue metastases through the induction of EMT.  We observed an 
intriguing RANKL autocrine signal amplification system in which RANKL induced its own 
expression in cancer but not normal cells through activation of the oncogenic cMyc transcription 
factor.  We showed that RANKL-RANK interaction activated downstream PI3K-Akt, P38-
MAPK, and NF-κB.  We suggest that fine-tuning the RANKL-RANK switch in prostate cancer 
cells could elicit insights in the biology of EMT and the osteoblastic versus osteolytic lesions 
induced by metastatic prostate cancer, and improve the therapeutic targeting of the RANKL-
RANK axis. Understanding the roles of tumor cell-derived RANKL in EMT and tumor 
dormancy could strengthen our rationale for targeting RANKL-c-Met-mediated downstream 
signaling and improve the effectiveness of targeting lethal bone metastasis in CRPC. 
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Future Directions 
Ectopic expression of RANKL induced EMT progression and metastasis in indolent prostate 
cancer cells, such as LNCaP and ARCaPE cells. Also, we could ablate the expression of RANKL 
or RANK in aggressive ARCaPM and PC3 cells, which express high levels of RANKL, using a 
shRNA approach. We will examine both the in vitro and in vivo behavior of these RANKL or 
RANK knock-down ARCaPM and PC3 cells.  
Since RANKL-c-Met signaling converges, by which RANKL expression induced both RANKL 
and c-Met expression by prostate cancer cells, we will treat mice bearing intracardially-injected 
or intratibially-injected LNCaP-RANKL cells with the anti-RANKL monoclonal antibody 
denosumab (Adler & Gill, 2011; Bishr et al., 2011; Fizazi et al., 2011; George & Moul, 2011; 
Scott & Muir, 2011) and the small molecule cabozantinib (XL-184, (Smith, 2011), which targets 
c-Met to determine if these drugs alone or in combination can prevent LNCaP-RANKL-induced 
bone and soft tissue metastasis or prevent local tumor growth in the tibial bone.  
We also aim to further study the reawakening of tumor dormancy by RANKL. We will generate 
tetracycline inducible (Tet-on) RANKL expressing prostate cancer cell lines using LNCaP and 
ARCaPE cells. We will repeat the in vivo co-inoculation experiment using RFP-tagged LNCaP 
cells and tetracycline inducible RANKL expressing LNCaP cells, for which we can control the 
time point for switching on the RANKL expression, and study LNCaP-RFP behavior in vivo. 
Alternatively, we will inoculate LNCaP-RFP cells either intracardially or intratibially in nude 
mice for a month followed by administration of recombinant human/mouse RANKL proteins via 
i.p. injection to examine if LNCaP-RFP cells can metastasize or grow in the tibia.  
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Furthermore, we will also be interested in ectopically overexpressing cMet in LNCaP cells to 
examine if cMet expression can drive EMT progression and metastasis in LNCaP cells similar to 
RANKL-expressing LNCaP cells. In conjunction, we are also generating cMet knock-down 
LNCaP-RANKL, ARCaPM, and PC3 cells. We found that their morphology changed from 
mesenchymal to more epithelial-like, suggesting a reversal of EMT or MET phenotype, which 
coincides with decreased in vitro migration and invasion potential. We will therefore further 
examine their tumorigenic and metastatic potential in vivo. 
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